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ABSTRACT 
Worldwide, the prevalence of cardiometabolic diseases, particularly type II diabetes 
mellitus (T2DM), and to a lesser extent, metabolic syndrome (MetS), has increased 
dramatically. Despite this increase, there is still a lack of robust biomarkers for 
cardiometabolic diseases to secure better clinical outcomes. The enzymatic attachment of 
oligosaccharides (glycans) to proteins-glycosylation is of metabolic and physiological 
significance, as exploring aberrations of glycosylation profiles can reveal novel 
biomarkers. In parallel, this process could also explain the biological mechanisms that 
underpin a suboptimal health status (SHS), a reversible subclinical stage of a 
cardiometabolic disease. However, studies on the correlation between glycosylation and 
MetS/T2DM are scarce and none has thus far been performed on a West African 
population. Thus, the overall aim of this thesis was to explore complementary biomarker 
panels of healthy and diseased patients considered relevant to Ghanaian residents. The 
thesis is structured in the form of five related studies, each addressing a specific aim. From 
January 2016 to October 2016, a longitudinal case-control study comprising 253 T2DM 
patients and 260 controls, aged 18-80 years was conducted in Ghana. Fasting plasma 
samples were collected for clinical assessment, after which plasma N-glycans were 
analysed by Ultra-Performance Liquid Chromatography (UPLC) and statistical analyses 
performed. Central adiposity, underweight, high systolic blood pressure (SBP), high 
diastolic blood pressure (DBP) and high triglycerides (TG) were found to be independent 
risk factors associated with high SHS after adjusting for age and gender (Study I). SHS 
score was associated with age, physical inactivity, fasting plasma glucose (FPG), TG and 
MetS. MetS was associated with increased high branching (HB), trigalactosylated (G3), 
antennary fucosylated (FUC_A), triantennary (TRIA) and decreased low branching (LB) 
glycan structures (Study II). The levels of HB, G3, FUC_A, and TRIA N-glycans were 
increased in T2DM whereas levels of LB, non-sialylated (S0), monogalactosylation (G1), 
core fucosylation (FUC_C), biantennary galactosylation (A2G) and biantennary (BA) N-
glycans were decreased compared to controls (Study III). Biguanides alone, or in 
combination with sulfonylurea and thiazolidinedione, did not improve glycaemic status at 
follow-up. Many participants using angiotensin converting enzyme inhibitors achieved 
desired targets for blood pressure control while statins were effective for control of plasma 
lipids (Study IV). At a population level, the variability of N-glycan structures ranged from 
11% to 56% at both baseline and follow-up, with an average coefficient of variation of 
 iv 
 
28% and 29%, respectively. The intra-individual N-glycan peak (GP) variations were 
minor except for GP1 and GP29. However, there were no statistically significant 
differences in N-glycosylation profiles from baseline to follow-up (Study V). This thesis 
shows an association between SHS and MetS/T2DM while MetS and T2DM are 
characterised by increased levels of complex N-glycan structures, and these structures 
are stable in T2DM over six months. Many of the findings in this thesis agree with earlier 
studies from Chinese and Croatian populations with major differences attributed to 
genetic and environmental factors. Future longitudinal studies are required to provide a 
better understanding of the transition from SHS to T2DM, as well as to validate N-glycans 
as generic risk stratification biomarkers for a general population.  
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CHAPTER ONE 
1.1 General Introduction 
Type II diabetes mellitus (T2DM) (ICD: E11) is a chronic disease that kills many 
people in both developed and developing countries (The World Health Organisation- 
WHO, 2011; WHO, 2015). While massive investment has resulted in significant progress 
in T2DM research in developed countries, similar improvements have not been realised 
from the African public health perspective. In this thesis, novel, non-invasive screening 
tools, in conjunction with high-throughput analytical techniques and statistical 
approaches, were employed to unravel the potential of N-glycosylation profiles as 
biomarkers for T2DM in a Ghanaian population. 
T2DM is a debilitating disorder characterised by progressive and continuous 
plasma hyperglycaemia (American Diabetes Association, 2014; Kahn, Cooper, & Del 
Prato, 2014; Shrivastava, Shrivastava, & Ramasamy, 2013). This persisting 
hyperglycaemia leads to metabolic dysregulation that affects important cells in the 
kidneys, nerves, heart and blood vessels (American Diabetes Association, 2014). 
Consequently, T2DM sufferers experience multiple complications including 
ketoacidosis, urinary tract infections, hyperosmolar non-ketotic coma and stroke, as well 
as ophthalmic defects (Demirci et al., 2015; Nitzan et al., 2015). Taken together, these 
complications result in increased hospitalisation (Lim et al., 2013), decreased quality of 
life (Schofield et al., 2017) and increased mortality (Bao et al., 2017).  
Thus far, medical practice has evolved and it is now widely known that 
hyperglycaemia can be controlled with dietary modifications and changing lifestyles 
(Shrivastava et al., 2013). However, when these attempts fail to lower hyperglycaemia, 
parenteral or oral anti-diabetic medications are prescribed (Kahn et al., 2014; Shrivastava 
et al., 2013). Although these medications have improved clinical outcomes and 
fundamentally enhanced the lives of T2DM sufferers, they are often associated with 
adverse effects that lead to withdrawal (Ho et al., 2006). Therefore, targeting and 
recognising individuals who are at risk of developing T2DM will be more beneficial as 
such people can be isolated for alternative interventions that may delay the onset of the 
disease.  
Early diagnosis of T2DM may be possible by recognising a reversible, 
intermediate state, or subclinical disease, hereafter referred to as suboptimal health status 
(SHS) (Yan et al., 2009). SHS is characterised by poor health, low energy or vitality and 
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general body weakness (Adua, Roberts, & Wang, 2017; Wang & Yan, 2012; Yan et al., 
2014;Wang et al., 2016; Yan et al., 2009; Kupaev et al., 2016). It can be measured using 
a simple subjective instrument called the SHS-questionnaire (SHSQ-25) (Yan et al., 
2009). The SHSQ-25 explores human health from five domains: cardiovascular, fatigue, 
immune system, digestive system and mental status (Figure 1.1) and SHS is scaled based 
on a cut-off score. Since its introduction, the SHSQ-25 has been successfully applied to 
chronic disease screening across different populations Wang & Yan, 2012; Yan et al., 
2014;Wang et al., 2016; Yan et al., 2009; Kupaev et al., 2016) but this is the first instance 
of this tool being applied in a West African population (Adua et al., 2017).  
 
Figure 1.1 SHSQ-25 assesses five components of health. Figure reproduced with permission from 
Wang et al., (2014). 
Alternatively, research has advanced and has led to the introduction of objective 
biomarkers that can gauge human health, monitor disease progression and response to 
therapy (Herder, Karakas, & Koenig, 2011; Krämer et al., 2010). Fasting plasma glucose 
(FPG) and the oral glucose tolerance test (OGTT) were introduced in the early 1970s and 
are still used to diagnose T2DM, but the results of these tests are affected by fluctuations 
of daily glucose levels (American Diabetes Association, 2010; Bennett, Guo, & 
Dharmage, 2007; Kilpatrick & Atkin, 2014). After multiple years of investigation, it was 
revealed that sugars or sugar phosphates irreversibly bind to the β-N-terminal valine 
residues of globin chains (Schiff base), then undergoes an Amadori rearrangement into a 
1-deoxy-1-N-valyl-fructose and forms a ring structure. This product was later referred to 
as glycated haemoglobin (HbA1c) (Gillery, 2012). HbA1c was evaluated for clinical 
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practice and has been used to monitor glycaemic control since the 1980s (Kennedy & 
Baynes, 1984; Brownlee, Vlassara & Cerami, 1984). In 2010, the American Diabetes 
Association recommended its use for diagnosing prediabetes and diabetes (Gebel, 2012). 
Thus far, it has been shown that the HbA1c has better diagnostic potential compared to 
FPG and OGTT by having a lower biological variability, being analytically stable, 
reflecting glycaemic control over 2-3 months, and not requiring fasting prior to testing 
(American Diabetes Association, 2014; Kharroubi & Darwish, 2015). However, HbA1c 
values can be influenced by carbamylated haemoglobin, haemoglobin variant, 
haemoglobinopathy or abnormal erythrocyte turnover, folic acid deficiency and vitamin 
B12 deficiency (d’Emden, 2012; Rodbard et al., 2009; Gillery, 2012). Moreover, these 
traditional tests are not robust enough to detect latent or underlying disorders of glucose 
regulation or metabolism (Keser et al., 2017). More robust biomarkers are therefore 
needed not only to complement the existing biomarkers, but also to improve early 
diagnosis. One such biomarker is complex oligosaccharides (glycans) that bind to 
proteins in glycosylation (Bieberich, 2014; Taylor & Drickamer, 2011).  
In fact, studies have established that alteration in profiles of complex sugars (N-
glycan) are potential biomarkers for cardiometabolic diseases. Using high performance 
liquid chromatography (HPLC) and the matrix assisted laser desorption ionisation time 
of flight (MALDI-TOF) technique, a study reported altered N-glycans in 16 T2DM 
patients and 16 diabetic (db/db) mice (Itoh et al., 2007). However, this study could 
identify only one N-glycan trait that was associated with T2DM (i.e. α-1, 6-fucosylation) 
and the sample size was too small to reach statistical significance. Testa et al., (2015) 
performed N-glycan analysis using DNA sequencer-aided fluorophore-assisted 
carbohydrate electrophophoresis (DSA-FACE) and found an alteration in N-glycan 
profiles in T2DM patients compared to controls. However, the DSA-FACE technique 
yielded only 10 N-glycan peaks and therefore did not provide adequate structural N-
glycan characterisation and quantification. In 2011, Lu et al., (2011) applied hydrophilic 
interaction chromatography (HILIC) and weak anion exchange (WAX) HPLC to detect 
10 N-glycan traits that were associated with components of metabolic syndrome (MetS) 
in Chinese Han and Croatian populations. Five years later, McLachlan (2016) applied the 
same technique to detect 21 N-glycan traits that were associated with MetS in individuals 
from Orkney Islands (UK). However, both studies employed a technique that allowed for 
the detection of 24 N-glycan peaks, only included few MetS components, and did not 
include markers of liver function. 
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Recently, another study showed that higher branching, decreased agalactosylated 
and monogalactosylated, decreased neutral and increased trisialylated N-glycans were 
associated with T2DM risk in a Croatian population. However, this study failed to adjust 
for multiple confounders and did not cover other possible risk factors such as lipid levels, 
waist size, liver enzymes (proteins) and renal biomarkers (Keser et al., 2017). Further, 
Lemmers et al., (2017) also reported that 5 IgG N-glycans and 13 derived traits were 
associated with T2DM. However, this study was restricted to only plasma IgG, where 
IgG only represents a fraction of the total protein in the blood. Hence, total human plasma 
N-glycome profiling would give a better prediction (Lemmers et al., 2017). Moreover, 
after reviewing the literature, it became obvious that N-glycosylation studies have largely 
been conducted among Chinese and Caucasian populations (Lu et al., 2011; McLachlan 
et al., 2016) and none have thus far, been documented among West African populations.  
In the translation of the body of scientific knowledge from the Ghanaian perspective, it 
is argued in this thesis that N-glycosylation profiles among T2DM and healthy controls 
would be different considering the genetic and environmental factors that contribute to 
the disease and pharmacotherapies of the disease. 
1.2 Thesis aims 
In accordance with the limitations of previous studies, and to fill in the gaps in knowledge 
highlighted above, this thesis is structured as a series of five related studies (Figure 1.2) 
or publications, with each study/publication satisfying a particular aim. These aims are: 
1. To examine SHS in a Ghanaian population and, in parallel, examine the 
anthropometric, clinical and biochemical parameters among T2DM patients. 
2. To explore N-glycosylation profiles as risk biomarkers for SHS and MetS. 
3. To profile cardio-metabolic risk factors and explore medication utilisation among 
T2DM patients. 
4. To perform high-throughput profiling of whole plasma N-glycans in T2DM 
patients and healthy individuals. 
5. To longitudinally examine N-glycosylation profiles of T2DM from baseline to 
follow-up.  
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Figure 1.2 an overview of this thesis. The thesis is structured in the form of related studies. Studies I & 
II are cross-sectional, Study III is an age-gender matched case-control and Studies IV & V are 
longitudinal.  
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CHAPTER TWO 
Prelude 
Having provided a brief introduction of the thesis and the study aims in Chapter One, 
the Second Chapter provides a review of T2DM, highlighting the epidemiology, 
pathophysiology, genetic and environmental factors that contribute to the disease and 
pharmacotherapies of the disease. 
Literature Review 
2.1 Type II Diabetes Mellitus 
2.1.1 Epidemiology 
Diabetes mellitus (DM) is a disease that may have existed more than two centuries 
ago and could kill within weeks or months of diagnosis (Polonsky, 2012). After two 
centuries, the disease can now be managed with medication and lifestyle changes, thereby 
increasing longevity (Polonsky, 2012). Unfortunately, the route to cure the disease has 
been slow despite major advances in research and, in fact, the disease is still associated 
with a significant reduction in life expectancy (Polonsky, 2012). According to the WHO, 
DM killed 2.2 million people in 2012, and affected 422 million people in 2014 (WHO, 
2015). The WHO further states that the disease took 1.6 million lives in 2015 and 
projected that by 2030 it will be the seventh major cause of adult death worldwide (WHO, 
2015). T2DM is the predominant type of DM and it was more prevalent in the developed 
or high-income countries (Esposito, Kastorini, Panagiotakos, & Giugliano, 2010; 
Mokdad et al., 2003; Zou et al., 2017). However, recent statistics show that T2DM has 
reached epidemic levels in low- to middle-income countries (LMIC) and it is even 
projected that, in the next few decades, two thirds of all DM cases will be found in these 
countries (Doherty et al., 2014). Sub Saharan Africa (SSA) remains one of the most 
affected, as an estimated 19.8 million adults above 20 years had T2DM in 2013 while 
41.5 million cases are expected by 2030 (Peer et al., 2014). In parallel, an estimated 46% 
of individuals with T2DM are yet to be diagnosed (Peer et al., 2014) and this is partly due 
to ageing, such as in the Ghanaian population (Mba, 2010). In Ghana, the disease affected 
302,000 adults in 2000 and this is projected to reach 815,000 by 2030 (Guariguata, 2014). 
Another study also estimated that up to 6% of the adult population in Ghana has DM 
(Danquah et al., 2012). 
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2.1.2 Pathophysiology of T2DM  
Feedback Regulation of Glucose Metabolism  
Under normal conditions, blood glucose levels are maintained via a cross 
communication involving insulin secretion and tissue sensitivity to insulin (Kahn, 
Cooper, & Del Prato, 2014). Upon pancreatic β cell stimulation, insulin is released from 
the islet cells to regulate glucose uptake by insulin sensitive tissues (Kahn et al., 2014). 
In turn, glucose stimulates the production of insulin from the β cells. However, under 
abnormal conditions such as T2DM, two main defects occur that disrupt the homeostatic 
mechanism. These are 1) impaired insulin secretion due to progressive loss of β cell 
function and, 2) impaired insulin action because of insulin resistance. Combined, these 
defects lead to decreased glucose uptake by muscle cells, decreased hepatic glucose 
output and decreased triglyceride uptake by fat cells. To compensate for this defect, the 
β cells continue to secret insulin in order to maintain normal glucose levels. However, 
when the β cells are unable to meet this demand, plasma glucose levels rise and lead to 
impaired glucose levels (Figure 2.1) (Cornell, 2015; Epstein, Shepherd, & Kahn, 1999; 
Kasuga, 2006; Kharroubi & Darwish, 2015; Mellitus, 2005). 
 
Figure 2.1 Pathophysiology of T2DM. Under normal conditions, insulin is secreted from the β cells of 
the pancreas to regulate glucose by the liver, promotes muscle glucose uptake and blocks lipolysis 
(breakdown of lipids into fatty acids). However, in T2DM, insulin secretion is reduced due to progressive 
loss of β cell function and concurrently, there is impaired insulin action on tissues because of insulin 
resistance. These effects lead to increased production of fatty acids and blood glucose. Figure reproduced 
from Stumvoll, Goldstein & van Haeften, 2005. 
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Insulin Signalling  
Insulin mediates the metabolism of carbohydrates, lipids and proteins through a 
complex signaling cascade. This begins with the binding of insulin to a tyrosine kinase 
receptor leading to the phosphorylation of insulin receptor substrates 1 and 2 (IRS 1 and 
IRS 2) (Epstein et al., 1999; Kharroubi & Darwish, 2015; Saltiel & Pessin, 2002). The 
binding of IRS 1 or IRS 2 to the insulin receptor stimulates phosphoinositol 3-kinase 
(PI3K) which leads to the recruitment of phosphatidylinositol (4, 5)-bisphosphate (PIP2) 
and phosphoinositol 3, 4, 5-triphosphate (PIP3) (Gual, Le Marchand-Brustel, & Tanti, 
2005; Saltiel & Pessin, 2002). PIP3 binds to Ser/Thr (Akt) or protein kinase B (PKB) that 
is activated by 3-phosphoinositide-dependent protein kinase 1 (PDK1). Adenosine 
monophosphate (AMP) then binds, activates and induces a conformational change in 
adenosine monophosphate-activated protein kinase (AMPK). The activated AMP-K then 
phosphorylates and activates glucose transporter 4 (GLUT-4). GLUT-4 is a member of 
the integral membrane glycoprotein family that applies facilitative diffusion to transport 
saccharides through the cell membrane to generate energy (Ohtsubo et al., 2005; Center, 
2000; Epstein et al., 1999) (Figure 2.2). Because this is a regulated process, it can be 
argued that a defect in the signalling cascade can lead to glucose intolerance and insulin 
resistance. However, it should be noted that T2DM is a multifactorial disease arising from 
an interplay between environmental and genetic factors.  
 
Figure 2.2 Insulin signalling pathway. The insulin receptor is a tyrosine kinase, which phosphorylates 
IRS 1 and IRS 2. This leads to the activation of PI3K and PDK. Activated PDK 1 can stimulate PKB/AKT 
or PKC. This effect stimulates the translocation of GLUT 4 to the cell membrane to promote glucose uptake. 
Exercises tend to influence AMPK, which stimulate the translocation of GLU 4 to the cell membrane 
(Epstein et al., 1999). 
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2.1.3 Environmental Factors   
T2DM development is largely attributed to dietary and lifestyle habits (American 
Diabetes Association, 2014; Doherty et al., 2014; Esposito et al., 2008; Frank et al., 2014; 
Nolan, Damm, & Prentki, 2011). Generally, consumption of foods such as vegetables, 
fruit, poultry, whole grains, cereal fibre and polyunsaturated fats are associated with 
decreased risk of T2DM, whereas excess intake of red meat, refined carbohydrates, fried 
or processed foods and sweets or sugar-sweetened beverages are associated with 
increased risk of T2DM (Esposito et al., 2008; Frank et al., 2014; Yu et al., 2011). 
Moreover, consumption of foods that are deficient in micronutrients such as vitamin B12, 
vitamin D and folic acids increase the risk of T2DM (Pflipsen et al., 2009; De, 2010). 
Conversely, increased energy expenditure through regular exercise or physical activity 
reduces the risk of developing T2DM (Phillips, 2017). In fact, studies have shown that 
30 minutes of brisk walking per day decreases T2DM risk by 34%, whereas a sedentary 
lifestyle, including prolonged watching of TV and prolonged sitting at work, was 
associated with a higher risk (Hu, 2011; Willi et al., 2007). In addition, T2DM risk is 
fuelled by cigarette smoking and excessive alcohol consumption (Willi et al., 2007). One 
study has even shown that smoking increases T2DM risk by 45% while heavy alcohol 
intake leads to impaired glucose metabolism, liver dysfunction and consequently, 
impaired glucose tolerance (Hu, 2011). Also, depression (Mezuk et al., 2008), sleep 
deprivation (Shaw et al., 2008) and consistent antidepressant use (Kivimäki et al., 2010) 
have been implicated in T2DM development. Further, endocrine disrupting chemicals 
including pesticides, organic pollutants, and toxins contribute to T2DM development 
(Brook et al., 2010; Chen, Magliano, & Zimmet, 2012; Krämer et al., 2010). It is 
worthwhile mentioning that developmental reprogramming (poor intrauterine 
environment with associated fetal growth restriction) contributes to the onset of T2DM 
(Fernandez-Twinn and Ozane, 2006). 
 
2.1.4 Genetic Susceptibility Genes for T2DM 
T2DM is largely a consequence of genetic factors and different approaches have 
been employed to reveal genetic susceptibility genes. Until recently, genetic mapping for 
T2DM was mainly by genetic linkage analysis and candidate gene association studies, 
both of which were limited by small sample size or small pedigree and focus on limited 
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genes (Grarup, Sandholt, Hansen, & Pedersen, 2014). However, in the past decade, 
advances in array-based genotyping have made it possible for complete scans of genetic 
variations in individuals to identify variants that are associated with a particular trait, 
otherwise referred to as genome wide association studies (GWAS) (Long et al., 2012). 
The GWAS have not only overcome the shortcomings of genetic linkage analysis and 
candidate gene association studies but have also provided a better understanding of how 
genetic defects are associated with insulin resistance and T2DM. Thus far, GWAS have 
enabled the identification of 176 genomic loci that are associated with metabolic traits 
and phenotypes (Grarup et al., 2014).  Below are a few of the widely reported loci: 
 
1. T2DM-Wolfram syndrome 1 (WFS 1), hepatocyte nuclear factor 1-beta (HNF 
1B), insulin-like growth factor 2 mRNA binding protein 2 (IGF2BP2), 
transcription factor 7-like 2 (TCF7L2), solute carrier family 30 (Zinc 
Transporter), ankyrin 1 (ANK 1), Potassium Voltage-Gated Channel Subfamily J 
Member 11 (KCNJ11), cell division cycle 123 (CDC 123), member 8 (SLC30A8), 
JAZF zinc finger 1 (JAZF 1), melatonin receptor 1B (MTNR1B), and 
haematopoietically expressed homeobox (HHEX).  
2. Insulin-peroxisome proliferator-activated receptor gamma (PPARγ), insulin 
receptor substrate 1 and 2 (IRS 1 and 2), and krupel like factor 14 (KLF). 
3. BMI- cyclin dependent kinase 5 regulatory subunit associated protein like- 1 
(CDKAL1), fat mass and obesity associated (FTO), SEC16 homolog B 
(SEC16B), proprotein convertase subtilisin/kexin type 1 (PCSK1), protein kinase 
D1 (PRKD1), neuronal growth regular 1 precursor (NEGR1). 
4.  Fasting glucose- purinergic receptor P2X 2 (P2rX2), DNL-type zinc finger 
(DNLZ), sine oculis-related homeobox 3 (SIX3), DNA topoisomerase 1 (TOP 1), 
tryptophanyl-tRNA synthetase (WARS). 
5. WHR-WARS2, zinc and ring finger 3 (ZNR F 3), homeobox C13 (HOXC13). 
 
It should be noted that T2DM susceptibility genes differ among populations. For 
example, single nucleotide polymorphism (SNP) r864745 in JAZF 1 is associated with 
T2DM among European populations (Hu et al., 2009; Zeggini et al., 2008). Similarly, 
r7754840 in cyclin dependent kinase A like 1 (CDKAL 1) is associated with T2DM from 
Swedes and Finns. In addition to CDKAL 1,  SLC30A8, HHEX, CDKN2A/B, IGF2BP2, 
FTO and WFS1 are associated with T2DM in Koreans, Chinese and Pima Indians (Hu et 
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al., 2009; Lee et al., 2008; Rong et al., 2008; Saxena et al., 2007), whereas C2CD4A and 
KCNQ1 is associated with T2DM among Japanese (Unoki et al., 2008; Yamauchi et al., 
2010). Until recently, genome-wide mapping studies in Africa were scarce. The earliest 
of such studies was the African American Diabetes Mellitus study (AADMS) (Rotimi et 
al., 2004) involving Ghanaians and Nigerians. In this study, chromosomal locus 20q13.3 
was identified as strongly linked with T2DM, a link previously found among non-African 
populations (Rotimi et al., 2004; Rotimi et al., 2001). Other studies have shown that 
calpain 10 (CAPN10), PCSK1 and glycoprotein 2 (GP2) were associated with T2DM in 
Africa and Asia (Chen et al., 2005; Grarup et al., 2014). Further, a genetic risk map of 
allelic frequencies of 16 variants in 51 ethnic groups in Africa showed that Africans are 
more genetically susceptible to T2DM than other populations (Tekola-Ayele, Adeyemo, 
& Rotimi, 2013). Overall, these genetic discoveries could guide T2DM management by 
providing clues for pharmacological targets and enable precise identification or 
characterisation for therapeutic interventions for high risk individuals (McCarthy, 2010)  
 
2.1.5 Metabolic Syndrome and Prediabetes  
Metabolic syndrome (MetS) is the concurrence of central obesity, dysregulated 
glucose and insulin metabolism, and hypertension. According to the National Cholesterol 
Education Program (NCEP) - Adult Treatment Panel ATP III guidelines (NCEP, 2002; 
Cleeman, 2001), an individual is diagnosed as having MetS when he/she meets the 
following criteria 1) systolic blood pressure (SBP) ≥ 130 mmHg and/or diastolic blood 
pressure (DBP) ≥ 85 mmHg,  2) FPG ≥ 100 mg/dL (5.55 mmol/L), 3) waist measurement 
of ≥102 cm in men and ≥ 88 cm in women; 4) triglyceride (TG) ≥150 mg/dL (1.7 mmol/L) 
or the use of any lipid controlling medication; or 5) high density lipoprotein cholesterol 
(HDL-c) of <40 mg/dL (1.0 mmol/L) in men and <50 mg/dL (1.3 mmol/L) in women. 
Over the past four decades, MetS has received worldwide recognition mainly because 
of its association with overt diabetes or prediabetes (Wellen & Hotamisligil, 2005; Wilson 
et al., 2005; Morrison, Friedman, Wang & Glueck, 2008). Prediabetes is an intermediate 
stage characterised by hyperglycaemia below the level considered to be diagnosed as 
T2DM but has the likelihood to progress to T2DM (Buysschaert & Bergman, 2011; 
Kharroubi & Darwish, 2015). For many years, the determination of this intermediate state 
was via blood glucose measures such as the FPG) and OGTT tests (Sacks et al., 2011). 
Prediabetes is established when FPG levels are between 100 mg/dl (5.6mmol) to 125 
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mg/dL (6.94 mmol/l ) or impaired glucose tolerance (IGT) is between 140 mg/dL (7.8 
mmol/l) to 199 mg/dL (11.0 mmol/l) or HbA1c ≥ 6% (126 mg/dL; 7 mmol/l) but ≤ 6.5% 
(8.0 mmol/l; 138 mg/dL) (American Diabetes Association, 2014; Buysschaert & 
Bergman, 2011; Kharroubi & Darwish, 2015). T2DM diagnosis is as follows: plasma 
glucose after 2hr OGTT ≥ 200 mg/dl (11.1 mmol/l), FPG ≥ 126 mg/dl (7.0 mmol/l) or 
random FPG of ≥ 200 mg/dL and HbA1c ≥ 6.5%. If any one of these criteria is met, 
confirmatory tests are performed to establish T2DM (American Diabetes Association, 
2014; Sacks et al., 2011).   
 
2.1.6 Pharmacotherapy 
Since the description of T2DM many years ago, intense research has led to the 
discovery of parenteral and oral medications to manage and treat the disease (Kahn et al., 
2014). These medications belong to distinct categories based on their modes of action:  
1. Biguanides: These are oral hypoglycaemic agents and first line drugs for 
controlling blood glucose (Saisho, 2015). They regulate blood glucose by 
reducing hepatic glucose production and inducing muscle glucose uptake by 
activating AMPK (Saisho, 2015). An example is metformin.   
2. Sulfonylureas: These are second line drugs that bind and block adenosine 
triphosphate (ATP)-sensitive potassium (K) channels in pancreatic cells and 
stimulate insulin secretion (Rendell, 2004; Stumvoll et al., 2005). Examples of 
drugs belonging to this class are tolbutamide, tolazamide, glipizide (Glucotrol), 
glyburide and glibenclamide. Apart from sulfonylureas, other second line drugs 
include: 
3. Glucagon-like receptor agonists (GLP-1): GLP-1 binds to the GLP-1 receptor 
expressed in pancreatic cells and mediates glucose-dependent insulin secretion 
and suppresses overproduction of glucagon (Blair & Keating, 2015; St Onge & 
Miller, 2010). Examples are albiglutide, exenatide, liraglutide and lixisenatide. 
4. Dipeptidyl peptidase 4 (DPP4) inhibitors: This class of oral hypoglycaemic agents 
blocks DPP4, induces incretin (GLP1) levels, has trophic effects on β-cells and 
decreases glucagon release (Kahn et al., 2014; Stumvoll, Goldstein, & van 
Haeften, 2005). Examples include Anagliptin, Alogliptin, Sitagliptin, Saxagliptin 
and Gemigliptin.  
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5. Peroxisome proliferator-activated receptor γ agonists (PPARγ): This class of 
drugs act by binding and activating PPARs, receptors that regulate fat storage and 
glucose metabolism. They reduce inflammatory cytokines that are involved in 
insulin resistance, lower lipid content in the liver, increase tissue adiponectin and 
promote insulin sensitisation (Krentz, Bailey, & Melander, 2000). Examples of 
drugs belonging to this class are pioglitazone, rosiglitazone and lobeglitazone.  
6. α-glucosidase inhibitors: These are competitive inhibitors that decrease blood 
glucose load by prolonging carbohydrate metabolism in the gastrointestinal tract 
(GIT) and reducing glucose absorption (van de Laar et al., 2005). An example is 
acarbose. 
7. Cannabinoid receptor (CB1) antagonists: These bind and block CB1 receptors 
leading to a reduction in triglyceride levels and induce weight loss (Scheen et al., 
2006). A typical example of such a drug is Rimonabant. 
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CHAPTER THREE 
Prelude 
By focusing on T2DM, Chapter Two has given a background to the disease, reporting 
the prevalence of the disease across the globe and providing insights into the genetic as 
well as environmental factors that contribute to the diseases’ progression. Further, 
Chapter Two has shown that research in T2DM has progressed and has led to the 
introduction of biomarkers, as well as oral and parenteral medications for control and 
management of T2DM associated risk factors. However, the pathway to cure still remains 
far-fetched and therefore, there is the urgent need for additional biomarkers. Chapter 
Three reviews the literature and describes post-genomic biomarkers for chronic diseases 
such as T2DM.  This review has been published in Omics: Journal of Integrative Biology 
and it can be cited as:  
Adua, E., Russell, A., Roberts, P., Wang, Y., Song, M., & Wang, W. (2017). Innovation 
analysis on postgenomic biomarkers: Glycomics for chronic diseases. OMICS:  Journal 
of Integrative Biology, 21(4), 183-196. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 22 
 
Innovation Analysis on Postgenomic Biomarkers: Glycomics for 
Chronic Diseases 
 
3.1 Abstract 
Despite decades of investment in biomarker research, we still do not have robust and 
optimised biomarkers for many chronic diseases to anticipate clinical outcomes and thus 
move towards personalised medicine. Biomarker innovations have tended to focus on 
genomics but the next generation biomarkers from the nascent field of glycomics now 
offer fresh vistas for innovation in chronic disease biomarkers and systems diagnostics. 
Glycosylation, regarded as a complex enzymatic process where sugars (glycans) bind to 
proteins and lipids, affects many human biological functions including cell signalling, 
adhesion and motility. Notably, and contrary to proteins, glycan biosynthesis does not 
require a template; rather its final structure is catalysed by a repertoire of enzymes that 
attach or detach monosaccharides in the glycosylation pathway, making glycomics 
research more challenging than proteomics or genomics. Yet, given glycans’ biological 
significance, alterations in their processing may be detrimental to human health and offer 
insights for preventive medicine and wellness interventions. Therefore, studying glycans’ 
structure and understanding their function and molecular interactions in the emerging 
field of glycomics is key to unravelling the pathogenesis of various common chronic 
diseases. This review summarises the major concepts in glycomics including glycan 
release methods, techniques for large-scale glycan analysis and glycoinformatic tools for 
data handling and storage. In all, this analysis of glycomics offers strategies to build a 
robust postgenomics innovation roadmap for glycan driven biomarkers as the field is 
anticipated to mature further and gain greater prominence in the near future. 
 
 
Key words: Biomarker, glycoinformatics, glycomics, innovation analysis, postgenomics 
biomarkers 
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3.2 Introduction 
Many chronic diseases still lack innovative diagnostics and biomarkers to anticipate 
clinical outcomes and thus move towards personalised medicine. Genomics has been a 
key focus across the biomarker innovation ecosystem but the next generation biomarkers 
from the nascent field of glycomics now offer fresh vistas for innovation in chronic 
disease biomarkers and systems diagnostics. Glycosylation, regarded as a complex 
enzymatic process where sugars (glycans) bind to proteins and lipids, affects many human 
biological functions including cell signalling, adhesion and motility. Glycans are complex 
carbohydrates located on the surface of all eukaryotic cells and modify proteins in 
glycosylation, forming glycoconjugates which thus far, are the most significant post-
translational modifications (PTM) (Cummings & Pierce, 2009; Harada, Hirayama, & 
Suzuki, 2015; Stanley & Cummings, 2009). For the over 19,709 human protein genes 
known, an estimated 39% are predicted to be either on the intracellular surface or outside 
of the cell (Gordan Lauc, 2016). Thus, about 7,686 proteins have these glycans bound to 
them (Apweiler, Hermjakob, & Sharon, 1999; Gordan Lauc, 2016). When attached to 
proteins, glycans affect all aspects of the protein including function, trafficking, folding 
and clearance (Helenius & Aebi, 2001; Stanley, 2011; Zoldoš, Horvat, & Lauc, 2013). So 
far, four protein modifying glycan types have been identified: 1) N-glycans (Figure 3.1); 
2) O-glycans; 3) glycosaminoglycan (GAG); and 4) C-glycans (Ajit Varki, 2009; Fuster 
& Esko, 2005; Hofsteenge et al., 1994; Jensen, Karlsson, Kolarich, & Packer, 2012; 
Schachter, 2000; Stanley & Cummings, 2009; Weerapana & Imperiali, 2006).  
 
Figure 3.1 N-linked glycan structure, redrawn from Dube and Carolyn, 2005. 
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3.3 Mechanism of Glycosylation 
The mammalian cell is known to contain a repertoire of glycans (Cummings & 
Pierce, 2009). These glycans comprise chains of monosaccharide units that are linked by 
α and β-glycosidic bonds (Ajit Varki, 2009; Taylor & Drickamer, 2011). As mentioned 
earlier, four main types of glycans exist: N-glycans, O-glycans, GAGs and C-glycans. 
These glycans differ in their core structure, whether they are branching or not, and the 
recognition sequence, if any, by which they attach (Varki, 2009; Stanley & Cummings, 
2009). 
N-glycans are the most common and well understood, with an estimated 50%-90% 
of plasma proteins being N-glycosylated (Bieberich, 2014; Lu et al., 2011; National 
Research Council (US) Committee on Assessing the Importance and Impact of 
Glycomics and Glycosciences, 2012). In contrast to proteins, N-glycan biosynthesis is 
not directly template driven (Brooks, 2009). Instead, a repertoire of enzymes that create, 
degrade, or modify monosaccharide glycosidic bonds in the endoplasmic reticulum (ER) 
and the Golgi apparatus determine the final glycan structure (Rini, Esko, & Varki, 2009; 
Stanley, 2011; Taylor & Drickamer, 2011). In brief, a given oligosaccharide glycan 
precursor, made up of three glucose (Glc), nine mannose (Man), and two N-
acetylglucosamine (GlcNAc) monosaccharides (Glc3Man9GIcNAc2), is formed in the ER 
on a lipid dolichol phosphate (Dol-PP) (Rosnoblet et al., 2013; Yan & Lennarz, 2005). 
The oligosaccharide complex is transferred from the Dol-PP to the N-group of Asn on a 
given protein, catalysed by oligosaccharyltransferases (OSTs) (Figure 3.2) (Yan & 
Lennarz, 2005). Proteins having the conserved sequence asparagine [(Asn)-X-Serine 
(Ser)] or [Asn-X-Threonine (Thr)], where X is any amino acid except proline; for 
glycosylation within the lumen of the ER serve as acceptors (Smith, Ploegh, & Weissman, 
2011; Taylor & Drickamer, 2011). In the ER and following different folding states of the 
newly synthesised glycoprotein, the oligosaccharide precursor undergoes trimming by 
specific enzymes, known as glycosidases (Rosnoblet et al., 2013). This trimming signals 
that the glycoprotein is being correctly folded. It is then translocated to the cis portion of 
the Golgi apparatus for further trimming by glycosidases and elongation by 
glycosyltransferases into different structural types—all N-glycans maintaining the 
conserved common core G1cNAc2Man3 (Varki, 2009).  
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Additionally, other modifications, such as N-acetylglucosaminylation, 
fucosylation, sialylation, and galactosylation, occur in the medial to trans Golgi during 
maturation (Ohtsubo & Marth, 2006; Schwarz & Aebi, 2011). 
 
 
Figure 3.2 Mechanism of N-glycosylation. The process of N-glycosylation begins with the transfer of pre-
formed glycans by means of a lipid precursor in the ER. Oligosaccharide-dolichol precursor then binds to 
the asparagine residue of a nascent protein. The complex undergoes trimming and additional processing in 
the Golgi. Figure reproduced from http://www.thermofisher.com/au/en/home/life-science/protein-
biology/protein-biology-learning-center/protein-biology-resource-library/pierce-protein-methods/protein-
glycosylation.html. 
 
The three main structural types of N-glycans are oligomannose (or high-mannose), 
complex, and hybrid (Stanley & Cummings, 2009). The high-mannose type, consisting 
of Man5-9G1cNAc2, is formed after Glc and Man removal, and lacks additional 
monosaccharide units at the N-glycan periphery (Bieberich, 2014). Complex N-glycans 
have antennae attached to the core of the structure and can be further subcategorised into 
bi-antennary, tri-antennary, and tetra-antennary based on the degree of branching 
(Bieberich, 2014). The branching is formed by the addition of galactose (Gal) and sialic 
acid monosaccharides to the G1cNAc by galactosyltransferases and sialyltransferases, 
 26 
 
respectively (Stanley & Cummings, 2009; Taylor & Drickamer, 2011). Combined 
structural features from the high-mannose and complex types form the hybrid structural 
type of N-glycans (Stanley, 2011). Usually, the hybrid N-glycans have only Man residues 
on the α-1, 6-arm of the core, with one or two branches on the α-1, 3-arm (Figure 3.3). 
The complex and hybrid types predominantly have a fucose (Fuc) group attached either 
to a branch or the G1cNAc side chain, known as fucosylation or core fucosylation, 
respectively (Stanley & Cummings, 2009). 
 
 
Figure 3.3 Structural types of N-glycans. N-glycans have two core GlcNAcs; having F before the 
abbreviation represents a core fucose. The two main stereochemical types (orientation) of glycosidic bonds 
are “α” and “β”. The numbers indicate the ring position of the carbon on the saccharide (sugar) which gives 
rise to the glycosidic bond. For example, a biantennary structure with two GlcNAcs as α-1-2 linked, [3] G1 
and [6]G1 indicates that the galactose is on the antenna of the α-1-3 or a α-1-6 mannose. N-glycans can 
differentiate into bisecting, tri-antennary tetra-antennary (Stanley & Cummings, 2009). 
 
O-glycans are the second most common type of glycan. Unlike N-glycosylation, O- 
glycosylation is a spontaneous process, akin to tyrosine phosphorylation and occurring in 
the Golgi apparatus (Dias & Hart, 2007; Lefebvre et al., 2003). The O-glycosylation 
recognition site is currently unknown (Butkinaree, Park, & Hart, 2010; Christlet & 
Veluraja, 2001; Schachter, 2000); however, it is a sequential process that involves the 
attachment of O-linked GlcNAc (O-G1cNAc) to Ser or Thr residues by O-G1cNAc-
transferase (OGT). A series of enzymatic steps in the Golgi yields the eight O-glycan 
cores that are modified by sulfation, acetylation, and fucosylation to form branched 
structures (Figure 3.4) (Butkinaree et al., 2010). O-glycans are similar to N-glycans, as 
they contain branches extended by monosaccharide units (Alley & Novotny, 2013; Jensen 
et al., 2012). 
Glycans are able to interact with other molecules based on the structural elements 
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present. GAGs are unbranched polysaccharides which can exist either as part of a 
proteoglycan or as a free oligosaccharide (hyaluronan) (Fuster & Esko, 2005) (Figure 
3.4). GAGs attach to oxygen in Ser and Thr residues at the consensus sequence Ser-
Glycine (Gly)-X-Gly, where X is any amino acid (Varki, 2009). Proteoglycans, such as 
heparan sulfate and chondroitin sulfate, are synthesized via a different pathway; they are 
more sulfated than O-glycans, but with the same binding specificity. Hyaluronan, a 
distinct form of GAG, does not bind to lipids or proteins (Fuster & Esko, 2005; Ohtsubo 
& Marth, 2006) and is involved in cell signaling and tissue homeostasis. In rare cases, C-
glycosylation occurs where Man residues are bound to tryptophan (Trp) in the sequence 
Trp-X-X-Trp through a carbon-carbon bond, where X is any amino acid (Hofsteenge et 
al., 1994). 
Glycans can be involved in both homotypic and heterotypic interactions that form 
glycolipids (Ohtsubo & Marth, 2006). Glycolipids are also biosynthesized in the ER and 
the Golgi apparatus. Two types of glycolipids are known, namely glycosphingolipids and 
glycosylphosphatidylinositol (GPI)-anchors (Figure 3.4). Glycosphingolipids are 
amphipathic membrane-bound glycoconjugates (e.g., glycocalyx) or secreted molecules 
within the extracellular matrix, and are important mediators of cell motility and signaling 
events (Fuster & Esko, 2005). Glycosphingolipid biosynthesis begins with the addition 
of Glc to ceramide moieties in the ER. Further modification of the Glc-ceramide complex 
with other Glc residues yields the matured structure in the Golgi. GPI-anchors are formed 
when glycan chains are attached to phosphatidylinositol (Figure 3.4). GPI-anchors are 
biosynthesised in the ER and mature in the Golgi. In the Golgi, the GPI-anchor is either 
modified with phosphatidylethanolamine or GlcNAc molecules before they are 
complexed with a Gal or sialic acid. Final GPI-anchor structures are then translocated to 
the plasma membrane (Fuster & Esko, 2005; German et al., 2007).  
 
 
 28 
 
 
Figure 3.4 Different types of glycans in the cell. The diagram shows the different glycan types in the 
Golgi apparatus including N-glycans, O-glycans, two examples of proteoglycans (heparin sulphate and 
chondroitin), and membrane bound glycans such as glycocalyx, glycosphingolipids and GPI-anchors 
(Fuster & Esko, 2005). Abbreviations: glucose, Glu, Mannose-Man, N-acetylgalactosamine-GaINAc-, N-
acetylglucosamine-GIcNAc, fucose-Fuc, Glucuronic acid-GIcA, Sialic acid- Sia Xylose-Xyl. Diagram 
obtained from Golgi glycosylation, with permission from Cold Spring Habour publishers. 
 
 
N-glycans’ role in cellular processes has been extensively reviewed, including cell 
communication, signalling, adhesion, motility and host pathogen interactions (Brooks, 
2009; Helenius & Aebi, 2001; Jianguo Gu, 2012; Ohtsubo & Marth, 2006). N-glycans 
are stable over extended periods and therefore a change in their structure can be as a 
consequence of an environmental or pathophysiological condition (Gornik et al., 2009; 
Lu et al., 2011). Perhaps this is the reason why aberrant N-glycans are linked to several 
chronic diseases such as cancers (Arnold, Saldova, Hamid, & Rudd, 2008; Lauc et al., 
2013; Saldova, Arnold, & Rudd, 2011; Wang, 2013), hypertension (Wang et al., 2016), 
metabolic syndrome (MetS) (Lu et al., 2011; McLachlan et al., 2016), diabetes (Testa et 
al., 2015), systemic lupus erythematosus (SLE) (Vučković et al., 2015), rheumatoid 
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arthritis (Sebastian et al., 2016), Parkinson’s disease (Russell et al., 2017) and congenital 
disorders of glycosylation (CDG) (Grünewald, Matthijs, & Jaeken, 2002). Given the 
critical role of N-glycans in human physiology, high-throughput techniques and 
glycoinformatic tools that fine-tune structural determination and analyses are mandatory.  
Transfer of plasma/serum into 96 well 
plate
N-glycan release
Chemical release 
 Reductive and non-reductive β 
elimination
 Hydrazinolysis
Enzymatic release
 PN-Gase F & A
 Pronase
 N-endoglycosidase
N-glycan derivatization
Fluorescent labelling (Reductive 
animation)
2-aminobenzamide & 2-aminobenzoic acid
2,6-diaminopyridine (DAP)
1-aminopyrene-3, 6, 8-trisulfonic acid
2-aminonaphthalene trisulfonic acid (ANTS)
Analytical methods for N-glycan profiling
Electrophoretic methods
CZE
CE-LIF
MEKC
GE
Mass spectrometric methods
MALDI-TOF & SELDI-TOF
MALDI-MSI
FT-ICR-MS
Chip-based MS
LC-ESI-MS/MS
Chromatographic methods
HPLC, HILIC, UPLC,
Coupled HILIC-UPLC
HPAEC-PAD
GPC
GCC
Chemical methods
Permethylation
Solid phase esterification
Isotopic tags
Hydrazide coupling
Glycoinformatic tools 
 GlycoBase
 GlycoExtractor
 EUROCarbDB
 GlycomeDB
 GLYCOSCIENCE.de
 GlycoWorkBench
Structural assignments and normalisation of 
peaks
 
Figure 3.5 Schematic representation of N-glycan profiling. N-glycans can be released from proteins 
either by chemical or enzymatic approaches. N-glycans are then derivatised by chemical methods or by 
flourescent labelling. Different analytical approaches are then employed for charactisation and separation. 
Glycoinformatic tools are employed to aid experimental data storage, N-glycan structure annotation and 
interpretation into computer-readable formats that can be easily accessed by glycobiologists. 
 30 
 
3.4 Methods of N-glycan Release 
N-glycans exist as protein or lipid conjugates (Helenius & Aebi, 2001). Therefore, 
in order to analyse and determine their structural features, they are liberated from their 
bound proteins or lipids in a process termed deglycosylation (Hägglund et al., 2007). In 
the past, deglycosylation was a challenging task to accomplish but recent advances in 
deglycosylation methods have made it possible to release N-glycans with less difficulty. 
The choice of a particular method depends on the type of glycosylation, the composition 
and the amount of sample to be analysed (An et al., 2009; An et al., 2003). Generally, N-
glycans are released either by enzymatic or chemical means (Alley & Novotny, 2013; 
Hägglund et al., 2007; Merry & Astrautsova, 2003; Yang et al., 2016) (Figure 3.5). In 
the enzymatic approach, the enzyme mostly used is peptide-N-glycosidase (PNGase) F 
or N-glycanase, which cleaves N-glycans with efficiency (Hägglund et al., 2007; 
Krishnamoorthy & Mahal, 2009; Mechref, 2011). Here, N-glycans are first cleaved into 
their 1-amino forms followed by a deamination process that converts Asn to aspartic acid 
(Mechref, 2011). However, α-1, 3-linked fucose modified proteins are cleaved with 
PNGase A since it leaves the fucose group intact, thereby enabling the identification of 
complex and hybrid forms (Alley & Novotny, 2013; Hägglund et al., 2007; Mechref, 
2011). For glycoproteins that are resistant to both PNGase F and A, pronase, a collection 
of proteolytic enzymes from Streptomyces griseus, is preferred.  Pronase is only limited 
by its long incubation period, which is now known to be reduced after immobilising on 
solid supports (Alley & Novotny, 2013). By way of enhancing pronase activity, Song et 
al., (2014) recently described the threshing and trimming method (TaT) where 
glycoproteins in tissues were first digested (threshed) with pronase into small peptides 
and glycoamino acids. Glycoamino acids were then trimmed with N-bromosuccinamide 
(NBS) to yield free N-glycans. TaT has several advantages: 1) because the method 
requires mild conditions using non-toxic reagents, both labile groups and N-glycan 
reducing ends are unaffected; 2) compared to other chemical methods, it is less expensive, 
making it a robust alternative for large-scale deglycosylation (Song et al., 2014); and 3) 
like PNGase F, TaT is also effective at cleaving α-1-3-linked fucose modified proteins 
(Song et al., 2014).  
Other deglycosylation enzymes are peptide N-endoglycosidase (Endo) H, D, F1, 
F2 and F3 (Merry & Astrautsova, 2003). While Endo H and Endo F1 cleave both high 
mannose and hybrid N-glycans, Endo D is specific for complex N-glycans (Tarentino, 
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Trimble, & Plummer Jr, 1989). Endo F2 and Endo F3 cleave biantennary and triantennary 
N-glycans, respectively, while tetraantennary N-glycans are cleaved by Glycosamidases 
(Hägglund et al., 2007; Merry & Astrautsova, 2003). N-glycans are released chemically 
by β-elimination (reductive and non-reductive). Here, N-glycans are cleaved from 
glycoproteins in an alkaline medium that converts monosaccharides at the reducing end 
to alditol or GalNAc-ol (Cummings & Pierce, 2014; Roth, Yehezkel, & Khalaila, 2012). 
The non-reductive β-elimination method is sometimes preferred because the reducing end 
aldehyde is left intact for fluorescent labelling and the presence of strong reducing agents 
minimises peeling reactions, thus making it useful for large-scale N-glycan release 
(Cummings & Pierce, 2014). Another means of releasing N-glycans is by hydrazinolysis 
under high temperatures (95oC) (Brooks, 2009). Hydrazinolysis entails complexing 
glycoproteins with hydrazines immobilised on beads, resulting in the breakdown of the 
protein portion of a glycoprotein (Lazar, Lee, & Lazar, 2013). However, hydrazinolysis 
is rarely used for N-glycan release because the reagents are toxic and destroy important 
labile groups (Lazar et al., 2013; Song et al., 2014). Additionally, the reagents interfere 
with the bonds linking glycans to Asn, making it difficult to determine the glycosylation 
site. Furthermore, integrity of the N-glycans may be compromised since some reagents 
are incorporated into the terminus of their structure (Cummings & Pierce, 2014).       
Overall, the described deglycosylation methods are effective and once detached; N-
glycans are ready for characterization, purification and structural assignment.  
3.5 N-glycan Derivatising Methods 
Considering N-glycans are non-UV absorbing biomolecules, detection using 
various chromatographic methods is often difficult. At the same time, several hydroxylic 
side chains disallow sensitive detection using mass spectrometry (MS). Thus, they are 
usually derivatised to enhance detection (Ruhaak et al., 2010). Two main derivatisation 
approaches are generally employed; permethylation (chemical) and reductive animation. 
Selecting a particular approach is in part dependent on which analytical technique is to 
be used. While permethylation is often required prior to MS (Hung et al., 2012), reductive 
animation is usually preferred during chromatographic separations (Zaia, 2008) (Figure 
3.5).  
In 1960, Hakomori described permethylation, which involves replacing hydrogen 
groups bonded to oxygen and nitrogen in the presence of dimethylsulfoxide, methyliodide 
and sodium hydroxide (NaOH) to form hydrophobic derivatives (Hakomori, 1964). When 
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compared to native N-glycans, permethylated ones are more stable, less solvated and have 
higher surface activity, resulting in increased ion abundance in MS (Alley Jr & Novotny, 
2013; Walker, 2011; Zaia, 2008). In addition, permethylation allows uniform ionization 
and simultaneous measurement of both neutral and acidic N-glycans. Further, the ease of 
predicting fragments of permethylated N-glycans as compared to the native ones 
facilitates structural assignment (Ruhaak et al., 2011). Although traditional 
permethylation has improved MS analysis, peeling reactions and oxidative degradation 
due to excess NaOH arise, thereby reducing sensitivity (Furukawa, Fujitani, & Shinohara, 
2013; Kang et al., 2005). However, this has been ameliorated by solid-phase 
permethylation, which employs reduced NaOH in micro spin columns. This new method 
not only improves permethylation efficiency by limiting peeling reactions and removing 
excess reagents, but also enhances sample recovery (Desantos‐Garcia et al., 2011; Kang 
et al., 2005).  For complex N-glycans, permethylation is often not used because of 
possible loss of N-acetylneuraminic acid (sialic acid) groups; rather solid-phase 
esterification (SPE) is preferred. SPE stabilises the sialic acids by converting all 
carboxylic acid groups to methyl esters. When compared to underivatised N-glycans, 
esterified N-glycans significantly improve the overall MS sensitivity (Alley & Novotny, 
2013).  
Due to the lack of fluorescent moieties and chromophores on the free reducing ends 
of N-glycans, they are derivatised with specific labels or tags by reductive animation. 
Among the widely used labelling tags are 2-aminobenzamide (2-AB) (Bigge et al., 1995; 
Watanabe et al., 2000), 2-aminobenzoic acid (2-AA), 2-aminopyridine (2-AP), 2,6-
diaminopyridine (DAP)(Xia et al., 2005), 2-aminonaphthalene trisulfonic acid (ANTS) 
and 1-aminopyrene-3, 6, 8-trisulfonic acid (APTS) (Callewaert et al., 2004). The 
drawback with this method is the long period for sample analysis because of persistent 
salt contamination, which necessitates sample clean up. Other isotopic tags that are 
commonly used are [12C6] or [
13C6]-aniline, 
13CH3I (Gerardo et al., 2007) and hydrazide 
coupling (Walker et al., 2011). 
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Table 3.1. N-glycans as biomarkers for chronic diseases 
 
 
Type of disease Technique Sample Glycan biomarker Nature of 
change 
 
 
Breast cancer 
(Radka Saldova 
et al., 2014a) 
 
 
UPLC- 
HILIC, 
WAX-
HPLC 
 
 
Serum 
 Biantennary core fucosylation 
 Outer-arm fucosylation 
 Monosialylation 
 Sialylation 
 Branching 
 
↓ 
↑ 
↓ 
↑ 
↑ 
 
Gastric cancer  
(Liu et al., 
2013) 
 
DSA-FACE 
 
Serum 
 α-1,3-fucosylated triantennary 
 Core- α-1,6-fucosylated 
biantennary 
 Core- α-1,6-fucosylated bisecting 
biantennary 
 Bigalacto- core- α-1,6-fucosylated  
biantennary 
 
↑ 
 
↑ 
 
↑ 
 
↓ 
Hepatocellular 
carcinoma 
(Fang et al., 
2010) 
 
DSA-FACE 
 
Cell line 
 α-1, 3-fucosylated triantennary 
 
 Biantennary glycans 
↑ 
 
↑ 
Rheumatoid 
arthritis 
(Nakagawa et 
al., 2007) 
 
HPLC, MS 
 
Serum 
 
 Mono-galactosyl bi-antennary 
   N-glycans 
 
↑ 
 
 
Metabolic 
syndrome (Lu et 
al., 2011) 
 
HILIC, 
WAX-
HPLC 
 
 
 
Plasma 
 Core-fucosylation 
 Triantennary  
 Monosialylation 
 Diasialylation 
 Triasialylation 
 Biantennary 
 Trigalactosylation 
↓ 
↑ 
↓ 
↑ 
↑ 
↓ 
↑ 
 
 
 
Type II diabetes 
(Testa et al., 
2015) 
 
 
DSA-FACE 
 
 
 
Serum 
 Core- α-1,6-fucosylated 
biantennary 
 Digalactosylated biantennary  
 α-(1,6)-arm mono galactosylation 
 α-(1,3)-arm mono galactosylation 
↓ 
 
↑ 
↓ 
↓ 
Type II diabetes 
(Itoh et al., 
2007) 
HPLC, 
MALDI-
TOF 
 
Sera 
 
 α-1,6-fucosylation 
 
↑ 
Systemic lupus 
erythematosus 
(Vučković et al., 
Barrios, 2015) 
 
UPLC 
 
Plasma 
(IgG) 
 Galactosylation of IgG 
 Sialylation 
 Core fucose 
 Bisecting GlcNAc 
↓ 
↓ 
↓ 
↓ 
Rheumatoid 
arthritis 
(Nakagawa et 
al., 2007) 
 
LC-MS 
 
Serum 
(IgG) 
 Mono-galactosyl bi-antennary  
 Triantennary  
↓ 
 
↑ 
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3.6 N-glycosylation in Precision Medicine 
As stated earlier, a growing number of disorders have been directly linked to N-
glycosylation (Table 3.1). In addition, because genetic polymorphisms are distant from 
the phenotypes, and the sophisticated nature of gene-gene interactions, glycans may be 
“intermediate” and “dynamic” biomarkers for risk stratification, diagnosis, and prognosis 
of diseases (Dube & Bertozzi, 2005; Ohtsubo & Marth, 2006; Russell et al., 2017). 
3.6.1 N-glycosylation in Risk Stratification 
At least one third of deaths are potentially preventable by reducing the prevalence 
of known risk factors (e.g., smoking, poor, diet and inadequate physical activity) 
(Hulsegge et al., 2017; Lim et al., 2013; Mokdad et al., 2003). Assuming that precision 
medicine is to provide the right treatment to the right patient at the right time, precision 
public health can be viewed as providing the right intervention to the right population at 
the right time (Golubnitschaja, Kinkorova, & Costigliola, 2014). More accurate methods 
for measuring disease, pathogens, exposure, behaviours, and susceptibility could be used 
to stratify the risk of disease. However, no models are currently available that predict 
disease prevalence based on glycosylation biomarkers. 
3.6.2 N-glycosylation in Diagnosis 
Evidence that glycans are altered in many chronic diseases (Table 3.1) make it 
prudent to underscore the power of investigating and utilising N-glycans as disease 
biomarkers. N-glycans are present in serum and plasma, as well as other tissues and 
fluids, making them easily accessible (Gornik et al., 2009; Trbojevic-Akmacic, Vilaj, & 
Lauc, 2016). Characterization of glycan biomarkers relies on the precise identification of 
the connection between the glycan modification and the disease (Dube & Bertozzi, 2005; 
Lauc et al., 2016a). This knowledge may then be further applied to pharmacologic agents 
that could alleviate the clinical and subclinical symptoms of disease (Taniguchi & 
Kizuka, 2015). 
3.6.3 N-glycosylation in Cancer 
Glycans are involved in numerous fundamental molecular and cell biology 
processes in cancer cells including cell signaling and communication, tumor cell 
dissociation and invasion, cell–matrix interactions, tumor angiogenesis, immune 
modulation, and metastasis formation. Therefore, glycans may be utilised as potential 
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cancer biomarkers and provide a set of specific targets for therapeutic intervention (Alley 
et al., 2012; Fuster & Esko, 2005; Miyoshi, Moriwaki, & Nakagawa, 2008; Taniguchi & 
Kizuka, 2015; Wang, 2013). 
An analysis of 140 N-glycan peaks from the serum of 107 breast cancer patients 
and 62 healthy controls showed that the former had increased fucosylation and sialylation 
(Saldova et al., 2014). Based on the analysis of nine structural glycan peaks from 375 
people, comprising 247 gastric cancer (GC) patients and 128 healthy controls, there was 
a decrease in the level of core fucose residues and fucosyltransferase in GC patients 
compared with controls (Liu et al., 2013). An increase in branched α-1, 3-fucosylated 
triantennary and biantennary glycans in cell lines is associated with hepatocellular 
carcinoma (HCC) (Fang et al., 2010; Miyahara et al., 2015) and an increase in α-1, 6-
fucosylation of α-fetoprotein is also linked to HCC (Aoyagi, 1995). Levels of α-1, 6-
fucosyltransferase are higher in human ovarian serous adenocarcinomas, liver cirrhosis, 
and hepatomas compared with controls (Miyoshi et al., 1999). Recently, Ren et al., (2016) 
performed for the first time a large-scale, multi-institute study to assess the quantitative 
changes of IgG glycosylation in 12 types of cancers and non-malignant controls, and 
found that the Gal-ratio of IgG could distinguish these 12 types of cancers from non-
cancer controls, as well as early-stage cancers from non-cancer controls.  
3.6.4 N-glycosylation in Inflammatory and Autoimmune Diseases 
The N-glycosylation of the immunoglobulin G (IgG) Fc domain mediates the 
effector function of IgG, and hence IgG glycosylation disorders are implicated in 
inflammatory and autoimmune diseases (Lauc et al., 2013; Vučković et al., 2015). A 
study of 15 rhematoid arthritis (RA) patients and 18 matched controls showed a decrease 
in monogalactosyl bi-antennary glycans and an increase in triantennary serum glycans of 
IgG in RA (Itoh et al., 2007; Nakagawa et al., 2007). Analysis of 251 SLE patients and 
252 healthy controls in Latin America as well as replication cohorts from Trinidad (108 
cases and 193 controls) and China (107 cases and 200 controls) has shown that there is a 
decrease in sialylation and galactosylation of plasma IgG among systemic lupus 
erythematosus (SLE) patients. Similarly, these patients have a decrease of core-fucose 
and increased bisecting plasma GIcNAc in SLE (Vučković et al., 2015). An investigation 
of plasma IgG glycome composition in patients with ulcerative colitis (UC) (n = 507), 
Crohn's disease (CD) (n = 287), and controls (n = 320) showed that both UC and CD were 
associated with significantly decreased IgG galactosylation and a significant decrease in 
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the proportion of sialylated structures in CD (Trbojevic-Akmačić et al., 2015). One study 
explored the association between IgG glycans and renal function in 3274 individuals from 
the Twins UK registry, and found 14 glycan traits were associated with renal function in 
the discovery sample and remained significant after validation (Barrios et al., 2016). 
Recently, in a clinical-based case-control study comprising 128 Han Chinese patients 
suffering from chronic RA and 195 gender- and age-matched controls, it was found that 
IgG glycans might have potential as a putative biomarker for RA in the Han Chinese 
population, and differs in RA active and remission states (Sebastian et al., 2016). 
3.6.5 N-glycosylation in Metabolic Diseases 
It has been shown that serum protein α-1, 6-fucosylation was increased in 16 
diabetic mice (db/db) compared with controls (Itoh et al., 2007). The study further 
demonstrated that α-1, 6-fucosylated biantennary and bisecting N-acetylglucosamine 
serum glycans were increased in 20 T2DM patients (Itoh et al., 2007). Similarly, 10 
analysed N-glycan peaks in 562 T2DM patients and 599 healthy controls, demonstrated 
that T2DM patients had significant increases in fucosylation and galactosylation of serum 
proteins (Testa et al., 2015). Previous investigation of the association between core 
fucosylated plasma glycans and MetS in 212 Chinese Han and 520 Croatian individuals, 
found 10 N-glycan structures (monosialylated, FUC-C, trisialylated, trigalactosylated 
(G3), digalactosylated (G2), disialylated (S2), triantennary (TRIA), biantennary 
agalactosylated (A2), biantennary (BA), and agalactosylated (G0) N-glycans) tended to 
be associated with MetS components, body mass index (BMI), systolic blood pressure 
(SBP), diastolic blood pressure (DBP), and fasting plasma glucose (FPG) levels (Lu et 
al., 2011). The association between IgG glycosylation and hypertension in a multiple 
ethnic cross-sectional study (Chinese Han, Croatian, and Scottish ethnicity) was recently 
described (Wang et al., 2016). 
3.6.6 N-glycosylation in Prognosis 
Acute systemic inflammation is a part of many pathological events and a patient’s 
inflammatory response often determines the outcome of a disease. Given that N-
glycosylation can meditate the inflammatory effect of IgG, N-glycan biomarkers may be 
crucial for disease prognosis. One study reported that a rapid increase in galactosylated 
glycoforms was associated with nearly double the mortality risk measured by 
EuroSCORE II following cardiac surgery (Novokmet et al., 2014). Another study 
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reported that serum IgG Fc glycosylation in Guillain-Barré syndrome (GBS) is related to 
disease severity and clinical recovery after intravenous immunoglobulin therapy and may 
help to develop new measures to monitor the efficacy of treatment (Fokkink et al., 2014). 
A separate study reported that treatment response in Kawasaki disease is associated with 
sialylation levels of endogenous, but not therapeutic, intravenous IgG (Ogata et al., 2013).  
3.7 Congenital Disorders of Glycosylation 
Although glycosylation is not a direct template driven biosynthetic process, it is 
regulated by at least 1% of genes, termed “glyco-genes” (Janković, 2011). A high 
proportion of these genes encode specific enzymes that promote the glycosylation process 
(Eklund & Freeze, 2006). Alterations, such as a point mutation, can change the orientation 
of genes at glycosylation sites, thereby preventing the glycosylation of the given 
polypeptide chains and affecting glycoprotein capabilities (Jaeken & van den Heuvel, 
2014). It is, therefore, not a surprise that an alteration in the genetic and the molecular 
machinery can lead to human diseases, generally termed congenital disorders of 
glycosylation (CDGs) (Jaeken, 2011; Jaeken & Matthijs, 2007; Rosnoblet et al., 2013). 
CDGs are genetic or inherited disorders due to defects in the glycosylation process 
that form glycoproteins and glycolipids (Grünewald et al., 2002; Heywood et al., 2013). 
Diverse enzymes, including glycosyltransferases and glycosidases, catalyse the 
biosynthesis of glycan structures, and mutations in the genes encoding for these enzymes 
lead to CDGs (Helander, Bergström, & Freeze, 2004). Presently, there are two main types 
of CDGs. CDG type I arises from mutations that affect the assembly of N-glycans to 
polypeptide chains in the cytosol of the ER (Cummings & Pierce, 2009). CDG type II 
arises from mutations that lead to N-glycan processing defects in the Golgi apparatus 
(Barone, Sturiale, & Garozzo, 2009; Cummings & Pierce, 2009). Other subgroups also 
exist based on the given gene mutation. 
The first and most widely used method is to detect under-glycosylated serum 
transferrin (Tf) by isoelectric focusing (IEF) electrophoresis (Freeze, 2006; Grünewald et 
al., 2002). Tf has two N-glycosylation sites with branched glycans attached to Asn 432 
and Asn 630 (Freeze, 2006; Guillard et al., 2011). Glycosylation defects modify the 
pattern of sialylation to these sites, leading to a decrease in tetrasilo-Tf, an increase in 
disialo or asialo-Tf in CDG type I, and an increase in monosialo and trisialo-Tf in CDG 
type II (Barone et al., 2009; Guillard et al., 2011; Jaeken, 2011). 
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Over the years, several analytical methods have emerged for diagnosing and identifying CDGs. The various diagnostic approaches can be 
classified into glycan structure analysis, enzymatic assays, lipid-linked oligosaccharide analysis, and molecular diagnostics (Grünewald et al., 2002). 
 
Table 3.2 Congenital disorders of glycosylation 
  
 
CDG-type         Gene                                 Enzyme                                                     Reaction                        Symptoms                Diagnosis 
 
CDG-1a               PMM2                Phosphomannomutase                                       Man-6-Phosphate                
                                            
                                                    (Hansen, Frank, & Casanova, 1997)                    Man-1-Phosphate    
                                        
CDG-Ib                MPI                  Phosphomannose isomerase                                  Fructose-6-P        
                                         
                                                           (Niehues et al., 1998)                                   Man-6-phosphate   
                                                                          
CDG-Id               ALG3                   Mannosyltransferase VI                                Man5GlcNAc2-PP-Dol 
                                                  
                                                       (Cummings & Pierce, 2009)                          Man6GlcNAc2-PP-Dol 
 
CDG-Ih               ALG8                 Glucosyltransferase 2                               Glc1Man9GlcNAc2-PP-Dol 
                                                      (Haeuptle & Hennet, 2009)                     Glc2Man9Glc1NAc2-PP-Dol  
CDG-Ik               ALG1                 Mannosyltransferase                                        GlcNAc2-PP-Dol 
                                                   
                                                    (Cummings & Pierce, 2009)                          Man1GlcNAc2-PP-Dol 
 
CDG-In              RFT1                   RFT1 protein                                              Man5GlcNAc2-PP-Dol 
 
                                                     (Haeuptle & Hennet, 2009)                                         ER             
 
CDG-IL            DIBD1             Glycosyltransferase                                           Man5GlcNAc2-PP-Dol 
 
                                                    (Haeuptle & Hennet, 2009)                                Man5GlcNAc2-PP-Dol 
 
CDG-IIa           MGAT2                GlcNAc transferase II                                  GlcNAc-Man3-GlcNAc-Protein 
 
                                                        (Eklund & Freeze, 2006)                          GlcNAc2-Man3-protein 
 
CDG-IIb   GCS1                          α-glycosidase                                               Glc3Man9GlcNA2-protein    
           
                                                     (De Praeter et al., 2000)                              Glc2Man9GlcNA2-protein 
Ataxia, inverted nipples, Psycho-motor retardation 
(Grünewald et al., 2002) 
 
Diarrhoea, vomiting seizures,hypoglycae- mia 
(Grünewald et al., 2002; Haeuptle & Hennet, 2009) 
 
Coaguloparthy, strabism, seizure 
 
 
Dysmorphic features, 
Cardiorespiratory problems,  
Hypotonia 
 
Psychomotor retardation, hypogonadism (Supraha 
Goreta, Dabelic, & Dumic, 2012) 
 
 
Seizures, hypotonia, 
Dysmorphic features(Haeuptle & Hennet, 2009) 
 
 
Sensorineural deafness, cerebellar hypoplasia 
 
 
Muscular hypotonia 
facial dysmorphism 
 
 
 
Seizures, muscular hypotonia, recurrent 
Edema (Grünewald et al., 2002) 
Transferrin, hypoglycosylation Test, 
enzymatic assays (Eklund & Freeze, 2006) 
 
Enzymatic assays (Eklund & Freeze, 2006) 
 
 
 
Mutational analysis (Eklund & Freeze, 2006) 
 
 
Genetic analysis 
 
 
 
Enzymatic assays and genetic analysis 
(Eklund & Freeze, 2006) 
 
 
Mutational analysis  
 
 
 
Genetic analysis (Eklund & Freeze, 2006) 
 
 
 
Enzymatic assays 
Lipid linked oligosaccharide analysis 
(Eklund & Freeze, 2006) 
 
Enzymatic assays   
 
 
 39 
 
3.8 Analytical Techniques in Glycomics 
Since glycomics became a recognised discipline, developing techniques for 
complete N-glycan analysis has been challenging, mainly because of the complex nature 
of N-glycans. In fact, over 200 glycosyltransferases are involved in their biosynthesis, 
with synthesized forms having different glycosylic linkages, varied anomeric orientations 
and different degrees of branching (Hizal et al., 2014; Stanley & Cummings, 2009). 
Consequently, unravelling the structural architecture of these complex biomolecules to 
appreciate their role in pathophysiology is difficult unless highly sensitive and robust 
analytical techniques are employed. Generally, N-glycans are analysed by MS (Bindila 
& Peter‐Katalinić, 2009), liquid chromatography (LC) and capillary electrophoresis (CE) 
(Raman et al., 2005). While this review will not provide a detailed overview of these 
techniques, a concise introduction on the mode of operation will be necessary. 
3.8.1 Mass Spectrometry 
Mass spectrometers operate by the formation of charged ions and separate ions 
according to their mass-to-charge ratio (m/z). Two main ionisation modes are currently 
known: matrix-assisted laser desorption ionization (MALDI) and electrospray ionization 
(ESI) (Wuhrer, 2013). Briefly, MALDI involves dissolving an analyte in a solution of 
organic molecules (matrix) which is dried to form solid analyte matrix crystals. Matrix 
crystals are heated and irradiated by laser pulses causing sublimation into a gaseous 
phase. Although the exact origin of the ions is not completely clear, it is suggested that 
ions for MALDI are generated during proton transfer and photon-atomic/molecular 
interaction (Hoffmann & Stroobant, 2001). Gaseous ions then migrate via an electrostatic 
field to the analyser. The peculiarity of MALDI is its ability to ionise and desorb analytes 
in a single run allowing an in depth detection even at the femtomole level (Hoffmann & 
Stroobant, 2001).  
ESI, however, involves the application of a high voltage or electric field to a liquid-
analyte mixture via a capillary tube, forming charged droplets. The liquid droplets 
undergo repeated evaporation as they pass through an inert gas-heated capillary tube. As 
solvent evaporation is continuous, offspring droplets are formed which increase with 
increasing electric field intensity, resulting in multiply charged ions that are then 
analysed. A unique feature of ESI is that the multiply charged ions from large molecular 
weight molecules are easily detected even on analysers with poor mass limits, making it 
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very useful for large-scale glycomics (Hoffmann & Stroobant, 2001; Zaia, 2008). Overall, 
both modes can ionise N-glycans but regardless of which mode is chosen, derivatisation 
is critical for detection, identification and resolution of the MS spectra (Harvey, 2011; 
Weiskopf, Vouros, & Harvey, 1998).  
A typical example of MS method that has become popular in glycomics is the 
MALDI-Time of Flight MS (MALDI-TOF-MS). This technique has its strengths and 
weaknesses. The main advantages include: 1) a low cost per sample because of high-
throughput per instrument; 2) the ability to perform site-specific glycosylation analysis; 
3) high sensitivity; and 4) adequate structural elucidation. Some of its main disadvantages 
are: 1) a loss of sialic acid linkages; 2) unable to achieve isomer separation; and 3) it is 
not reliable for effective quantification (Huffman et al., 2014).  Nonetheless, successful 
application of MALDI-TOF-MS in population-based glycomics is recognised. A typical 
illustration was when Zuzana and colleagues (2007) examined N-glycan variations in 10 
healthy individuals and 24 prostate cancer patients. In brief, serum samples were 
alkylated and reduced in the presence of ammonium bicarbonate and dithiothreitol 
(DTT). Aided by PNGase F, serum glycoproteins were deglycosylated and released N-
glycans were then extracted by loading onto activated charcoal micro columns in the 
presence of acetonitrile and trifluroacetic acid (TFA). Eluted N-glycans were derivatised 
by solid-phase permethylation using NaOH, methyl iodide and dimethylsulfoxide 
(DMSO). Aliquots of the permethylated N-glycans were then loaded onto a MALDI-plate 
and at 355 nm wavelength, N-glycan peaks (spectra) of both healthy and prostate cancer 
patients were analysed (Figure 3.6). Employing this technique, the authors identified 
over 50 N-glycan structures of which 12 structures differed significantly between healthy 
and prostate cancer patients (Zuzana et al., 2007). 
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Figure 3.6 MALDI spectra of N-glycans in prostate cancer and controls. MALDI spectra of N-glycans 
in prostate cancer and controls. Circles, mannose; triangles fucose; squares Nacetylglucosamine; rhomboid 
N-acetylneuraminic acid. MALDI, matrix-assisted laser desorption–ionisation. Figure reproduced with 
permission from Zuzana et al., 2007. 
In recent years, MALDI-MS Imaging (MALDI-MSI) has been developed to 
spatially resolve N-glycan structures and provide molecular distribution or maps of the 
relative amount of each N-glycan trait in a given tissue section (Powers et al., 2013). 
MALDI-MSI has several advantages: 1) multiple N-glycan structures can be determined 
in a single run, allowing complete profiling of all analytes present within a tissue; 2) a 
combination of MSI with other quantitative MS provides an unprecedented profile of 
tissue specific N-glycan variations (Eshghi et al., 2014); and 3) N-glycans which are 
visualised in the form of images, allow the sensitive detection of the morphological 
changes of structures in each tissue section. MALDI-MSI was employed for imaging N-
glycans in formalin-fixed paraffin embedded (FFPE) tissues of ovarian cancer patients 
(Everest-Dass et al., 2016). Shortly thereafter, tissues from ovarian cancer patients were 
dipped in a formalin solution. After rinsing in deionised water, the tissues were processed 
in xylene, ethanol and paraffin to form paraffin complexed tissue blocks. Following 
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further washing with ethanol and incubation with NH4HCO3, N-glycans within tissues 
were released using PNGase F. Released N-glycans were then purified on porous 
graphitised carbon and cation exchange columns and analysed using porous gel 
chromatography (PGC)-LC-ESI-MS/MS while MSI was used for visualising the spatial 
distribution of N-glycans in ovarian cancer tissues (Everest-Dass et al., 2016). It was 
observed that high mannose and hybrid/complex N-glycans were abundant in the tumour 
tissues and the stroma respectively (Figure 3.7). 
 
Figure 3.7. N-glycan in formalin-fixed paraffin-embedded tissue sections analysed using MSI. (a) 
Adipose and necrotic tissues, which predominately contained a pauci mannose structure and an 
agalactosylated structure (m/z 1339.4. Images in (b) depict tumour areas in the tissues, which predominately 
contained agalactosylated N-glycans. Images in (c) depict tumour areas in the tissues, which were mostly 
characterised by high-mannose N-glycans with m/z ranging from 1257.4 to 1905.6. In the stroma (c), were 
high levels of complex/hybrid N-glycans with m/z ranging from 1501.5 to 2174.7, while sialylated N-
glycans were mostly found in (d) with m/z from 1954.6 to 2391.8. MSI, mass spectrometry imaging. Figure 
reproduced with permission from Everest-Dass et al., 2016.
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Apart from MALDI-MSI, other highly sensitive MS equipment are tandem MS, chip-
based MS (Bindila & Peter‐Katalinić, 2009), Fourier transform ion cyclotron MS (FT-
ICR-MS) (Park & Lebrilla, 2005) and surface-enhanced laser desorption/ionisation 
(SELDI) (Cummings & Pierce, 2009; Lebrecht et al., 2009). While N-glycan analysis 
using MS has been remarkable, it is limited by its inability to provide detailed information 
of structural isomers. This has necessitated the coupling of MS to other chromatographic 
techniques for in-depth structural characterisation (Wuhrer, 2013).   
3.8.3 Liquid Chromatography 
Rapid advances in technology have made it possible to resolve N-glycan structures 
using chromatographic techniques. While recognising different separation methods such 
as gel permeation chromatography (GPC) and graphitised carbon chromatography 
(GCC), this review will, focus on high-performance liquid chromatography (HPLC) 
based methods. HPLC separates complex N-glycans by the adsorptive interaction of N-
glycans in solution (mobile phase) with a stationary phase. Solvents mostly used as 
mobile phases include ethanol, methanol and acetonitrile, while amides, silanols/silica 
gels/particles and diols are often used as stationary phases (Novotny, Alley, & Mann, 
2013; Zauner, Deelder, & Wuhrer, 2011). In HPLC, N-glycans in solution are first loaded 
and after gradually altering the conditions of the mobile phase, N-glycans are eluted based 
on their retention times on the column, generating peaks (chromatogram) which are 
observed on a detector (Rudd et al., 2001). Constituent N-glycan monosaccharides are 
often expressed as glucose units (GU) and peaks are quantified by calculating the area 
under curve and dividing by the sum of the individual peaks (Royle et al., 2008).  
Depending on the composition of the mobile and stationary phases, HPLC can be 
either a normal phase (NP) or a reverse-phase (RP). While NP-HPLC employs a polar 
stationary phase and a non-polar mobile phase, RP-HPLC is the direct opposite. Although 
HPLC has been useful for separating N-glycans, it is limited by possible co-elution and 
hence, requires several purification steps, which leads to long sample runs and high 
solvent consumption. For this reason, an automated and highly sensitive form of HPLC 
known as Hydrophilic Interaction Liquid Chromatography (HILIC) has been developed 
(Zauner et al., 2011). As an advanced form of HPLC, HILIC employs a partition 
mechanism to separate N-glycans according to their charge, size and oligosaccharide 
composition. Very often, N-glycans for HILIC separation are derivitised with 2-AB to 
enhance UV detection. Since these labels confer some hydrophobic properties, derivitised 
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N-glycans have weak interaction with the stationary phase, causing them to be eluted first 
(Zauner et al., 2011). Structural assignment of the eluted N-glycans, expressed as GU are 
then performed by comparing to reference databases which are discussed later in this 
review (Royle et al., 2008). HILIC has several advantages over HPLC. Some of these are; 
a single and efficient separation of both charged (sialylated) and uncharged/ highly polar 
(OH) N-glycans, full isometric separation and high-resolution potential (Novotny et al., 
2013).  
In recent years, HPLC-HILIC has been applied to identifying biomarkers for 
chronic diseases. For example, Lu et al., (2011) investigated the correlation between 
plasma N-glycan profiles and metabolic syndrome (MetS) among 212 Chinese Han and 
520 Croatian individuals. Briefly, N-glycans were released from 5 µl of plasma in a 
microplate using PNGase F and fluorescently labelled with 2-AB. This was followed by 
exoglycosidase digestion with Arthrobacter ureafaciens sialidase. Using a TSK gel 
Amide-80 5-μm (250 x 4.6 mm) column, formic acid and ammonia buffer, with 
acetonitrile as the organic solvent, N-glycans were separated on HPLC-HILIC. Weak 
anion exchange (WAX)-HPLC was used to separate complex N-glycans based on the 
number of sialic acid groups attached. Using this technique, it was possible to assign 16 
N-glycan peaks (Figure 3.8) of which 9 significantly correlated with established MetS 
biomarkers including systolic blood pressure, diastolic blood pressure, body mass index 
and fasting blood sugar (Lu et al., 2011).Similarly, McLachlan et al., ( 2016) employed 
the HPLC-HILIC technique to investigate the association between plasma N-glycans and 
MetS in a large Orcadian population comprising 2,039 individuals. This study identified 
21 N-glycan traits that were altered in MetS (McLachlan et al., 2016). 
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Figure 3.8. Plasma N-glycome Enabled by HPLC-HILIC. Thirty-three plasma N-glycan peaks from 
MetS in Chinese Han and Croatian populations were categorised into 16 groups. Structural assignment of 
each N-glycan peak was determined after comparing with a reference database. HILIC, hydrophilic 
interaction liquid chromatography; HPLC, high-performance liquid chromatography; MetS, metabolic 
syndrome. Figure reproduced with permission from Lu et al., 2011. 
 
Progressing from HPLC, ultra-performance liquid chromatography (UPLC) has 
been designed, allowing shorter analytic runs, less solvent consumption and improved 
resolution (Saldova et al., 2014). Like HPLC-HILIC, UPLC has been employed for 
studying N-glycan structures on a large scale (Figure 3.9). An example of such a study 
is by Saldova et al., (2014), who examined N-glycan profiles in the serum of 62 breast 
cancer patients and 107 healthy controls. Briefly, N-glycans were released from the serum 
using PNGase F after which they were fluorescently labelled with 2-AB. Following 
several washing steps, N-glycans were separated on UPLC using 1.7 BEH Glycan in a 
2.1 × 150 mm column.  WAX-HPLC was then performed to separate the N-glycans based 
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on their sialic acid attachments and confirmed by exoglycosidase digestions. Through this 
technique, over 140 N-glycans were assigned which are potential biomarkers for breast 
cancer (Saldova et al., 2014). 
 
 
Figure 3.9 N-glycosylation analysis by UPLC-HILIC  
Glycoproteins are immobilised on 96 well plates, denatured with sodium dodecyl sulfate (SDS), and 
washed. N-glycans are freed with PNGase F and incubated at 37oC. After elution, N-glycans are labelled 
with 2-aminobenzamine (2-AB) and followed by a series of washing and elution steps. N-glycans are 
separated by hydrophilic interaction chromatography on a Waters Acquity ultra performance liquid 
chromatography (UPLC) instrument (Waters Corporation, Milford, MA, USA). Structural assignments are 
performed by reference database matching. Figure is modified from Doherty et al., 2012. 
Similarly, Krištić et al., (2014) used UPLC to analyse immunoglobin G (IgG) in the 
plasma of 5,117 individuals from four European populations and observed major IgG 
changes such as fucosylation, bisecting G1NAc and sialylation that correlated with age. 
In particular, after analysing 24 IgG glycan peaks from the chromatogram (Figure 3.10), 
it was concluded that nongalactosylation was positively associated with age while 
digalactosylation decreased with age. These findings therefore show that glycosylation 
changes in IgG can be an important predictor of human aging (Krištić et al., 2014). Other 
scientists who have employed the UPLC technique for N-glycan analysis include Yu et 
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al., 2016; Wang et al., 2016 and Sebastian et al., 2016). Although not presently well 
known, another innovative technique that will soon flood the glycomic field is UPLC-
MS (e.g. UPLC-QTof). This technique allows the detection of multiple features in a given 
sample and exploits the advantages of MS for a better MS/MS glycan fragmentation and 
perfect mass confirmation of low-level peaks (Dunn et al., 2011). 
 
 
Figure 3.10. IgG glycosylation profiles using UPLC. Twenty-four N-glycan peaks were generated on the 
UPLC chromatogram. UPLC, ultra-performance liquid chromatography. Figure reproduced from Kristic´ 
et al. 2014.
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3.8.3 Capillary Electrophoresis 
Capillary electrophoresis (CE), since its emergence in the past few years, has been 
considered one of the most robust techniques for analysing N-glycans (Mechref, 2011; 
Rowena & Terabe, 2005). In principle, CE separates charged ions in solution in a narrow 
separating capillary tube. This capillary tube is dipped in two buffer-containing reservoirs 
connected to a high voltage source. When the analyte is introduced at the inlet of the 
reservoir, a voltage is applied generating an electric field, which causes the analyte to 
migrate. Based on their mass-to-charge ratios, the analytes are distinctly separated on the 
detector while generating an electropherogram on the data acquisition device (Altria, 
1996; Ewing, 1989). 
CE instrumentation is simple yet capable of distinguishing structural isomers which 
otherwise are not easily separated using MS (Mechref, 2011). Additionally, it is fast, 
efficient and requires only a small sample volume for analysis, making it an effective tool 
in situations where there is limited sample quantity (Zhao et al., 2012). In contrast to other 
analytical techniques, CE separation can be achieved under mild conditions, with low salt 
concentrations thereby protecting the integrity of the analyte (Rowena & Terabe, 2005). 
However, comprehensive and detailed information of the N-glycan structure can be 
obtained when CE is coupled to other analytical techniques such as laser-induced 
florescence (LIF). Similar to the other described techniques, CE-LIF will require 
derivatisation with fluorescent tags for sensitive detection. Among the most commonly, 
used tags are p-amino benzoic acid (p-ABA), 7-amino-1, 3-naphthalene disulfonic acid 
(ANDSA) and 2-aminonaphthalene-1-sulfonic acid (ANS). The main drawback of CE is 
that it is unable to perform site-specific glycosylation analysis (Huffman et al., 2014). 
Varadl et al., 2013 who profiled N-glycans of haptoglobin in pneumonia, chronic 
obstructive pulmonary disease (COPD) and lung cancer, described a clinical application 
of this technique. Briefly, plasma samples were washed with a binding buffer and after 
incubation; samples were centrifuged to separate the bound haptoglobin from the 
unbound material. The bound haptoglobin was then loaded onto a column containing a 
specific haptoglobin monoclonal antibody. Following several washing steps with 
phosphate buffered saline (PBS), haptoglobin was eluted and purified. N-glycans in 
haptoglobin were released using PNGase F and fluorescently labelled with APTS. Sialic 
acids on the complex N-glycans were then digested using exoglycosidase sialidase and 
the resultant profiles analysed on CE-LIF (Figure 3.11). As shown by this technique, 
there was an increase in α-1, 6-triantennary glycans in all patient groups compared to 
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controls. Additionally, when compared to COPD, lung cancer patients showed increased 
core and arm fucosylated tetraantennary N-glycans (Varadl, 2013).  
Similarly, by applying the CE-LIF technique, Schwedler and colleagues (2014) 
were able to identify 34 and 32 N-glycan isomers in the serum of epithelial ovarian cancer 
(EOC) patients and healthy patients respectively. They found that compared to healthy 
patients, core fucosylated tetraantennary N-glycans were higher in EOC, while 
diantennary and high mannose N-glycans decreased (Schwedler, 2014). 
Other types of CE-based techniques often employed for N-glycan analysis are capillary 
zone electrophoresis (CZE), and micellar electrokinetic chromatography (MEKC). 
 
 
 
Figure 3.11 N-glycan profiles of plasma haptoglobin in pneumonia, lung cancer, COPD, and controls. 
Different exoglycosidases such as sialidase, fucosidase, hexosaminidase, and galactosidase were used to 
digest haptoglobin and profiled using CE-LIF. CE, capillary electrophoresis; COPD, chronic obstructive 
pulmonary disease. Figure reproduced with permission from Varadl et al., (2013). 
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Despite the advancement of analytical and deglycosylation techniques, the relative 
complexities of glycan structures cannot be fully elucidated with these techniques alone. 
Adequate and comprehensive N-glycan databases are needed to aid experimental data 
storage, N-glycan structure annotation and interpretation into computer-readable formats 
that can be easily accessed by glycobiologists. 
3.9 Glycoinformatics Tools 
When compared to genomics and proteomics where there are large pools of 
databases, comparable databases for glycomics are still in the early stages (Hayes et al., 
2011; Krishnamoorthy & Mahal, 2009; Lazar et al., 2013; Raman et al., 2005; Von Der 
Lieth et al., 2004; Turnbull & Field, 2007). Notwithstanding this, a large pool of 
glycoinformatic databases containing a repertoire of N-glycan structures have been 
developed (Artemenko, Campbell, & Rudd, 2010; Campbell et al., 2008; Hayes et al., 
2011; Von Der Lieth et al., 2011). Many of these databases are not well known due to 
inadequate resources, website inaccessibility and lack of public awareness (Hizal et al., 
2014). While this review will not fully cover all the N-glycan databases known, it will 
highlight some of them.  
The first attempt to set up glycan databases was in the early 1990s when the 
Complex Carbohydrate Structure Database (CCSD), often called the CarbBank, was 
established by the Complex Carbohydrate Research Centre at the University of Georgia 
(Doubet & Albersheim, 1992; Frank & Schloissnig, 2010; Lütteke et al., 2006). They 
created a catalogue of 9,200 carbohydrate sequences, which were pooled from over 2500 
publications during the early-1990s (Doubet & Albersheim, 1992). Lack of funding 
unfortunately led to this group discontinuing their efforts; however, their pioneering work 
led to the development of all the modern databases for glycomics research (Frank & 
Schloissnig, 2010; Von Der Lieth et al., 2011). 
3.9.1 EUROCarbDB  
The EUROCarbDB is a web-based, open access resource, which contains a cluster 
of N-glycan profile data from the HPLC and MS platforms (Campbell et al., 2008; Frank 
& Schloissnig, 2010). It also has unique features for storing curated and experimental 
data, and tools for visualising N-glycan structures (Von der Lieth et al., 2011). For 
example, it is possible to completely observe N-glycan structures, including their 
anomeric orientation, stereoisomers, and the type of monosaccharide linkages because of 
the embedded GlycanBuilder tool designed for an intuitive graphical visualisation 
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(Ceroni, 2007; Von Der Lieth et al., 2011). Importantly, it is possible to incorporate and 
integrate other databases in the EUROCarbDB platform to promote data exchange and 
accessibility. Given the structural diversity of N-glycans, uniform annotation of 
monosaccharides is challenging. However, in EUROCarbDB there is an embedded 
GlycoCT and MonosaccharideDB, which uses a controlled vocabulary for annotating 
constituent monosaccharides with unified names that are easily translated to computer-
readable formats (Ceroni, 2007; Aoki-Kinoshita, 2008; Frank & Schloissnig, 2010).  
3.9.2 GlycoBase 
GlycoBase is an open access resource containing N-glycan data for classifying and 
assigning N-glycan structures from the HPLC, UPLC and CE platforms (Hizal et al., 
2014; Saldova et al., 2014; Stöckmann et al., 2013). It is a repository of over 350 2-AB 
labelled N-linked structures in GU, and provides information of N-glycan positions and 
their exoglycosidase digest (Campbell et al., 2008). Likewise, with GlycoBase, it is also 
possible to visualise constituent monosaccharides and their linkage orientation (Campbell 
et al., 2008). Advancing GlycoBase is the data matching automation software, autoGU 
that assigns N-glycan peaks from HPLC and provides information of their exoglycosidase 
products (Artemenko et al., 2010; Campbell et al., 2008). While the GlycoBase software 
has improved glycomics research, the cumbersome task of manually exporting sample 
sets to other file formats and the likelihood of data integration errors limits its use 
(Artemenko et al., 2010). This appears to be overcome by the GlycoExtractor database 
(Artemenko et al., 2010). 
3.9.3 GlycoExtractor  
GlycoExtractor is another web-based resource for analysing spectra from HPLC, 
HILIC and MS platforms (Artemenko et al., 2010; Saldova et al., 2011; Saldova et al., 
2014). In GlycoExtractor, samples are assigned based on their peak number and the 
experimental date, and exports desired file formats to other platforms such as 
EUROCarbDB for detailed structural assignments (Artemenko et al., 2010; Hizal et al., 
2014). Unlike the GlycoBase, data extraction and exporting in GlycoExtractor is 
automated. For example, Artemenko et al., has shown that exporting data from 100 
profiles into XML or JSON formats, which manually would have taken 90 minutes to 
perform, could be done in 1-2 seconds using GlycoExtractor (Artemenko et al., 2010).  
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3.9.4 GlycomeDB 
GlycomeDB is a web-based resource containing a collection of N-glycan structures 
from several databases and comprises over 35,056 structures (Ranzinger et al., 2009). 
Embedded GlycoCT and the glycoUpdateDB interfaces makes cross-linking between 
databases possible, thereby providing complete specific information of each N-glycan 
(Hizal et al., 2014). In this context, GlycoUpdateDB uploads datasets from multiple 
databases, translates them into a GlycoCT format and then incorporates them into the 
GlycomeDB (Hizal et al., 2014). Additionally, species-specific N-glycan data and 
anomeric configuration of monosaccharides, whether alpha or beta can be obtained using 
this platform (Ranzinger et al., 2009).  
3.9.5 Consortium for Functional Glycomics Database 
The Consortium for Functional Glycomics (CFG) database is a large resource 
containing a collection of glycomics datasets (8,626 glycan sequences) from MALDI-
TOF MS, nuclear magnetic resonance (NMR) and N-glycan arrays (Frank & Schloissnig, 
2010; Hizal et al., 2014; Von Der Lieth et al., 2011). In the CFG, it is possible to search 
for an array of N-glycan profiles because it integrates other O- and N-databases such as 
CarbBank and glycominds. Here, N-glycans can be searched by name, molecular mass 
or monosaccharide composition, and aided by the substructure interphase, researchers are 
able to build and modify specific N-glycans by comparing with a given template (Hizal 
et al., 2014; Raman et al., 2006). Enabled by the cartoonist programme, N-glycan 
structures can be assigned and viewed in the form of a PDF or JPG. In the CFG, data 
analysis is hierarchical. For example, N-glycan profiles from tissues and cells using MS 
are organised according to these hierarchical levels: “species→tissue→sample→N-/O-
linked glycan profile→ high/low molecular weight glycans” (Raman et al., 2006).  
3.9.6 GLYCOSCIENCE.de  
The GLYCOSCIENCE.de is a web-based resource containing N-glycan structural 
data from NMR and MS platforms, and comprises over 23,233 structures. 
GLYCOSCIENCE.de is able to link different data sources, such as the protein data bank 
(PDB) and the CCSD, for adequate structural description (Frank & Schloissnig, 2010; 
Lütteke et al., 2006; Von Der Lieth et al., 2004). The complex nature of the glycans 
requires a unique encoding scheme that describes all the chains in the glycan structure. 
GLYCOSCIENCE.de applies the LInear Notation for Unique description of 
Carbohydrate Sequences (LINUCS) scheme that uniquely defines all monosaccharide 
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linkages present, thus simplifying the glycan search facility within this resource (Lütteke 
et al., 2006). A very important feature of GLYCOSCIENCE.de is the GlycoCT, which is 
useful for classifying cell surface macromolecules. Embedded in GLYCOSCIENCE.de 
are tools that display the three-dimensional representation of the glycan structural 
coordinates and glycosidic linkages (Aoki-Kinoshita, 2013). 
3.9.7 GlycoWorkbench 
The GlycoWorkbench is a unique resource designed as part of the EUROCarbDB, 
which provides a graphical interface for interpreting N-glycan data obtained from MS 
spectra (Ceroni et al., 2008; Von Der Lieth et al., 2011). In the GlycoWorkBench, N-
glycans from experimental MS peaks are first paired with N-glycans in the theoretical list 
using an in silico fragmentation engine. Specified N-glycans annotation in the 
GlycoWorkBench is achieved by cross-linking with other glycan databases such as the 
GLYCOSCIENCE.de, the CarbBank and the CFG databases (Ceroni, 2007). The 
embedded GlycanBuilder allows complete editing and visualisation of glycan structures. 
In the GlycanBuilder, various symbols can be assigned to monosaccharide units and 
modification of the glycan structures is possible. For example, the ring size, the anomeric 
configuration and the linkage types of the glycan structures can be defined (Ceroni et al., 
2008). 
3.10.1 Conclusion 
Glycans are very important biomolecules involved in cellular processes and 
characterised by complex biosynthetic mechanisms. N-glycan biomarkers are a dynamic 
tool for understanding the complexities underpinning various pathological conditions that 
in turn will stimulate therapeutic interventions for diseases. High-throughput analytical 
techniques have allowed the underlying structure and intricacies of these unique 
molecules to be unraveled. 
However, as interesting as N-glycan profiling is, it is not devoid of challenges. Most 
of the analytical methods highlighted here are unable to detect the concentration of 
glycans on a microscale level (Wang, 2013). Some of the methods also require high purity 
samples, which are difficult to generate. Heterogeneity and the complexity of the glycan 
structures make N-glycan analysis difficult, warranting the need for new streamlined and 
automated glycobioinformatic resources (Brooks, 2009). Additionally, only a few 
laboratories with advanced tools and technical expertise are able to analyse specific 
glycan structures at glycosylation sites, posing a challenge for glycobiologists who are 
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new to the field (Cummings & Pierce, 2014). 
The field of glycomics is undergoing a revolution and advances in this area are 
attributed to recent technological innovations that aid N-glycan analysis. When compared 
to genomics, metabolomics and proteomics where there are well-established databases, 
glycomics databases are still underdeveloped mainly because of N-glycan heterogeneity 
and different degrees of branching. Nonetheless, a combination of the few glycomics 
databases with the highly sensitive analytical techniques have made it possible to 
understand how aberrant N-glycans are linked to multiple chronic diseases. This suggests 
that N-glycan profiles might, in the near future, be one of the most robust biomarkers for 
risk stratification that will improve detection and set the pace for preventive treatments 
for chronic diseases. Although at present, glycan studies are mainly focused on chronic 
diseases, it will be intriguing to explore and identify specific N-glycan traits that relate to 
certain acute diseases. 
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CHAPTER FOUR 
Prelude 
The contextual literature search thus far has shown that the process of developing 
T2DM may take many decades and therefore the approach for testing the current status 
of T2DM is improvident. There is the need to recognise early signs of risk to enable an 
early intervention and delay the onset of the disease. In this present study (Study I), the 
SHSQ-25 is employed to identify individuals who may have SHS, the reversible stage of 
a chronic disease like T2DM. Further, this study presents an overview of the health status 
of participants (T2DM and healthy controls) involved in the overall project. This study 
has been published in the Journal of European Association of Predictive, Preventive and 
Personalised Medicine (EPMA Journal) and it can be cited as:  
Adua, E., Roberts, P. & Wang, W. (2017). Incorporation of suboptimal health status as 
a potential risk assessment for type II diabetes mellitus: a case-control study in a Ghanaian 
population. EPMA Journal, 8(4), 345-355. 
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Incorporation of suboptimal health status as a potential risk 
assessment for type II diabetes mellitus: A case-control study in Ghana 
 
4.1 Abstract 
Due to a paradigm shift in lifestyles, there is growing concern that Type 2 Diabetes 
Mellitus (T2DM) will reach epidemic proportions in Ghana. However, specific 
characteristics of the disease are under explored in this region. More challenging are those 
who are yet to be diagnosed or who complain of poor health in the absence of a diagnosed 
disease - suboptimal health status (SHS). We conducted a study to examine various 
factors that characterise SHS and T2DM. Using a cross-sectional design, we recruited 
264 people as controls and 241 T2DM patients from January to June 2016. The controls 
were categorised into high and low SHS based on how they rated on the SHS 
questionnaire-25 (SHSQ-25). Anthropometric and biochemical parameters: body mass 
index (BMI), systolic blood pressure (SBP) and diastolic blood pressure (DBP), fasting 
plasma glucose (FPG), glycated haemoglobin (HbA1c), serum lipids [(total cholesterol, 
triglycerides (TG), high and low-density lipoprotein-cholesterol (HDL-c & LDL-c)] were 
measured. The male to female ratio for T2DM and controls were 99/142 and 98/166 
respectively, while the mean ages were 55.89 and 51.52 years. Compared to controls, 
T2DM patients had higher FPG (8.96 ± 4.18 vs 6.08 ± 1.79; p<0.0001) and HbA1c (8.23 
± 2.09 vs 5.45 ± 1.00; p<0.0001). Primarily sedentary [aOR=2.97(1.38-6.39); p=0.034)], 
SBP (p=0.001) and DBP (p=0.001) significantly correlated with high SHS. After 
adjusting for age and gender, central adiposity [aOR=1.74(1.06-2.83); p=0.027)], 
underweight [aOR=5.82(1.23-27.52); p=0.018)], high SBP [aOR=1.86(1.14-3.05); 
p=0.012)], high DBP [aOR=2.39 (1.40-4.07); p=0.001)] and high TG [aOR=2.17(1.09-
4.33); p=0.029)] were found to be independent risk factors associated with high SHS. The 
management of T2DM in Ghana is suboptimal and undiagnosed risk factors remain 
prevalent. The SHSQ-25 can be translated and applied as a practical tool to screen at-risk 
individuals and hence prove useful for the purpose of predictive, preventive and 
personalised medicine.  
 
Key words: chronic diseases, biomarkers, predictive preventive and personalised 
medicine  
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4.2 Introduction 
The rising prevalence of diabetes mellitus (DM) is a major health threat worldwide. 
Presently, DM affects more than 422 million people with an enormous proportion (≈90%) 
of these being type II diabetes mellitus (T2DM) (WHO, 2015). Data from the World 
Health Organisation (WHO, 2015) and the International Diabetes Federation (IDF) (IDF, 
2015) suggests that T2DM is directly related to urbanisation, mechanisation, physical 
inactivity and unhealthy diet and since many adults are still adopting these characteristics, 
the prevalence of T2DM is likely to escalate. The projected trajectory of prevalence in 
the years 2025-2030 is 500 million worldwide (Golubnitschaja, Kinkorova, & 
Costigliola, 2014). More disconcerting is the increasing prevalence of the disease among 
adolescents and young adults. These individuals are likely to spend more on medical costs 
and have more time to suffer from both microvascular and macrovascular complications 
than older adults (Bao et al., 2017; Chew, 2017; Nadeau et al., 2016).  
T2DM affects multiple organs in the human body and people with the disease have 
an elevated risk of blindness, cognitive decline, kidney failure, cardiovascular diseases, 
fractures, brain damage, depression and consequently premature death (Action to Control 
Cardiovascular Risk in Diabetes Study Group, 2008; Chen, Magliano, & Zimmet, 2012; 
Gerstein et al., 2005; Luchsinger, 2012; Rich, Shaefer, Parkin, & Edelman, 2013; Stratton 
et al., 2000). Many of these complications may be averted or delayed with timely health 
education and intervention (Adua et al., 2017; DeFronzo & Abdul-Ghani, 2011; Frank et 
al., 2014; Rich et al., 2013; Suckling & Swift, 2015). Unfortunately, the majority of 
people, especially those residing in less healthcare-resourced and low income developing 
countries are not aware of their risk status.  
In Ghana, up to 440, 000 people had been documented to have T2DM in 2013 but 
the number of those with pre-diabetes are not known (Guariguata et al., 2014). These 
individuals can remain undiagnosed for a long period, even for many decades of their life. 
Effective therapeutic intervention can only be started following the manifestation of 
clinical symptoms. This, from the perspective of a preventive, predictive and personalised 
medicine (PPPM) standpoint is a delayed response (Golubnitschaja et al., 2014). PPPM 
is defined as “an integrative concept that enables the prediction of individual’s 
predisposition before the onset of a disease, to provide targeted preventive measures and 
create personalised treatment algorithms tailored to a person” (Lemke & Golubnitschaja, 
2014). Over the past few years, PPPM has made a significant impact on the prevention 
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and treatment of diseases because it adopts a holistic approach (e.g. environmental, 
behavioural and traditional factors) to solving health problems (Golubnitschaja, 2010; 
Golubnitschaja et al., 2016; Golubnitschaja et al., 2014).  
As with many chronic diseases, screening for pre-diabetes is central in PPPM and 
it provides the stimulus for initiating treatment and delaying long-term complications. 
Most often, screening is performed in a health care facility in order to allow health care 
providers to perform appropriate follow up testing and institute quality health care 
(Lindström & Tuomilehto, 2003). However, with recent developments in public health 
research, there are robust screening tools that are non-invasive, inexpensive and can be 
applied both in a health care setting and in the field or the wider community. One such 
tool is the suboptimal health status questionnaire (SHSQ-25) (Wang et al., 2016; Yan et 
al., 2014). 
SHSQ-25 identifies individuals who complain of poor health in the absence of any 
diagnosable condition (Yan et al., 2009). It explores human health from five domains: 
fatigue, cardiovascular, immune, digestive and mental and over the years, it has been 
successfully applied for screening purposes among Caucasians (Kupaev et al., 2016) and 
Chinese (Wang, Russell, & Yan, 2014; Wang et al., 2016; Yan et al., 2009; Yan et al., 
2012; Yan et al., 2014). In these studies, it was apparent that a high SHS (i.e. SHS score 
> median score), is associated with chronic disease risk factors and that these scores are 
largely under the influence of external factors such as employment type, lifestyle, 
socioeconomic, cultural and climatic conditions.  
In this study, SHS in a Ghanaian population is examined as well as examining the 
anthropometric, clinical and biochemical parameters among T2DM patients. 
Understanding these factors in both healthy and T2DM participants will be instrumental 
in the pursuit of PPPM. 
4.3 Methods and Study Design 
Data Collection 
This cross-sectional study was conducted from January to June 2016.  Recruitment 
for the study was based on purposeful sampling where T2DM patients, who reported at 
the Diabetic Centre, Komfo Anokye Teaching Hospital (KATH), were invited to 
participate. KATH is a referral hospital with over 1200 beds with not less than 100 
diabetic/hypertensive patients attending the hospital every fortnight. Utilising a 
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convenient sampling method, 264 control participants from three suburbs (Ash-town, 
Pankrono and Abrepo) were recruited within the Kumasi metropolis.  
Ethics Clearance 
The Committee on Human Research, Publication and Ethics (CHRPE), Kwame 
Nkrumah University of Science and Technology (KNUST), Kumasi, and the Human 
Research Ethics Committee (HREC), Edith Cowan University (ECU), Australia, 
reviewed and approved the study protocol. Written informed consent was obtained from 
all participants. Data was collected in accordance with the principles of the Declaration 
of Helsinki.  
SHSQ-25 Questionnaire 
The SHSQ-25 questionnaire was used to measure SHS. The SHSQ-25 comprises 
25 items, categorised into five domains: fatigue (9 items), cardiovascular system (3 
items), digestive system (3 items), immune system (3 items) and mental health (7 items). 
Each participant was asked to rate a statement on a five-point Likert type scale, based on 
how often they had experienced a particular complaint in the previous 3 months. 1) Never 
or almost never, 2) Occasionally, 3) Often, (4) Very often and (5) Always. The raw scores 
of 1 to 5 on the SHSQ-25 were recoded as 0-4. SHS score was calculated by summing 
the ratings for the 25 items. A high SHS score represents poor health (Wang et al., 2014; 
Wang et al., 2016; Yan et al., 2009; Yan et al., 2014). To test for reliability of the SHSQ-
25, we determined the Cronbach’s α coefficient that was found to be 0.91. 
Anthropometric Examination  
Weight (kg) and height (cm) were measured with a standard stadiometer (SECA, 
Hamburg, Germany). These data were used to determine the body mass index (BMI), 
calculated as BMI = weight (kg)/height (m)2. Waist and hip circumference were measured 
in cm using a tape measure and waist-to-hip ratio (WHR) was calculated as WHR = waist 
(cm)/hip (cm). Systolic blood pressure (SBP) and diastolic blood pressure (DBP) were 
measured using a standard sphygmomanometer (Omron HEM711DLX, UK). 
Clinical Data  
After an overnight fast, blood samples were collected from each participant. 
Samples were collected into tubes containing ethylenediaminetetraacetic acid (EDTA) 
anticoagulant, gel separator and fluoride oxalate. Samples were centrifuged 
(Mendelssohn, USA) at 3000g at 4oC for 10 mins (centrifuge Eppendorf 5702R, 
Germany) to separate the whole blood. Serum levels of total cholesterol (TC), 
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triglycerides (TG) and high-density lipoprotein (HDL) cholesterol were determined 
enzymatically with commercial reagents (Elitech Clinical Systems Elitech Group; Roche 
Diagnostics, COBAS INTEGRA 400 Plus, USA). Serum lipid levels were quantified 
based on the National Cholesterol Education Program, Adult Treatment Panel (NCEP-
ATP) III guidelines. Low-density lipoprotein (LDL) cholesterol was calculated using 
Friedewald formula: LDL=TC−[HDL+TG/5] (Friedewald, Levy & Fredrickson 1972).  
Inclusion and Exclusion Criteria  
This study was conducted in consultation with clinicians and qualified health 
professionals. In this study, T2DM was established based on the international 
classification of disease (ICD-10-CM Diagnosis Code E11.9).  Each patient was 
carefully examined and his or her medical records thoroughly reviewed. As a result, 
we excluded all those individuals who were suffering from cancer, arthritis, 
infectious diseases, cardiovascular disease, thyroid disorders, pituitary disorders and 
adrenal disorders. The study did not include pregnant and lactating mothers. Since 
T2DM is largely a disease of ageing, the study recruited only individuals who were 
30 years and above. Further, to limit potential confounding and the likelihood of 
recruiting participants with type 1 diabetes, we excluded participants on insulin 
injections. In order to screen for individuals with undiagnosed risk factors (controls), we 
excluded all participants who had been previously diagnosed with diabetes and/or 
hypertension. In addition, individuals who were suffering from other chronic diseases 
related to the genitourinary, digestive, respiratory and haematological systems were 
excluded. We included participants aged 18-80 years.  
4.4 Statistical Analysis 
All continuous data were recorded as mean ± standard deviation (SD) and 
percentages for categorical variables. Between group comparisons for continuous 
variables were determined using student t-tests, while intergroup comparisons of 
categorical variables were done with chi-square tests and analysis of variance (ANOVA). 
Association between SHS and cardiovascular risk factors were performed using linear 
regression and multiple logistic regression models. Odds ratios (ORs) at 95% confidence 
intervals (95% CI) were recorded for logistic regression analysis. All statistical analysis 
was performed on the Statistical Package for Social Sciences (SPSS), version 22. A two 
sided p< 0.05 was considered significant.  
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4.5 Results 
The characteristics of the 505 participants comprising 264 controls and 241 cases are 
shown in Table 4.1. Over 44% of all T2DM patients had hypertension, with a male to 
female ratio of 98/142. Other demographic measures were overweight (33.19%), obese 
(18.26%), tertiary education (14.52%), moderate activity (67.21%), employed (55.17%), 
smoking history (14.10%) and alcohol history (42.32%). 
Table 4.1 Characteristics of study participants with or without T2DM or hypertension (HPT) 
Variable Control T2DM Only T2DM+HPT             X2 p-value 
Age groups    27.75 0.001 
31-40 years 14(5.3) 12(9.1) 2(1.9)   
41-50 years 31(11.7) 32(24.2) 17(15.7)   
51-60 years 74(28.0) 45(34.1) 36(33.3)   
61-70 years 87(33.0) 31(23.5) 37(34.3)   
71-80 years 58(22.0) 12(9.1) 16(14.8)   
Gender    0.985 0.611 
Male 98(37.1) 52(39.4) 46(42.6)   
Female 166(62.9) 80(60.6) 62(57.4)   
BMI    15.39 0.017 
Underweight 13(4.9) 8(6.1) 1(0.9)   
Normal weight 107(40.5) 67(51.1) 39(36.1)   
Overweight 87(33.0) 32(24.4) 48(44.4)   
Obese 57(21.6) 20(18.5) 24(18.3)   
Marital status    23.77 0.003 
Married 174(65.9) 91(68.9) 72(66.7)   
Never married 29(11.0) 3(2.3) 1(0.9)   
Divorced 24(9.1) 12(9.1) 13(12.1)   
Widowed 37(14.0) 26(19.7) 22(20.4)   
Education    15.66 0.048 
Tertiary 36(13.6) 17(12.9) 18(16.7)   
Senior High school 82(31.1) 38(28.8) 19(17.6)   
Junior high school 93(35.2) 38(28.8) 40(37.0)   
Lower primary 31(11.7) 26(12.1) 12(11.1)   
No formal education 22(8.3) 23(17.4) 19(17.6)   
Occupation    69.88 0.0001 
Employed 107(40.5) 82(62.1) 51(47.2)   
Retired 23(8.7) 12(9.1) 22(20.4)   
Unemployed 32(12.2) 28(21.2) 23(21.3)   
Informal employment 102(38.6) 10(7.6) 12(11.1)   
Physical activity    11.07 0.086 
Primarily sedentary 87(33.0) 35(26.5) 43(39.8)   
Moderate activity 177(67.5) 97(73.5) 65(60.1)   
Family history    54.59 0.0001 
Yes 121(46.0) 97(73.5) 85(78.7)   
Smoking history    11.09 0.026 
Yes 17(6.5) 17(12.9) 17(15.7)   
History of alcohol intake    9.57 0.048 
Yes 83(31.7) 54(40.9) 48(44.4)   
Tests of significance were two tailed (p<0.05) and are bolded in the table.  
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Table 4.2 shows the clinical data of the participants. The mean age for T2DM only and 
T2DM with hypertension were 55.89 ± 11.27 and 60.07 ± 9.93, respectively whereas. 
BMI was not different between T2DM and hypertensive T2DM patients (p=0.158). In 
addition, WHR was higher among T2DM patients with hypertension (0.92 ± 0.55 vs 0.94 
± 0.061; p<0.0001). However, FPG, HbA1c, TC, TG, HDL-c, LDL-c, and CR were not 
different in T2DM and T2DM with hypertension (p>0.05). Further, T2DM patients were 
generally older than controls (p<0.0001), had a higher WHR (0.94 ± 0.061 vs 0.88 ± 0.08; 
p<0.0001), higher FPG (8.96 ± 4.18 vs 6.08 ± 1.79; p<0.0001) and higher HbA1c (8.23 
± 2.09 vs 5.45 ± 1.00; p<0.0001). However, compared with non-hypertensive T2DM 
patients, the controls had higher SBP (143.69 ± 25.82 vs 122.17 ± 11.86; p<0.0001), DBP 
(84.27 ± 15.37 vs 89.16 ± 12.62, P<0.0001) and CR (5.37 ± 1.49 vs 4.90 ± 1.52; p < 
0.011). There were no differences in TC, TG, LDL-c, and VLDL-c between controls and 
non-hypertensive T2DM patients. Similarly, compared to controls, hypertensive T2DM 
patients were older (p<0.0001), had higher WHR’s (0.94 ± 0.061 vs 0.88 ± 0.08 
p<0.0001), higher SBP (160.48 ± 18.24 vs 84.27 ± 15.37; p<0.0001), and higher DBP 
(89.16 ± 12.62 vs 84.27 ± 15.37 p<0.0001). 
Table 4.2 Clinical data of study participants with or without T2DM or hypertension 
Variables Controls T2DM Only T2DM+HPT p-value 
Age(years) 51.62 ± 11.92  55.89 ± 11.27† 60.07 ± 9.93*¥ <0.0001          
BMI(kg/m2) 25.86 ± 5.06  25.60 ± 5.38 26.80 ± 4.72 0.158 
WHR 0.88 ± 0.08  0.92 ± 0.55† 0.94 ± 0.061*¥ <0.0001 
SBP (mmHg) 143.69 ± 25.82  122.17 ± 11.86† 160.48 ± 18.24*¥ <0.0001 
DBP (mmHg) 84.27 ± 15.37  75.45 ±11.29† 89.16 ± 12.62*¥ <0.0001 
FPG (mmol/l) 6.08 ± 1.79  8.96 ± 4.18† 9.49 ± 4.68* <0.0001 
HbA1c (%) 5.45 ± 1.00  8.23 ± 2.09† 8.35 ± 2.09* <0.0001 
TC (mmol/l) 4.57 ± 1.25  4.71 ± 1.17 4.76 ± 1.39 0.342 
TG (mmol/l) 1.32 ± 0.91  1.22 ± 0.57 1.33 ± 0.55 0.484 
HDL-c (mmol/l) 1.23 ± 0.31  1.37 ± 0.35† 1.33 ± 0.29* <0.0001 
LDL-c (mmol/l) 2.77 ± 1.06  2.77 ± 1.11 2.81 ± 1.23 0.1 
VLDL-c(mmol/l 0.59 ± 0.35  0.55 ± 0.26 0.60 ± 0.25 0.928 
CR 5.37 ± 1.49  4.90 ± 1.52† 5.05 ± 1.53 0.011 
Values are presented as mean ± SD. One-way ANOVA followed by Tukey Post hoc multiple comparison. 
BMI: p<0.05 was considered statistically significant. †p-value is significant (Comparison between control 
and DM only) *p-value is significant (Comparison between control and DM+HTN) ¥p-value is significant 
(Comparison between DM only and DM+HTN). Tests of statistical significance were two tailed (p<0.05) 
and are bolded in the table.  
 72 
 
Table 4.3 outlines the gender stratification data of participants. The mean age of control 
participants was 51.67 ± 11.45 years with a male to female ratio of 98/166. A high 
proportion had at least a basic education (35.2%), were married (65.9%), and employed 
(40.5%). Women were generally obese compared to men when BMI (33.1% vs. 2.0%; 
p=0.001) and central adiposity (68.7% vs. 5.1%; p=0.001) were used respectively as an 
obesity index. A higher proportion of men than women were smokers (15.3% vs. 1.2%; 
p=0.001) and had a history of alcohol intake (41.8% vs. 25.6%; p=0.005). There was a 
significantly higher DBP (p=0.034), HbA1c (p=0.043), TC (p=0.001), HDL-c (p=0.011), 
non-HDL-c (p=0.004) and LDL-c (p=0.006) among women compared to men. Levels of 
SBP, FPG, TG, VLDL-c, CR and WHR among women were not significantly different 
from men (p>0.05).  
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Table 4.3 Characteristics of controls stratified by gender  
Data is expressed as mean ± standard deviation or (n %) and tests of significance were two tailed 
(p<0.05) and are bolded in the table. 
 
Characteristics Total  Men (n=98) 
Women 
(n=166) p-value 
Age (years) 51.67 ± 11.45 51.09 ± 12.02 51.44 ± 11.89 0.761 
Anthropometric data     
Waist to hip ratio 0.88 ± 0.07 0.89 ± 0.06 0.87 ± 0.08 0.148 
Body mass index (kg/m2)    <0.0001 
       Underweight 13(4.9) 8(8.2) 5(3.0)  
       Normal weight 107(40.5) 60(61.2) 47(28.3)  
       Overweight 87(33.0) 28(28.6) 59(35.5)  
       Obese 57(21.6) 2(2.0) 55(33.1)  
Central obesity    <0.0001 
      Normal  145(54.9) 93(94.9) 52(31.3)  
      Obese 119(45.1) 5(5.1) 114(68.7)  
Socio-economic data     
Education    <0.0001 
      Tertiary 36(13.6) 26(26.5) 10(6.0)  
      Senior high school 82(31.1) 26(26.5) 56(33.7)  
      Junior high school 93(35.2) 35(35.7) 58(34.9)  
      Lower primary 31(11.7) 6(6.1) 25(15.1)  
      No formal education 22(8.3) 5(5.1) 17(10.2)  
Marital status    0.001 
      Married 174(65.9) 75(76.5) 99(59.6)  
      Never married 29(11.0) 14(14.3) 15(9.0)  
      Divorced 24(9.1) 3(3.0) 21(12.6)  
      Widowed 37(14.0) 6(6.1) 31(18.7)  
Occupation    <0.001 
      Employed 107(40.5) 52(53.1) 55(33.1)  
      Retired 23(8.7) 13(13.3) 10(6.0)  
      Unemployed 32(12.2) 1(1.0) 31(18.6)  
      Informal employment 102(38.6) 32(32.7) 70(42.2)  
Biochemical data     
SBP (mmHg)  144.12 ± 26.61 145.82 ± 30.96 142.43 ± 22.25 0.305 
DBP (mmHg) 83.74 ± 15.70 81.66 ± 18.02 85.81 ± 13.38 0.034 
FPG (mmol/l) 6.08 ± 1.79 6.04 ± 1.78 6.11 ± 1.79 0.751 
HbA1c (%) 5.41 ±  0.98 5.28 ± 0.91 5.54 ± 1.04 0.043 
TC (mmol/l) 4.50 ± 1.17 4.24 ± 1.00 4.76 ± 1.33 0.001 
TG (mmol/l) 1.29 ±  0.89 1.19 ± 0. 81 1.39 ± 0.96 
                   
0.105 
HDL-c (mmol/l) 1.12 ± 0.30 1.16 ± 0.28 1.26 ± 0.32 0.011 
NonHDL-c (mmol/l) 3.23 ± 1.09 3.07 ± 0.91 3.50 ± 1.26 0.004 
VLDL-c (mmol/l) 0.58 ± 0.35 0.54 ± 0.36 0.61 ± 0.34 0.133 
LDL-c (mmol/l) 2.73 ± 2.03 2.54 ± 0.91 2.91 ± 1.12 0.006 
CR 5.33 ± 2.87 5.22 ± 1.28 5.45 ± 1.59 0.236 
Family history and activity     
Diabetes family history (yes) 121 (46.0) 43(43.9%) 78(47.3%) 0.343 
Smoking (yes) 17(6.5) 15(15.3) 2(1.2) <0.001 
Drinking (yes) 83(31.7) 41(41.8) 42(25.6) 0.005 
Physical activity    
 
0.037 
      Primarily sedentary 87(33.0) 29(29.6) 58(34.9)  
      Moderate activity 135(51.1) 46(46.9) 89(53.6)  
      Primarily physical 42(16) 23(23.4) 19(11.4)  
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Table 4.4 shows the distribution of clinical data of participants differing by SHS. With a 
median SHS score of 21, participants were grouped into high SHS (≥ 21) and low SHS 
(< 21). Gender (p=0.023), age (p=0.020), education (p=0.001), marital status (p=0.019), 
occupation (p<0.0001) and physical activity (p=0.006) were significantly associated with 
high SHS. Meanwhile, being a female [aOR=1.7(1.04-2.85); p=0.034)], elderly 
[aOR=10.8(1.69-68.97); p=0.018)], illiterate [aOR=5.34(1.61-17.77); p=0.007)], lower 
primary education [aOR=3.14(1.14-8.65); p=0.029)], widowed [aOR=2.75(1.28-5.91); 
p=0.011)], retired [aOR=7.0(2.40-20.40); p=0.0001)], unemployed [aOR=4.28(1.83-
9.99); p=0.0009)], informal employment [aOR=2.68(1.52-4.68); p=0.0008)] and 
primarily sedentary [aOR=2.97(1.38-6.39); p=0.034)] were significant independent risk 
factors for high SHS after adjusting for age and gender. Participants with high SHS had 
a significantly higher mean SBP (p=0.004) and DBP (p=0.001) compared to those with 
low SHS. However, there were no significant differences between the mean lipid profile 
among participants with high SHS compared to low SHS (p>0.05).  
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Table 4.4 Distribution of factors with or without SHS 
Variables 
Total  
n (%) 
SHS Score 
≥21  
n (%) 
SHS score<21  
n (%) p-value X2 aOR (95%CI)   p 
 
Gender    0.023 4.49   
 
Male 98(37.3) 42(31.1) 56(43.8)   1.0#   
Female 165(62.7) 93(68.9) 72(56.3)   1.7 (1.04-2.85) 0.034 
 
Age (years)    0.02 13.34    
21-30 14(5.3) 5(3.7) 9(7.0)   1.0#   
31-40 30(11.4) 17(12.6) 13(10.2)   2.35(0.63-8.73) 0.332  
41-50 74(28.1) 41(32.0) 33(24.4)   1.45(0.44-4.72) 0.574  
51-60 87(33.1) 47(36.7) 40(29.6)   1.53(0.47-4.94) 0.569  
61-70 44(16.7) 28(20.7) 16(12.5)   3.15(0.89-11.04) 0.119  
71-80 14(5.3) 12(8.9) 2(1.6)   10.8(1.69-68.97) 0.018  
Education    0.001 19.81    
Tertiary 36(13.7) 14(10.4) 22(17.2)   1.0#  
 
Senior high school 82(31.2) 30(22.2) 52(40.6)   0.91(0.40-2.03) 0.838  
Junior high school 93(35.4) 54(40.0) 39(30.5)   2.17(0.99-4.78) 0.076  
Lower primary 30(11.4) 20(14.8) 10(7.8)   3.14(1.14-8.65) 0.029  
No education 22(8.4) 17(12.6) 5(3.9)   5.34(1.61-17.77) 0.007  
Marital Status    0.019 11.76    
Married 173(68.5) 80(59.3) 93(72.7)   1.0#   
Never married 29(11.0) 13(9.6) 16(12.5)   0.94(0.42-2.08) 0.999  
Divorced/separated 24(9.1) 16(11.8) 8(6.2)   2.32(0.94-5.72) 0.081  
Widowed 37(14.1) 26(19.3) 11(8.6)   2.75(1.28-5.91) 0.011  
Occupation    <0.001 27.09    
Employed 106(40.3) 36(26.7) 70(54.7)   1.0#   
Retired 23(8.7) 18(13.3) 5(3.9)   7.00(2.40-20.40) 0.0001  
Unemployed 32(12.2) 22(16.3) 10(7.8)   4.28(1.83-9.99) 0.0009  
Informal 
employment 102(38.8) 59(43.7) 43(33.6)   2.68(1.52-4.68) 0.0008 
 
Physical activity    0.006 12.35    
Primarily sedentary 87(33.1) 57(42.2) 30(23.4)   2.97(1.38-6.39) 0.007  
moderate activity 135(51.3) 62(45.9) 73(57)   1.32(0.65-2.71) 0.476  
Primarily physical 41(15.6) 16(11.9) 25(19.6)   1.0#   
Biochemical data         
SBP (mmHg) 143.69 ± 25.82 148.33 ± 24.05 139.20 ± 26.58 0.004    
 
DBP (mmHg) 84.27 ± 15.37 87.33 ± 15.35 81.24 ± 14.7 0.001     
FBG (mmol/l) 6.08 ± 1.78 6.15 ± 1.75 6.01 ± 1.84 0.544     
HbA1c (%) 5.45 ± 0.99 5.44 ± 0.94 5.44 ± 1.06 0.997     
TC(mmol/l) 4.57 ± 1.25 4.66 ± 1.3 4.47 ± 1.18 0.217     
TG (mmol/l) 1.32 ± 0.91 1.41 ± 1.01 1.22 ± 0.79 0.099     
HDL-C (mmol/l) 1.23 ± 0.31 1.25 ± 0.32 1.20 ± 0.3 0.177     
VLDL-C (mmol/l) 0.59 ± 0.35 0.62 ± 0.35 0.56 ± 0.36 0.155     
LDL-C (mmol/l) 2.77 ± 1.06 2.81 ± 1.09 2.73 ± 1.02 0.554     
CR 5.37 ± 1.49 5.40 ± 1.5 5.35 ± 1.47 0.805     
aOR: adjusted odds ratio, CI confidence interval. Multivariate regression model was adjusted 
for age and gender; #: reference, p < 0.05. Tests of significance were two tailed (p<0.05). 
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Table 4.5 shows that after adjusting for age and gender, central adiposity 
[aOR=1.74(1.06-2.83); p=0.027)], underweight [aOR=5.82(1.23-27.52); p=0.018)], high 
SBP [aOR=1.86(1.14-3.05); p=0.012)], high DBP [aOR=2.39(1.40-4.07); p=0.001)] and 
high TG [aOR=2.17(1.09-4.33); p=0.029)] were found to be significant independent risk 
factors associated with high SHS. 
Table 4.5 Association between SHS and metabolic risk factors 
aOR: adjusted odds ratio, CI confidence interval. #: reference, p < 0.05. Tests of significance 
were two tailed (p<0.05) and are bolded. 
 
 
Variables Total (n %) 
SHS  
Score ≥21  
(n %) 
SHS 
score<21  
(n %)      x2 p OR (95%CI)     P  
Central Obesity    4.88 0.018   
  Normal 144(54.8) 65(48.1) 79(61.7)   1.0#  
  Obese 119(45.2) 70(51.9) 49(38.3)   1.74 (1.06-2.83) 0.027 
BMI    6.75 0.08   
  Underweight 13(4.9) 11(8.1) 2(1.6)   5.82(1.23-27.52) 0.018 
  Normal weight 107(40.7) 52(38.5) 55(43.0)   1.0#  
  Overweight 86(32.7) 41(30.4) 45 (35.2)   0.96(0.54-1.70) 0.987 
  Obese 57(21.7) 31(11.8) 26(20.3)   1.26(0.66-2.40) 0.514 
Blood Pressure        
SBP       
  Normal SBP 121(46.0) 52(38.5) 69(53.9) 6.26 0.009 1.0#  
  High SBP 142(54.0) 83(61.5) 59(46.1)   1.86(1.14-3.05) 0.012 
DBP       
  Normal SBP 176(66.9) 78(57.8) 98(76.6) 10.47 0.001 1.0#  
  High SBP 87(33.1) 57(42.2) 30(23.4)   2.39(1.40-4.07) 0.001 
FPG    2.87 0.090   
  Normal 113(43.1) 51(38.1) 62(48.4)   1.0#  
  High  149(56.9) 83(61.9) 66(51.6)   0.65(0.40-1.07) 0.105 
HbA1c    1.93 0.164   
   Normal 195(75.6) 98(73.7) 97(77.6)   1.0#  
   High  63 (24.4) 38(29.2) 25(19.5)   1.50(0.84-2.86)         0.192  
TC    0.03 0.489   
   Normal 186(72.1) 96(71.6) 90(72.6)   1.0#  
   High 72(27.9) 38(28.4) 34(27.4)   1.05(0.61-1.81)         0.867  
TG    4.97 0.03   
   Normal 215(83.3) 105(78.4) 110(88.7)   1.0#  
   High 43(16.7) 29(21.6) 14(11.3)   2.17(1.09-4.33)         0.029  
HDL-c        
  Normal 151(58.5) 78(58.2) 73(58.9) 0.12 0.508 1.0#  
  Low 107(41.5) 56(41.8) 51(41.1)   1.03(0.63-1.69)         0.999  
Non-HDL-c    1.66 0.123   
 Normal 137(53.1) 66(49.3) 71(57.3)   1.0#  
 High 121(46.9) 53(42.7) 68(50.7)   1.38(0.85-2.25)         0.532  
LDL-c        
 Normal 126(48.8) 65(48.5) 61(49.2) 0.12 0.506 1.0#  
 High 132(51.2) 69(51.5) 63(50.8)   1.03(0.63-1.68)         0.999  
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Table 4.6 demonstrates that after controlling for age and gender, significant positive 
linear relationships were observed between SHS score and SBP, DBP and CR irrespective 
of gender (p <0.05). There were inconsistent correlations between other risk factors and 
high SHS. SHS scores were significantly associated with LDL-c in men while FPG, TC 
and non-HDL-c were significantly associated with SHS in women (p<0.05). There was 
no significant linear relationship between BMI, HbA1c, TG, HDL-c, VLDL-c and high 
SHS in either men or women (p>0.05).  
 
Table 4.6 Multivariate linear regression model for SHS score in relation to metabolic risk factors 
stratified by sex 
 MALE    FEMALE   
 β SE p-value  β SE p 
BMI 0.52 0.44 0.237  0.16 0.22 0.454 
SBP 2.09 0.51 0.035  1.52 0.05 0.046 
DBP 2.16 0.84 0.012  2.11 0.07 0.005 
FPG 0.67 0.86 0.442  2.09 0.62 0.0009 
HbA1c 0.13 1.68 0.936  1.17 1.1 0.118 
TC 1.33 1.52 0.387  1.75 0.85 0.043 
TG 2.07 1.89 0.276  1.18 1.2 0.329 
HDL-C -9.27 5.32 0.085  -1.42 3.64 0.696 
Non-HDL 2.56 1.68 0.131  2.08 0.91 0.024 
VLDL 4.60 4.16 0.272  4.19 3.39 0.219 
LDL-C 3.31 1.66 0.049  2.02 1.02 0.051 
CR 2.79 1.16 0.019  1.45 0.72 0.049 
β: regression coefficient; SE: Standard error. Tests of significance were two tailed (p<0.05) and 
are bold. 
 
4.6 Discussion 
T2DM is largely a consequence of accumulating metabolic damage due to 
increasing urbanisation, physical inactivity, unhealthy eating and sedentary lifestyle (Bi 
et al., 2012; Chen et al., 2012; Rich et al., 2013; Stumvoll, Goldstein, & van Haeften, 
2005). Earlier diagnosis remains the blueprint for preventing T2DM and promoting better 
health outcomes (Deepa, Anjana, & Mohan, 2017; DeFronzo & Abdul-Ghani, 2011; 
Hulsegge et al., 2017; Zou et al., 2017). This study is premised on the hypothesis that 
cardiometabolic risk factors are prevalent in Kumasi, an urban city in Ghana (Roberts, et 
al., 2017). As such, we have explored modifiable risk factors in both T2DM sufferers and 
healthy controls (Tables 4.1, 4.2 & 4.3).  
Among the controls, we used a simple and inexpensive tool (SHSQ25) to determine 
highly at-risk individuals. Participants were classified into two groups based on how they 
rated on the SHSQ25. Here, a median score <21 represents low SHS (good health) 
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whereas a median score >21 represents high SHS (poor health). Ideally, filling in this 
short questionnaire alone should encourage individuals who obtain a high SHS score to 
have their clinical/biochemical indicators measured. Health providers on dietary/lifestyle 
modifications that will enable them to live healthier and delay the onset of T2DM could 
advise such persons. Alternatively, a person with a high SHS may have undiagnosed, 
asymptomatic T2DM, or its related co-morbidities and may need immediate intervention 
or therapy.  
In this study, undiagnosed hypertension is prevalent, and similar to previous 
findings, high SHS is significantly associated with both DBP and SBP (Tables 4.4 & 
4.6). This also confirms the findings of another community-based study in the subregion, 
which showed that a high proportion of adults in Sub-Saharan Africa (SSA) (44-93%) 
who have high blood pressure are unaware of it (Cappuccio & Miller, 2016; Echouffo‐
Tcheugui, Kengne, Erqou, & Cooper, 2015). Yet another study in a peri-urban 
community in Ghana showed the prevalence of undiagnosed hypertension at 28.7% 
(Cappuccio & Miller, 2016). This is in fact disturbing because high BP is by far the main 
risk factor for T2DM and cardiovascular disease (CVD) (Cappuccio & Miller, 2016; 
Mendis, Puska, & Norrving, 2011; Ofori-Asenso & Garcia, 2016). High BP, for example, 
causes 42% of all ischaemic heart diseases (Mensah, 2008) and one-third of all heart 
failures (Khatibzadeh et al., 2013). As such, there is an overarching need to identify these 
individuals and begin treatment to avoid complicated health outcomes.  
Similar to previous findings, age was associated with high SHS (Table 4.4). This 
is not surprising since ageing is associated with less physical activity and sedentary 
lifestyle, making it a high order independent risk factor for T2DM (Yu et al., 2016). From 
the perspective of metabolism, this age range is accompanied by an imbalance in the 
production of reactive oxygen species (ROS) and inflammation that together lead to 
metabolic dysregulation. Metabolic dysregulation will lead to insulin resistance and 
consequently T2DM (Franco et al., 2009).  
In addition, gender, education, marital status, occupation and physical activity were 
associated with high SHS (Table 4.4). However, we could not validate the association 
between high SHS and higher FPG, HbA1c, TC, LDL-c and Low HDL-c (Table 4.5). In 
part, this observation could be attributed to the small sample size used for this 
investigation. All previous investigations involved large cohorts in China i.e.  2,799 
participants in 2009 (Yan et al., 2009), 3,019 in 2012 (Yan et al., 2012), 3,405 in 2012 
(Wang & Yan, 2012) and 4,313 in 2016 (Wang et al., 2016). Cohorts from geographically 
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distinct populations are exposed to different stressors (e.g. variation in job types, 
lifestyles, and socioeconomic, environmental and cultural factors). For example, while 
the majority of the Ghanaian participants are primarily sedentary and engage in less 
energy demanding jobs, the Chinese cohorts are mainly industry workers who spend long 
hours at work, and are therefore more likely be stressed. Consequently, these disparities 
in stressful conditions, especially in the hours preceding testing, may affect biochemical 
assessments. Further, it is possible that the biochemical assessments of this present study 
are somewhat influenced by laboratory conditions (Bonora & Tuomilehto, 2011). 
Therefore, other highly sensitive and state-of-the art health facilities should be available 
to enable validation.  
Among T2DM sufferers, hypertension was high and this agrees with a previous 
study reported from the Kumasi region (Table 4.2) (Danquah et al., 2012). Further, the 
results of the present study show that the majority of T2DM patients had FPG and HbA1c 
levels higher than the recommended targets (i.e. > 7 and > 7.2 respectively), many of 
whom are on the path to developing complications and co-morbidities. Surprisingly, all 
these individuals have been provided with both blood pressure lowering and lipid 
lowering medications. This could be attributed to delayed intervention, ineffective 
treatments, untargeted medications, and drug response and drug resistance. Alternatively, 
the suboptimal management could be due to other factors including: 1) Institutional (e.g., 
health care policies, facilities and resources), 2) Environmental, dietary and lifestyles 3) 
Genetic and epigenetics and 4) Individual factors (physical, mental, social and spiritual 
wellbeing). In order to address such a complex situation, there must be a transition from 
the current medical practise to PPPM. PPPM holds the key to revolutionising T2DM care 
by promoting adequate patient stratification, disease modelling, surveillance, optimal 
diagnosis and prediction of adverse drug-drug interactions (Golubnitschaja, 2010; 
Golubnitschaja et al., 2016; Golubnitschaja et al., 2014; Lemke & Golubnitschaja, 2014). 
Taken together, this will lead to better health outcomes, delay the onset of complications, 
improve quality of life and promote longevity. 
Overall, it is clear that modifiable risk factors are prevalent among T2DM sufferers 
but importantly, it is demonstrated that SHSQ-25 could be a risk stratification tool for 
T2DM.  Compared to many survey instruments and risk prediction models (Liu et al., 
2011; Mehrabi et al., 2010; Rathmann et al., 2010), the SHSQ-25 is simple, inexpensive 
and can be self-completed prior to, or administered during, a consultation. The scoring 
system is easy and data interpretation/analysis does not require special expertise to 
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perform. Whilst recognising this, this tool is a subjective health measure and it should be 
supported with advanced objective biomarkers. Currently, highly sophisticated and 
powerful analytical tools are available for measuring, detecting and characterising 
important biomarkers (Adua et al., 2017; Wang, 2016; Yu et al., 2016). This will assist 
in the understanding of the molecular intricacies that underpin the disease’ pathogenesis. 
For example, it is possible to determine transcriptional regulation, post-translational 
modifications, protein expression and interaction and altered enzyme activity (Adua, 
Russell, et al., 2017; Wang, 2016). Research has examined N-glycosylation profiles in 
metabolic syndrome (MetS) (Lu et al., 2011). It was shown that nine N-glycan traits were 
associated with DBP, SBP, FPG and BMI and these could be potential biomarkers for 
MetS (Lu et al., 2011). 
Before concluding, some limitations need to be mentioned. The major one is related 
to the cross-sectional design. There was an inability to determine the proportion of 
participants in the high SHS group who will develop T2DM over time. The study tried to 
perform age-gender matching but the recruited controls were still generally younger than 
cases. However, this does not invalidate the significance of the findings of this study since 
potential confounding was somewhat addressed by logistic regression and multivariate 
analyses. The sample size of the study does not allow a generalisation to be made. 
Moreover, metabolic risk factors such as blood pressure, blood glucose and lipid profiles, 
particularly among the controls were limited to only one time measurement and therefore 
the prevalence of risk factors may be under or overestimated. 
4.7 Conclusion 
There is poor management of risk factors among T2DM patients in this region of 
Ghana. More disturbing is the fact that the majority of people who are at risk, particularly 
of hypertension, are undiagnosed. This underscores the need for novel screening tools 
that can reveal such individuals. The SHSQ-25 represents an instrument of choice and in 
turn sets the platform for prediction, prevention and treatment of T2DM, which is vital, 
particularly for a region where laboratory-based measures are not routinely available.  
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CHAPTER SIX 
Prelude 
Study II (Chapter Five) showed that MetS was associated with an increase in plasma 
concentration of glycoproteins predominately carrying N-glycans. In this study, MetS 
was established based on the recognition of three risk factors: high blood pressure, 
high TG, LDL-c, FPG levels and central obesity. However, it was necessary to extend 
this research by profiling N-glycan structures in clinically diagnosed T2DM patients 
as per the ICD criteria. Further, it was crucial to examine how the structures in T2DM 
differ from aged-gender matched controls (Study III). This manuscript has been 
published in the Journal of Archives of Biochemistry and Biophysics and it can be cited 
as:  
 
Adua E, Memarian E, Russell A, Trbojević-Akmačić I, Gudelj I, Jurić J, Roberts P, Lauc 
G, Wang W (2018). High throughput profiling of whole plasma N-glycans in type II 
diabetes mellitus patients and healthy individuals: A perspective from a Ghanaian 
population. Archives of biochemistry and biophysics Arch Biochem Biophys. 661:10-21. 
. 
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High-throughput profiling of whole plasma N-glycans in Type II 
diabetes mellitus patients and healthy individuals: A perspective from 
a Ghanaian population 
 
6.1 Abstract 
Aberrant protein glycosylation may reflect changes in cell metabolism of type II diabetes 
mellitus (T2DM) and offers fresh vistas for discovering potential biomarkers. However, 
the functional significance of T2DM N-glycan alterations is underexplored, since to date 
N-glycan profiling studies have been mainly performed in selected populations. 
Geographically and genetically isolated populations are needed for validation of specific 
biomarkers. From January to June 2016, an age-gender matched cross-sectional study 
comprising 232 T2DM patients and 219 controls was conducted in Ghana, Western 
Africa. Blood plasma samples were collected for clinical assessment after which plasma 
N-glycans were freed, fluorescently labelled and analysed by ultra-performance liquid 
chromatography (UPLC). Statistical analyses were performed and false discovery rate 
(FDR) controlled by the Benjamini- Hochberg method. High branching (HB) [W= 46328; 
q=0.00072], tri-galactosylated (G3) [W= 44076; q=0.00096], antennary fucosylated 
(FUC_A) [W=43055; q= 0.0000763],  and triantennary (TRIA) [W= 44624; q=0.0025], 
N-glycan structures were increased in T2DM whereas low branching (LB) [W= 46328; 
q=0.00072], non-sialylated (S0) [W= 46929; q=0.00292], monogalactosylation (G1) [W= 
44091; q=0.0000763], core fucosylation (FUC_C), [W= 46497; q=0.00096],  biantennary 
galactosylation (A2G) [W= 45663; q=0.000763], and biantennary (BA) [W= 46376; 
q=0.00072], structures were decreased compared to controls. Nine N-glycan peaks (GPs 
(GP1, GP4, GP7, GP11, GP17, GP19, GP22, GP26, GP29)) were found to predict case 
status based on Akaike's information criterion (AIC) and Bayesian information criterion 
(BIC) model selection. Adjusting for age, sex and other co-variates in this model yielded 
an area under the curve (AUC) of 80.5% with sensitivity of 79% and specificity of 73%, 
indicating the predicting power of N-glycans as robust biomarkers. Our results show that 
hyperglycemia influences N-glycan complexities among Ghanaians. N-glycan profiling 
in distinct populations has affirmed the potentiality of N-glycan profiles as generic 
biomarkers, which may facilitate better prognosis for T2DM. 
 
Key words: biomarker, N-glycan, type II diabetes mellitus 
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6.2 Introduction 
Type II diabetes mellitus (T2DM) is a major health challenge worldwide, 
responsible for much mortality and morbidity (International Diabetes Federation, 2015; 
The World Health Organisation, 2014; Zilliox, Chadrasekaran, Kwan, & Russell, 2016). 
In fact, over one million deaths in 2015 were attributed to T2DM while the disease 
prevalence is still rising (International Diabetes Federation, 2015; WHO, 2015b). 
Additionally, those who survive it experience the debilitating effects of co-morbidities 
that can lead to a decreased quality of life and productivity (Zhong et al., 2015), as well 
as huge financial burden because of frequent hospitalisation and significant medication 
costs (Lim et al., 2013; WHO, 2015a). To date, T2DM has no cure but is only managed 
with disease-modifying drugs (Adua et al., 2017; Bolen et al., 2007; Chaudhury et al., 
2017; Reusch & Manson, 2017). This is primarily because the aetiology or the 
pathophysiology of T2DM is still obscure and complex, with many researchers attributing 
its complexity to the combined effects of genetic epigenetic and environmental factors 
(Grarup, Sandholt, Hansen, & Pedersen, 2014; Morris et al., 2012). However, complex 
oligosaccharides (glycans) represent the intermediary between our genetic make-up and 
the cellular environment (Knežević et al., 2010; Lauc, 2016; National Research Council 
(US) Committee on Assessing the Importance and Impact of Glycomics and 
Glycosciences, 2012; Raman et al., 2005; Russell et al., 2018).  
Glycans bind to protein backbones in a process termed glycosylation and thus far, 
it is regarded as the most complex and abundant co- and post-translational process in the 
cell (Varki, 2009). Protein glycosylation is vital for many biological functions including 
cell recognition and signalling, localisation, immune response and cellular regulation 
(Varki, 2009; Cummings & Pierce, 2014; Wang, 2016). Protein glycosylation can be O-
linked, glycosaminoglycan (GAG), C-linked and N-linked glycans, the latter being the 
most studied and well understood (Varki, 2009; Cummings & Pierce, 2009). N-glycans 
are a subclass of glycan types that bind to asparagine side chains of proteins in the 
consensus sequence Asn-X-Thr/Ser (where X is any amino acid except proline) (Varki et 
al., 2009). Although these structures are fairly stable within an individual they change 
under the influence of an external perturbation, with different physiological parameters 
such as age (Gornik et al., 2009; Knezevic et al., 2008), sex (Baković et al., 2013) and 
pathophysiological conditions such as rheumatoid arthritis (Bondt et al., 2018; Gudelj et 
al., 2018), cancers (Lauc et al., 2013; Theodoratou et al., 2016; Vuckovic et al., 2015), 
 116 
 
Parkinson’s disease (Russell et al., 2017), Alzheimer’s disease (Frenkel-Pinter et al., 
2017), metabolic syndrome (Lu et al., 2011) and T2DM (Lauc, 2016; Campbell, 2016).  
However, aberrant glycosylation in T2DM has only been reported in a few studies 
(Itoh et al., 2007; Keser et al., 2017; Lemmers et al., 2017) but these have indicated the 
functional significance of certain N-glycan structures in T2DM. For example, it was 
hypothesised in the early 1970’s that increased serum fucose was associated with diabetes 
(McMillan, 1972). This was confirmed by Itoh et al., (2007) who suggested a link 
between increased α-1,6-linked fucose with T2DM in the sera of db/db mice and humans 
(Itoh et al., 2007). Both of these studies were largely limited by sample size, suboptimal 
research design and lack of powerful analytical tools. After nearly four decades, Testa et 
al., (2015) performed a large-scale study on Caucasians and showed that core-fucosylated 
diantennary and α-1, 6-linked arm monogalactosylated N-glycans were reduced in T2DM 
compared to controls. However, since DNA sequencer-aided flourophore-assisted 
carbohydrate electrophophoresis (DSA-FACE) was the tool employed, they could not 
measure sialylation and the inadequate resolution resulted in quantification of only the 
ten most abundant N-glycan peaks (Testa et al., 2015).  
Advances in technology have allowed an effective and better large-scale N-glycan 
characterisation and analysis in a high throughput manner. Among the recently developed 
analytical tools including nuclear magnetic resonance (NMR) imaging, capillary 
electrophoresis (Schwedler, 2014), liquid chromatography (Royle et al., 2008), matrix-
assisted laser desorption/ionisation mass spectrometry (MALDI-MS)(Wuhrer, 2013) and 
ultra-performance liquid chromatography (UPLC), the latter has emerged as a powerful 
and widely accepted tool for N-glycosylation analyses because it can efficiently separate 
N-glycan isomers, it is cost effective, reliable and has robust quantification (Bones et al., 
2010; Trbojevic-Akmacic, Vilaj, & Lauc, 2016). Utilising this technique, Lemmers et al., 
(2017) investigated the immunoglobulin G (IgG) glycosylation patterns among 
independent European populations of T2DM individuals and healthy controls (Lemmers 
et al., 2017). Although this study provided insights into molecular mechanisms in the 
disease’s pathophysiology, it was restricted to specific immunoglobulin glycans. As such, 
their attempt to delineate the molecular basis of T2DM was limited. The need for a total 
human plasma N-glycome analysis is thus warranted since such efforts will not only 
represent N-glycosylation alteration in one protein but all proteins in circulation.  
After reviewing the literature, this is the first attempt to apply hydrophilic 
interaction liquid chromatography (HILIC) UPLC technology for a comprehensive N-
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glycan profiling of T2DM patients in a geographically and genetically isolated 
population: sub-Saharan Africa (SSA), Ghana. The outcome of this study will elucidate 
the molecular underpinnings of plasma N-glycosylation in T2DM, which in turn, will 
provide clues for early diagnosis, prognosis and amplify therapeutic opportunities. 
6.3 Methods and Study design 
In this cross-sectional study, we recruited 232 T2DM and 219 age-gender matched 
healthy controls from January to July 2016. T2DM individuals were purposively sampled 
from the Diabetic Unit of the Komfo Anokye Teaching Hospital (KATH), Kumasi, Ghana 
whereas the controls were recruited by convenient sampling from three suburbs within 
the Kumasi metropolis (Ash-town, Pankrono and Abrepo). The study was reviewed and 
approved as described in Chapter Four of this thesis. 
Inclusion Criteria 
T2DM was established based on the international classification of disease 10 (ICD-
10) criteria and known history of anti-diabetes medication use. The controls however, 
were individuals who were not suffering from T2DM and/or hypertension and had no 
history of anti-diabetes or antihypertensive medication use. In both groups, we excluded 
participants who were suffering from other chronic diseases related to the genitourinary, 
digestive, respiratory and haematological systems. The age range for all participants was 
30-80 years. 
Anthropometric Examination  
Anthropometric measurements including weight, height, BMI, WHR, WHtR, SBP 
and DBP were measured by standard methods (See Chapter Four for detailed 
description).  
Clinical Data  
Details of this section are provided in Chapter Four of this thesis. Briefly, venous 
fasting blood samples were collected from each participant into tubes containing EDTA 
(ethylene diamine tetraacetic acid), fluoride oxalate and gel separator. Different clinical 
tests including FPG, HbA1c, TC, HDL-c, LDL-c, TG and VLDL-c were measured on 
the automated chemistry analyser (Roche Diagnostics, COBAS INTEGRA 400 Plus, 
USA). WHtR was then calculated. Aliquots of processed plasma samples were stored at 
-80oC until N-glycan analysis.  
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N-glycan Analysis 
Whole plasma N-glycoprofiling was possible with HILIC-UPLC technique and 
details of this experiment are described in Chapter Five. Briefly, N-glycans in 5μl plasma 
were released by digestion with peptide N-glycosidase F (ProZyme, USA), and labelled 
with 2-aminobenzamide (2AB) (Ludger Tag 2-AB labelling kit, UK).  After incubation 
and washing steps, labelled N-glycans were separated by HILIC-UPLC instrument into 
39 N-glycan peaks (GPs) (Figure 6.1). Eleven derived traits were then calculated from 
the 39 peaks. Data processing was performed using an automated system and a dedicated 
software. 
 
 
Figure 6.1. A chromatogram of 39 fluorescently labelled glycan peaks from the HILIC-UPLC. 
Reproduced with permission from Genos Glycoscience Research Laboratory, Zagreb, Croatia. 
6.4 Statistical Analysis 
Prior to statistical analysis, normalisation and batch correction on the UPLC data 
was performed in order to control for non-biological variability. Normality distribution 
of data was checked by the Kolmogov Smirnoff test as well as visualisation of QQ plots. 
All continuous data was recorded as mean ± standard deviation (Mean ± SD) while 
categorical variables were expressed as frequencies (percentages). However, because of 
the skewed nature of N-glycan data, interquartile ranges (IQR) were used to describe the 
data, hence they were presented as a median depending on the normality distribution, 
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between groups, comparisons for continuous variables were performed using Mann-
Whitney U-tests or Student-t tests and intergroup comparisons of categorical variables 
were performed using Chi-square tests. The Spearman correlation method was used to 
calculate the correlation coefficients (rho) between biochemical parameters and N-
glycans. The association between N-glycans and age in both males and females for cases 
and controls were determined by linear regression. To adjust for multiple testing, the 
Benjamini-Hochberg (BH) method was used to control the false discovery rate (FDR) 
(q). Prior to logistic regression, the data was rank transformed. All statistical analyses 
were performed using the Statistical Package for Social Sciences (SPSS) version 23 and 
the R statistical package software version 3.4.3 (R Core team, 2017). Here, q-value is 
used to represent the p-value after correction for multiple testing and hence a q-value 
<0.05 was considered significant.  
6.5 Results 
Demographic and Biochemical Characteristics 
The mean age for the participants was 56.54 ± 9.89 and 55.10 ± 9.27 years for cases 
and controls respectively, with their ages ranging from 30 to 80 years. The number of 
females was generally higher than males in both groups (i.e. 61.4% females in controls and 
57.3% females in cases) but it was not statistically significant. A large proportion of 
participants in both groups were employed (χ2=26.74, q=0.0003) and educated (χ2=9.83, 
q=0.0812). Compared to controls, T2DM patients were primarily sedentary (χ2=9.77, 
q=0.0446) whereas there was no statistical difference in BMI in both groups. In the clinical 
assessment, T2DM patients had higher FPG (U=9871.5; q=0.0001) and HDL-c (U=17868, 
q=0.0010) than controls. However, SBP (U=20863.5, q=0.0084) was higher in the controls 
compared to those with T2DM. WHtR (U=24057, q=0.5999), TC (U=21918; q=0.9604), 
TG (U=22012, q=0.9050) and LDL-c (U=20545, q=0.3322) were not statistically different 
in the groups (Table 6.1). 
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Table 6.1 Characteristics of participants with and without T2DM. 
Variable  Control Case 
                
Statistic          p                        q  
Age (mean ± SD) 55.10 ± 9.27 56.54 ± 9.89 -1.466t 0.0648 0.1102 
Age (years)      
 31-40 years 8 (3.7) 14(6.0) 8.57^ 0.073 0.1128 
 41-50 years 70(32.0) 50(21.6    
 51-60 years 83(37.9) 87(37.5)    
 61-70 years 44(20.1) 63(27.2)    
 71-80 years 14(6.4) 18(7.8)    
Gender       
 Female 135 (61.4) 133 (57.30)    
BMI (Kg/m2)   1.302^ 0.729 0.8262 
 Underweight 11(5.0) 7(3)    
 Normal 91(41.6) 102(44.2)    
 Overweight 74(33.8) 77(33.0)    
 Obese 43(19.6) 45(19.5)    
Education    9.838^ 0.043 0.0812 
 Tertiary 29(13.3) 40(17.2)    
 Senior high  72(33.0) 53(22.8)    
 Junior high  71(32.6) 76(32.8)    
 Lower primary 28(12.8) 28(12.1)    
 No formal education 18(8.3) 35(15.1)    
Occupation   26.743^ 0.0001* 0.0003** 
 Employed 147(67.4) 152(65.8)    
 Retired 21(9.6) 27(11.7)    
 Keeping house 14(6.4) 23(10.0)    
 Unemployed 26(16.6) 29(12.5)    
Physical activity      
 Sedentary 30(13.8) 53(22.9) 9.772^ 0.021 0.0446** 
 Moderate activity 114(52.3) 94(40.7)    
 Active 74(34.0) 84(36.3)    
Clinical/biochemical data     
WHtR  0.56 ± 0.08 0.56 ± 0.08 24057u 0.4933 0.599 
SBP (mmHg) 145.96 ± 24.3 139.78 ± 24.91 20863.5u 0.0035* 0.0084** 
DBP (mmHg) 84.70 ± 14.42 82.52 ± 13.10 22652u 0.0925 0.131 
FPG (mmol/l) 5.86 ± 0.95 9.24 ± 4.26 9871.5u 0.0000* 0.0001** 
TC(mmol/l) 4.69 ± 1.26 4.66 ± 1.26 21918.5u 0.9604 0.9604 
TG(mmol/l) 1.35 ± 0.97 1.24 ± 0.54 22012.5u 0.8518 0.905 
HDL-c(mmol/l) 1.24 ± 0.33 1.35 ± 0.33 17868u 0.0003* 0.0010** 
LDL-c(mmol/l) 2.88 ± 1.05 2.74 ± 1.16 20545.5u 0.254 0.3322 
CR  5.47 ± 1.50 4.90 ± 1.52 17132u 0.0001* 0.0003** 
Data presented as Mean ± SD and n (%). ^χ2 test of independence, t Student’s t-test, u Mann Whitney U 
tests. Tests of significance were two tailed (*p <0.05); **q<0.05 significant after correction for FDR and 
are bold. 
 
Differential plasma N-glycan patterns in T2DM and healthy controls 
The median interquartile ranges of all measured N-glycans are shown in Table 6.2a 
and obviously, there were distinct levels of N-glycans between cases and controls. 
Generally, GP4 (FA2[6]G1), GP5(FA2[3]G1), GP6(FA2[6]BG1), GP10(FA2G2), 
GP11(FA2BG2), GP13(FA2[3]G1S[3]1), GP16(FA2G2S[6]1), GP17(FA2BG2S[3]1), 
GP18(A2G2S[3,6]2) and GP29(FA3G3S[3,3,3]3 were higher among the controls 
compared to T2DM patients. In contrast, GP14(A2G2S[6]1, GP24(A3G3S[3,6]2), 
GP26(A3G3S[3,3]2), GP30(A3G3S[3,3,6]3) GP31(FA3G3S[3,3,6]3), 
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GP32(A3F1G3S[3,3,3]3), GP34(A4G4S[3,3,6]3) and GP36 (A4G4S[3,3,3,3]4) were 
higher in T2DM compared to controls (q<0.05). 
Table 6.2a. Distribution of plasma N-glycan peak levels in cases and controls  
                                       Control                                                   Case 
                  Median (IQR)        Range                  Median (IQR)     range                     W               P              q          
GP1 6.34(2.61) 5.04 - 7.66 6.44(2.80) 5.07 - 7.88 48518 0.6364 0.68106 
GP2 2.36(0.73) 2.05 - 2.78 2.41(0.82) 2.04 - 2.87 48568 0.6627 0.69698 
GP3 0.09(0.048) 0.07 - 0.12 0.08(0.04) 0.07 - 0.11 48807 0.0574 0.09726 
GP4 5.21(1.67) 4.34 - 6.01 4.44(1.40) 3.85 - 5.26 43677 1.00E-05 7.63E-05** 
GP5 2.16(0.71) 1.76 - 2.47 1.84(0.65) 1.54 - 2.19 44732 1.00E-05 7.63E-05** 
GP6 1.28(0.42) 1.09 - 1.51 1.20(0.39) 1.02 - 1.42 47514 0.0045 0.01056** 
GP7 0.97(0.19) 0.89 - 1.09 0.99(0.18) 0.90 - 1.08 48644 0.7034 0.72671 
GP8 1.13(0.29) 1.01 - 1.31 1.12(0.32) 0.99 - 1.31 50910 0.7148 0.72671 
GP9 0.10(0.03) 0.09 - 0.12 0.09(0.03) 0.09 - 0.12 49516 0.1667 0.25422 
GP10 4.39(1.54) 3.47 - 5.02 3.69(1.45) 3.07 - 4.52 44785 1.00E-05 7.63E-05 
GP11 0.79(0.22) 0.68 - 0.91 0.73(0.20) 0.62 - 0.83 46026 1.00E-04 0.00051** 
GP12 0.98(0.16) 0.90 - 1.06 0.99(0.18) 0.91 - 1.09 47517 0.2288 0.3323 
GP13 0.85(0.28) 0.72 – 1.00 0.81(0.21) 0.71 - 0.92 48047 0.0141 0.02775** 
GP14 10.46(1.53) 9.69 - 11.23 10.87(1.54) 10.05 - 11.59 44881 0.0018 0.00458** 
GP15 0.37(0.08) 0.34 - 0.43 0.37(0.10) 0.34 - 0.44 48788 0.7829 0.7829 
GP16 5.96(1.50) 5.32 - 6.82 5.66(1.39) 5.03 - 6.42 46690 6.00E-04 0.00174** 
GP17 1.74(0.55) 1.46 - 2.01 1.55(0.55) 1.32 - 1.88 46047 1.00E-04 0.00051** 
GP18 3.52(0.71) 3.18 - 3.90 3.40(0.69) 3.05 - 3.75 47842 0.0092 0.02004** 
GP19 1.11(0.21) 1.01 - 1.22 1.11(0.21) 1.00 - 1.21 50554 0.5318 0.6161 
GP20 25.01(3.49) 23.26 - 26.76 25.66(3.90) 23.65 - 27.55 46313 0.0373 0.06895 
GP21 0.51(0.13) 0.46 - 0.59 0.51(0.17) 0.44 - 0.61 49992 0.3004 0.38988 
GP22 4.17(0.97) 3.79 - 4.77 4.31(1.05) 3.89 - 4.95 46308 0.037 0.06895 
GP23 1.99(0.64) 1.71 - 2.35 1.90(0.66) 1.61 - 2.28 49112 0.0934 0.15031 
GP24 1.63(0.55) 1.35 - 1.90 1.74(0.71) 1.38 - 2.10 45553 0.0084 0.01898** 
GP25 0.14(0.05) 0.12 - 0.17 0.15(0.06) 0.13 - 0.19 46439 0.0466 0.08361 
GP26 1.47(0.41) 1.27 - 1.69 1.64(0.53) 1.37 - 1.91 42630 1.00E-05 7.63E-05** 
GP27 0.45(0.32) 0.31 - 0.63 0.47(0.38) 0.30 - 0.68 48488 0.6209 0.67634 
GP28 0.77(0.27) 0.64 - 0.92 0.80(0.32) 0.63 - 0.96 47671 0.2753 0.36507 
GP29 0.20(0.06) 0.18 - 0.24 0.19(0.05) 0.16 - 0.22 46155 1.00E-04 0.00051** 
GP30 5.60(1.84) 4.50 - 6.34 5.89(2.20) 4.70 - 6.91 45661 0.0105 0.02209** 
GP31 0.47(0.20) 0.37 - 0.57 0.50(0.27) 0.41 - 0.69 44950 0.0021 0.00512** 
GP32 1.31(0.48) 1.09 - 1.57 1.46(0.57) 1.24 - 1.82 42435 1.00E-05 7.63E-05** 
GP33 1.79(1.28) 1.23 - 2.52 1.88(1.57) 1.15 - 2.73 48349 0.5511 0.6161 
GP34 0.36(0.09) 0.32 - 0.41 0.39(0.13) 0.33 - 0.47 43628 1.00E-04 0.00051** 
GP35 0.24(0.13) 0.18 - 0.32 0.26(0.16) 0.19 - 0.36 46479 0.0499 0.08697 
GP36 0.42(0.09) 0.38 - 0.47 0.44(0.11) 0.40 - 0.51 43969 2.00E-04 0.00072** 
GP37 0.51(0.21) 0.41 - 0.62 0.48(0.21) 0.38 - 0.59 49121 0.0947 0.15031 
GP38 0.89(0.24) 0.77 - 1.01 0.89(0.26) 0.77 - 1.03 48350 0.5516 0.6161 
GP39 0.49(0.24) 0.42 - 0.66 0.52(0.26) 0.42 - 0.68 47849 0.3365 0.42764 
Data presented as median interquartile range (IQR). Tests of significance were two tailed (p <0.05); 
q<0.05 significant after correction for FDR and are bold. W-Wilcoxon statistic 
From Table 6.2b, low branching (LB), non-sialylated (S0), monogalactosylated 
(G1), core fucosylated (FUC_C), biantennary (BA) and biantennary galactosylated 
(A2G) glycans were higher among the controls compared to T2DM whereas high 
branching (HB), di-sialylated (S2), tri-sialylated (S3), trigalactosylated (G3), antennary 
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fucosylated (FUC_A), and triantennary (TRIA) were higher among T2DM individuals 
compared to controls (q<0.05). 
 
 
Table 6.2b. Distribution of derived plasma N-glycan trait levels among cases and controls  
 Control   Case    
N-glycan Median(IQR) Range Median(IQR) Range       W         p         q 
Branching       
LB 82.65(3.60) 80.76 - 84.37 81.74(3.87) 79.66 - 83.53 46328 2.00E-04 0.00072** 
HB 16.94(3.84) 15.01 - 18.87 17.64(3.94) 16.00 - 19.95 44076 2.00E-04 0.00072** 
Level of sialylation       
S0 25.04(5.92) 22.02 - 27.94 23.63(5.30) 20.94 - 26.25 46929 0.0011 0.00292** 
S1 20.60(2.05) 19.60 - 21.65 20.46(2.11) 19.54 - 21.65 49856 0.2565 0.3477 
S2 39.75(4.12) 37.52 - 41.64 40.74(4.25) 38.39 - 42.65 45743 0.0125 0.02542** 
S3 11.43(2.60) 9.92 - 12.53 11.91(2.70) 10.75 - 13.46 44101 2.00E-04 0.00072** 
S4 2.37(0.60) 2.07 - 2.67 2.41(0.68) 2.09 - 2.78 48044 0.413 0.51414 
Level of galactosylation       
G0 9.74(3.17) 8.25 - 11.42 9.89(3.39) 8.24 - 11.64 48286 0.5209 0.6161 
G1 10.64(2.61) 9.31 - 11.92 9.49(2.36) 8.41 - 10.78 44091 1.00E-05 7.63E-05** 
G2 62.06(5.17) 59.47 - 64.65 62.03(4.71) 59.57 - 64.29 50395 0.4585 0.55937 
G3 12.24(3.42) 10.43 - 13.85 13.23(3.90) 10.99 - 14.90 44241 3.00E-04 0.00096** 
G4 4.45(1.52) 3.83 - 5.36 4.72(1.77) 3.89 - 5.67 47598 0.2525 0.3477 
A2 8.78(3.28) 7.17 - 10.45 8.95(3.32) 7.29 - 10.62 48358 0.5555 0.6161 
A2G 71.56(4.45) 69.35 - 73.8 70.25(4.01) 68.48 - 72.49 45663 1.00E-05 7.63E-05** 
Position of fucose       
FUC_A 2.10(0.60) 1.82 - 2.42 2.37(0.75) 1.98 - 2.74 43055 1.00E-05 7.63E-05** 
FUC_C 38.78(6.63) 35.20 - 41.84 36.57(6.69) 33.67 - 40.36 46497 3.00E-04 0.00096** 
Level of sialylation of biantennary glycans     
BAMS 20.60(2.05) 19.60 - 21.65 20.46(2.11) 19.54 - 21.65 49856 0.2565 0.3477 
BADS 35.56(3.76) 33.57 - 37.32 36.06(3.82) 34.02 - 37.84 46886 0.0961 0.15031 
Degree of branching       
BA 80.46(3.65) 78.61 - 82.27 79.67(3.94) 77.59 - 81.54 46376 2.00E-04 0.00072** 
TRIA 13.11 (3.47) 11.22 - 14.69 14.06(3.89) 11.90 - 15.8 44624 9.00E-04 0.0025** 
TA 4.74(1.62) 4.02 - 5.65 4.94(1.92) 4.05 - 5.97 47501 0.2243 0.3323 
Data presented as median interquartile range (IQR). Tests of significance were two tailed (*p <0.05); 
**q<0.05 significant after correction for FDR and are bold. W-Wilcoxon statistic 
 
Plasma N-glycan associations with T2DM 
After performing logistic regression and FDR correction, GP4(FA2[6]G1), GP5 
(FA2[3]G1),  GP10 (FA2G2), GP13 (FA2[3]G1S[3]1), GP14 (A2G2S[6]1), GP16 
(FA2G2S[6]1), GP17 (FA2BG2S[3]1), GP24 (A3G3S[3,6]2), GP 26 (A3G3S[3,3]2), 
GP32 (A3F1G3S[3,3,3]3) and GP36 (A4G4S[3,3,3,3]4)  were significant in both models 
(q<0.05) (Table 6.3a).  Here, covariates were entered without forward or backward 
selection.  
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Table 6.3a. Logistic regression analysis of N-glycans in the baseline and full models  
BASELINE ADJUSTED                         FULLY ADJUSTED 
      β   S.E       OR(95%CI)        p       q β S.E     OR(95%CI) p    q 
GP1 0.047 0.097 1.05(0.87 - 1.27) 0.63052 0.714444 -0.028 0.126 0.97(0.76 - 1.25) 0.82401 0.8707 
GP2 -0.017 0.098 0.98(0.81 - 1.19) 0.8639 0.86487 0.099 0.132 1.10(0.85 - 1.43) 0.45234 0.6554 
GP3 -0.25 0.100 0.78(0.64 - 0.95) 0.0120* 0.024828** -0.147 0.134 0.86(0.66 - 1.12) 0.27148 0.4791 
GP4 -0.544 0.107 0.58(0.47 - 0.72) 0.00001* 6.67E-05** -0.496 0.133 0.61(0.47 - 0.79) 0.0002 0.0042** 
GP5 -0.486 0.104 0.62(0.50 - 0.75) 0.00001* 6.67E-05** -0.5 0.133 0.61(0.47 - 0.79) 0.00018 0.0042** 
GP6 -0.276 0.096 0.76(0.63 - 0.92) 0.00394* 0.009092** -0.188 0.124 0.83(0.65 - 1.06) 0.12893 0.2658 
GP7 0.043 0.098 1.04(0.86 - 1.27) 0.66105 0.721145 0.069 0.127 1.07(0.84 - 1.38) 0.58538 0.7317 
GP8 -0.072 0.101 0.93(0.76 - 1.13) 0.47517 0.595102 0.211 0.14 1.24(0.94 - 1.63) 0.1329 0.2658 
GP9 -0.158 0.098 0.85(0.70 - 1.04) 0.1072 0.173838 -0.097 0.136 0.91(0.70 - 1.19) 0.47656 0.6554 
GP10 -0.523 0.111 0.59(0.48 - 0.74) 0.00001* 6.67E-05** -0.368 0.141 0.69(0.53 - 0.91) 0.00934 0.0313** 
GP11 -0.351 0.101 0.70(0.58 - 0.86) 0.00051* 0.001457** -0.256 0.132 0.77(0.60 - 1.00) 0.05184 0.1152 
GP12 0.098 0.098 1.10(0.91 - 1.34) 0.31796 0.433582 0.078 0.132 1.08(0.83 - 1.40) 0.55429 0.7076 
GP13 -0.237 0.095 0.79(0.65 - 0.95) 0.0129* 0.0258** -0.312 0.125 0.73(0.57 - 0.94) 0.01243 0.0373** 
GP14 0.258 0.097 1.29(1.07 - 1.57) 0.0081* 0.017357** 0.372 0.13 1.45(1.12 - 1.87) 0.00433 0.0278** 
GP15 0.039 0.095 1.04(0.86 - 1.25) 0.6848 0.733714 -0.005 0.127 1.00(0.78 - 1.28) 0.96892 0.9853 
GP16 -0.385 0.106 0.68(0.55 - 0.84) 0.00027* 0.000853** -0.335 0.133 0.72(0.55 - 0.93) 0.01159 0.0366** 
GP17 -0.344 0.100 0.71(0.58 - 0.86) 0.00059* 0.001609** -0.341 0.131 0.71(0.55 - 0.92) 0.00939 0.0313** 
GP18 -0.283 0.101 0.75(0.62 - 0.92) 0.00524* 0.011644** -0.066 0.134 0.94(0.72 - 1.22) 0.6233 0.732 
GP19 -0.043 0.092 0.96(0.80 - 1.15) 0.64299 0.714444 -0.09 0.127 0.91(0.71 - 1.17) 0.48066 0.6554 
GP20 0.183 0.096 1.20(1.00 - 1.45) 0.05672 0.103127 0.18 0.126 1.20(0.94 - 1.53) 0.15165 0.2935 
GP21 -0.128 0.099 0.88(0.73 - 1.07) 0.19371 0.270293 -0.094 0.13 0.91(0.71 - 1.18) 0.47074 0.6554 
GP22 0.192 0.096 1.21(1.00 - 1.46) 0.04558* 0.085463 -0.052 0.123 0.95(0.75 - 1.21) 0.67356 0.7625 
GP23 -0.173 0.097 0.84(0.70 - 1.02) 0.07371 0.130076 -0.277 0.125 0.76(0.59 - 0.97) 0.02597 0.0677 
GP24 0.321 0.105 1.38(1.12 - 1.69) 0.00228* 0.005472** 0.388 0.14 1.48(1.12 - 1.94) 0.00556 0.0278** 
GP25 0.171 0.099 1.19(0.98 - 1.44) 0.08286 0.142046 0.112 0.132 1.12(0.86 - 1.45) 0.39576 0.6475 
GP26 0.636 0.120 1.89(1.49 - 2.39) 0.00001* 6.67E-05** 0.548 0.155 1.73(1.28 - 2.34) 0.00041 0.0062** 
GP27 0.017 0.098 1.02(0.84 - 1.23) 0.86487 0.86487 0.061 0.129 1.06(0.83 - 1.37) 0.63444 0.732 
GP28 0.15 0.099 1.16(0.96 - 1.41) 0.13001 0.205279 0.156 0.133 1.17(0.90 - 1.52) 0.23924 0.435 
GP29 -0.406 0.104 0.67(0.54 - 0.82) 0.0001* 0.000353** -0.255 0.132 0.78(0.60 - 1.01) 0.05436 0.1165 
GP30 0.343 0.108 1.41(1.14 - 1.74) 0.00146* 0.00365** 0.304 0.142 1.36(1.03 - 1.79) 0.03189 0.0797 
GP31 0.435 0.112 1.55(1.24 - 1.92) 0.0001* 0.000353** 0.298 0.148 1.35(1.01 - 1.80) 0.04491 0.1078 
GP32 0.635 0.117 1.89(1.50 - 2.38) 0.00001* 6.67E-05** 0.472 0.156 1.60(1.18 - 2.18) 0.0025 0.0278** 
GP33 0.02 0.097 1.02(0.84 - 1.24) 0.83359 0.862334 0.084 0.129 1.09(0.85 - 1.40) 0.51431 0.6708 
GP34 0.568 0.120 1.76(1.40 - 2.23) 0.00001* 6.67E-05** 0.362 0.16 1.44(1.05 - 1.97) 0.0234 0.0638 
GP35 0.164 0.097 1.18(0.97 - 1.42) 0.09083 0.151383 0.106 0.127 1.11(0.87 - 1.43) 0.40378 0.6475 
GP36 0.396 0.106 1.49(1.21 - 1.83) 0.00019* 0.000633** 0.359 0.136 1.43(1.10 - 1.87) 0.00831 0.0312** 
GP37 -0.135 0.099 0.87(0.72 - 1.06) 0.17052 0.2436 -0.038 0.13 0.96(0.75 - 1.24) 0.7734 0.8437 
GP38 0.067 0.100 1.07(0.88 - 1.30) 0.49840 0.59808 0.102 0.133 1.11(0.85 - 1.44) 0.4446 0.6554 
GP39 0.047 0.095 1.05(0.87 - 1.26) 0.62330 0.714444 0.045 0.122 1.05(0.82 - 1.33) 0.71499 0.7944 
Baseline model: Age and gender adjusted. Full model: Age, gender, BMI, TC, TG, FPG and LDL-c. Tests 
of significance were two tailed (*p <0.05); **q<0.05 significant after correction for FDR and are bold.  
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After performing logistic regression and FDR correction, LB, HB, S3, G1, G3, 
FUC_C, BA, A2G and TRIA were significant in both models (p<0.05;q<0.05), while S0 
and FUC_A were significant in the fully adjusted model, but not in baseline adjusted 
(Table 6.3b).   
Table 6.3b Regression analyses of derived N-glycans for baseline adjusted and fully adjusted. 
BASELINE ADJUSTED FULLY ADJUSTED 
Glycan       β         S.E OR(95%CI)        p      q    β 
     
S.E. OR(95%CI)      p       q 
LB -0.37 0.136 0.69(0.53 - 0.90) 0.00656* 0.0281** -0.446 0.109 0.64(0.52 - 0.79) 0.00004* 0.000171** 
HB 0.403 0.142 1.50(1.13 - 1.98) 0.00448* 0.0278** 0.46 0.11 1.59(1.28 - 1.97) 0.00003* 0.000138** 
S0 -0.251 0.127 0.78(0.61 - 1.00) 0.04893* 0.1129 -0.32 0.101 0.73(0.60 - 0.88) 0.00145* 0.00365** 
S1 -0.062 0.127 0.94(0.73 - 1.20) 0.62346 0.732 -0.144 0.097 0.87(0.72 - 1.05) 0.13772 0.20658 
S2 0.161 0.126 1.18(0.92 - 1.51) 0.20087 0.3766 0.219 0.098 1.25(1.03 - 1.51) 0.02598* 0.050284 
S3 0.371 0.139 1.45(1.10 - 1.90) 0.00773* 0.0309** 0.457 0.109 1.58(1.28 - 1.95) 0.00003* 0.000138** 
S4 0.104 0.129 1.11(0.86 - 1.43) 0.42085 0.6475 0.068 0.097 1.07(0.88 - 1.30) 0.486 0.595102 
G0 0.017 0.128 1.02(0.79 - 1.31) 0.89658 0.9275 0.045 0.098 1.05(0.86 - 1.27) 0.643 0.714444 
G1 -0.49 0.132 0.61(0.47 - 0.79) 0.00021* 0.0042** -0.52 0.104 0.60(0.49 - 0.73) 0.00001* 6.67E-05** 
G2 -0.027 0.124 0.97(0.76 - 1.24) 0.82715 0.8707 -0.094 0.096 0.91(0.75 - 1.10) 0.33002 0.440027 
G3 0.422 0.147 1.53(1.14 - 2.04) 0.00412* 0.0278** 0.484 0.113 1.62(1.30 - 2.03) 0.00002* 0.00012** 
G4 0.102 0.124 1.11(0.87 - 1.41) 0.41174 0.6475 0.068 0.095 1.07(0.89 - 1.29) 0.47749 0.595102 
FUC_A 0.315 0.134 1.37(1.05 - 1.78) 0.01871* 0.0535 0.461 0.105 1.59(1.29 - 1.95) 0.00001* 6.67E-05** 
FUC_C -0.363 0.13 0.70(0.54 - 0.90) 0.00511* 0.0278** -0.352 0.101 0.70(0.58 - 0.86) 0.00048* 0.00144** 
BA -0.385 0.138 0.68(0.52 - 0.89) 0.00516* 0.0278** -0.451 0.109 0.64(0.52 - 0.79) 0.00003* 0.000138** 
A2 -0.001 0.128 1.00(0.78 - 1.28) 0.99191 0.9919 0.036 0.098 1.04(0.86 - 1.26) 0.70985 0.747211 
A2G -0.382 0.136 0.68(0.52 - 0.89) 0.00495* 0.0278** -0.48 0.107 0.62(0.50 - 0.76) 0.00001* 6.67E-05** 
BAMS -0.062 0.127 0.94(0.73 - 1.20) 0.62346 0.732 -0.144 0.097 0.87(0.72 - 1.05) 0.13772 0.20658 
BADS 0.083 0.125 1.09(0.85 - 1.39) 0.50657 0.6708 0.137 0.097 1.15(0.95 - 1.39) 0.15766 0.230722 
TRIA 0.396 0.145 1.49(1.12 - 1.97) 0.00633* 0.0281** 0.451 0.112 1.57(1.26 - 1.95) 0.00005* 0.0002** 
TA 0.102 0.124 1.11(0.87 - 1.41) 0.40823 0.6475 0.075 0.095 1.08(0.90 - 1.30) 0.42856 0.558991 
Baseline model: Age and gender adjusted. Full model: Age, gender, BMI, FPG, TC, TG and LDL-c. Tests 
of significance were two tailed (*p <0.05); **q<0.05 significant after correction for FDR and are bold.    
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Figure 6.2. Differences in expression of selected N-glycans after performing a logistic regression in 
the full model. While GP4 - FA2[6]G1, GP16 - FA2G2S[6]1 and GP17 - FA2BG2S[3]1 are higher in 
controls, GP32 -A3F1G3S[3,3,3]3 is higher in T2DM. 
After controlling for FDR, 9 N-glycan traits correlated with WHtR among the 
controls (6 positively and 3 negatively). Among the cases, 6 N-glycan traits correlated 
with WHtR (2 positively and 4 negatively). There were 13 correlations between N-
glycans and LDL-c among the controls (7 positively and 6 negatively). However, no 
correlations were found between N-glycan traits and LDL-c in the cases. Whereas there 
were 13 correlations between N-glycans and TC among the controls (7 positively and 6 
negatively), there were no correlations between derived N-glycan traits and TC in T2DM. 
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Further, 13 significant correlations were found between derived N-glycan traits and TG in controls (7 positively and 6 negatively) whereas 4 positive 
correlations were shown between derived plasma N-glycan traits and TG among the cases (Table 6.4). 
 
Table 6.4. Correlations between derived plasma N-glycan traits and WHtR, FPG, LDL-c, TC and TG 
      WHtR  FPG                     LDL-c                               TC                            TG  
 
      
CONTROLS  
         
CASES  CONTROLS     CASES      CONTROLS  CASES CONTROLS CASES CONTROLS CASES 
Peaks    rs    q      rs    q     rs     q    rs      q      rs q 
           
rs       q      rs         q 
       
rs      q     rs        q      rs q 
Branching                    
LB -0.22 0.0025** -0.15 0.0568 -0.02 0.862 -0.13 0.2704 -0.21 0.0029** 0.03 0.9927 -0.26 0.0001** -0.02 0.9522 -0.23 0.0006** -0.14 0.0933 
HB 0.25 0.0005** 0.15 0.0599 0.02 0.862 0.12 0.3084 0.21 0.0032** -0.01 0.9927 0.26 0.0001** 0.04 0.9522 0.25 0.0006** 0.15 0.0768 
Level of sialylation                   
S0 -0.14 0.0599 -0.01 0.9618 -0.06 0.5835 -0.11 0.3144 -0.20 0.0035** -0.02 0.9927 -0.20 0.0040** -0.06 0.9522 -0.13 0.0078** -0.11 0.2173 
S1 -0.14 0.0599 -0.29 0.0001** -0.09 0.3677 0.07 0.5611 -0.04 0.5837 0.06 0.9927 -0.09 0.2268 0.03 0.9522 -0.17 0.3074 -0.06 0.5652 
S2 0.15 0.054 0.07 0.4993 0.16 0.1454 0.04 0.8136 0.17 0.013** 0.03 0.9927 0.17 0.0165** 0.07 0.9522 0.13 0.0296** 0.12 0.2042 
S3 0.24 0.0011** 0.15 0.0568 0.04 0.7486 0.11 0.3144 0.18 0.0104** -0.02 0.9927 0.24 0.0006** 0.03 0.9522 0.24 0.0018** 0.14 0.1009 
S4 0.18 0.0205** 0.08 0.4094 -0.14 0.1659 0.06 0.5938 0.22 0.0019** -0.03 0.9927 0.21 0.0022** 0.00 0.9917 0.16 0.0053** 0.11 0.2173 
Level of galactosylation                   
G0 -0.08 0.3266 0.03 0.801 0.03 0.7677 -0.03 0.8388 -0.04 0.5854 -0.01 0.9927 -0.01 0.8793 0.00 0.9917 0.01 0.9248 0.03 0.7909 
G1 -0.11 0.1495 0.01 0.9618 -0.1 0.3554 -0.11 0.3144 -0.26 0.0002** -0.02 0.9927 -0.24 0.0005** -0.08 0.9522 -0.15 0.0016** -0.15 0.0768 
G2 -0.05 0.5756 -0.16 0.0521 0.04 0.7486 0.00 0.99 0.02 0.7833 0.05 0.9927 -0.04 0.5276 0.02 0.9522 -0.09 0.6072 -0.05 0.5652 
G3 0.29 0.0001** 0.15 0.0568 0.01 0.862 0.13 0.2704 0.19 0.0054** 0.00 0.9927 0.28 0.0001** 0.06 0.9522 0.25 0.0004** 0.18 0.0492** 
G4 0.00 0.9767 0.01 0.9651 0.01 0.8627 -0.02 0.8388 0.07 0.3072 0.00 0.9927 0.05 0.4907 0.01 0.9522 0.06 0.5757 -0.02 0.8382 
A2 -0.09 0.2679 0.04 0.7686 0.03 0.7677 -0.04 0.8233 -0.05 0.4799 -0.02 0.9927 -0.02 0.7559 0.00 0.9917 0.01 0.8089 0.02 0.8379 
A2G -0.16 0.0362** -0.18 0.0257** -0.04 0.7486 -0.08 0.4996 -0.17 0.0181** 0.04 0.9927 -0.23 0.0012** -0.02 0.9522 -0.21 0.0034** -0.14 0.11 
Position of fucose                   
FUC_A 0.33 0.0001** 0.27 0.0002** 0.15 0.1517 0.10 0.3292 0.16 0.0195** -0.02 0.9927 0.20 0.0037** 0.03 0.9522 0.31 0.0078** 0.22 0.0106** 
FUC_C -0.12 0.1251 0.01 0.9618 -0.08 0.4805 -0.05 0.7009 -0.24 0.0007** 0.00 0.9927 -0.23 0.0010** -0.05 0.9522 -0.16 0.0028** -0.11 0.2173 
Level of sialylation of biantennary N-glycans                 
BAMS -0.14 0.0599 -0.29 0.0001** -0.09 0.3677 0.07 0.5611 -0.04 0.5837 0.06 0.9927 -0.09 0.2268 0.03 0.9522 -0.17 0.3074 -0.06 0.5652 
BADS 0.09 0.2679 0.04 0.7686 0.14 0.1659 0.02 0.8643 0.12 0.0824 0.03 0.9927 0.10 0.1466 0.06 0.9522 0.07 0.2181 0.08 0.40 
Degree of branching                   
BA -0.25 0.0005** -0.16 0.0495** -0.03 0.823 -0.14 0.2704 -0.24 0.0006** 0.01 0.9927 -0.30 0.0000** -0.04 0.9522 -0.26 0.0002** -0.16 0.0768 
TRIA 0.31 0.0001** 0.16 0.0495** 0.02 0.8272 0.13 0.2704 0.21 0.0027** 0.01 0.9927 0.29 0.0000** 0.06 0.9522 0.26 0.0002** 0.18 0.0492** 
TA 0.00 0.9767 0.01 0.9651 0.02 0.8272 -0.02 0.8388 0.07 0.2913 0.00 0.9927 0.05 0.4624 0.02 0.9522 0.07 0.5531 -0.02 0.8382 
Tests of significance were two tailed **q<0.05 significant after correction for FDR and are bold.
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As shown in Table 6.5a, 19 N-glycan peaks correlated with WHtR among the 
controls (10 positively and 9 negatively) whereas 12 N-glycan peaks correlated with 
WHtR among the cases (7 positively and 5 negatively). No significant correlations existed 
between N-glycan peaks and FPG in both controls and cases. There were 22 correlations 
between N-glycan peaks and TC among the controls (13 positively and 9 negatively) 
whereas no correlations were seen among the cases.  
Table 6.5a. Correlation between plasma N-glycan peaks and WHtR, FPG, TC and TG 
 WHtR    FPG    TC    
 controls Cases Control Case Controls Cases 
Peak     rs      q  rs     q rs q rs q rs q rs q 
GP1 -0.06 0.4575 0.08 0.4114 0.04 0.7486 -0.01 0.884 -0.02 0.8045 0.00 0.9917 
GP2 -0.19 0.0113** -0.08 0.4094 0.00 0.9841 -0.10 0.3685 0.00 0.9897 -0.03 0.9522 
GP3 -0.29 0.0001** -0.21 0.0068** -0.14 0.1659 -0.07 0.4996 -0.27 0.0004** -0.05 0.9522 
GP4 -0.12 0.1251 0.03 0.801 -0.08 0.4805 -0.11 0.3144 -0.22 0.0044** -0.08 0.9522 
GP5 -0.06 0.4478 0.04 0.7489 -0.11 0.3106 -0.10 0.3302 -0.26 0.0007** -0.10 0.9522 
GP6 -0.02 0.8185 0.11 0.1745 -0.04 0.7628 -0.13 0.2704 -0.09 0.3074 -0.09 0.9522 
GP7 0.17 0.0305** 0.00 0.9652 -0.04 0.7486 0.02 0.8388 0.17 0.0281** -0.02 0.9522 
GP8 -0.32 0.0001** -0.33 0.0001** -0.12 0.3064 -0.11 0.3144 -0.21 0.0054** -0.02 0.9522 
GP9 -0.26 0.0003** -0.21 0.0064** -0.16 0.1454 0.02 0.8388 -0.21 0.0061** -0.04 0.9522 
GP10 -0.18 0.0205** -0.09 0.3481 -0.17 0.1454 -0.14 0.2704 -0.28 0.0003** -0.11 0.9522 
GP11 -0.05 0.5756 -0.04 0.7686 -0.11 0.3106 -0.03 0.8388 -0.09 0.2646 -0.11 0.9522 
GP12 -0.15 0.054 -0.31 0.0001** 0.04 0.7486 0.20 0.1568 0.21 0.0053** 0.08 0.9522 
GP13 -0.10 0.2254 0.03 0.8537 -0.15 0.1454 -0.04 0.8136 -0.25 0.0014** -0.03 0.9522 
GP14 -0.01 0.9372 -0.22 0.0039** 0.10 0.3677 0.00 0.9900 0.14 0.0691 0.06 0.9522 
GP15 -0.09 0.2679 -0.11 0.2187 -0.14 0.1659 0.14 0.2704 -0.13 0.1024 0.05 0.9522 
GP16 -0.18 0.0169** -0.14 0.0721 -0.17 0.1454 0.00 0.9900 -0.24 0.0016** -0.05 0.9522 
GP17 0.05 0.5032 -0.01 0.9618 -0.07 0.5281 0.04 0.8142 0.02 0.8032 -0.06 0.9522 
GP18 -0.37 0.0001** -0.33 0.0001** -0.11 0.3106 -0.11 0.3144 0.03 0.7459 -0.05 0.9522 
GP19 0.32 0.0001** 0.27 0.0002** 0.17 0.1454 0.04 0.8136 0.35 0.0001** 0.13 0.9522 
GP20 0.15 0.054 0.08 0.4105 0.15 0.1454 -0.02 0.8643 0.15 0.0603 0.05 0.9522 
GP21 -0.08 0.2954 -0.05 0.6698 -0.02 0.8314 -0.01 0.9421 -0.20 0.0078** 0.02 0.9522 
GP22 0.06 0.4575 0.04 0.7686 0.08 0.5008 0.16 0.2704 -0.07 0.3939 0.02 0.9522 
GP23 -0.02 0.8185 0.01 0.9651 -0.05 0.7486 0.07 0.4996 -0.11 0.1642 0.00 0.9917 
GP24 0.09 0.2407 -0.01 0.9651 -0.05 0.7229 0.06 0.6218 0.19 0.0150** 0.03 0.9522 
GP25 -0.17 0.0271** -0.17 0.0433** -0.07 0.5165 0.02 0.851 0.08 0.3181 0.01 0.9917 
GP26 0.38 0.0001** 0.22 0.0051** 0.08 0.5008 0.13 0.2704 0.30 0.0001** 0.07 0.9522 
GP27 -0.16 0.0375** -0.06 0.5571 0.06 0.6619 -0.09 0.3866 -0.06 0.5033 0.02 0.9522 
GP28 0.04 0.5756 -0.01 0.9618 -0.10 0.3554 0.07 0.4996 0.20 0.0078** 0.02 0.9522 
GP29 -0.28 0.0001** -0.15 0.0568 -0.16 0.1454 -0.05 0.6611 0.00 0.994 0.02 0.9522 
GP30 0.26 0.0004** 0.13 0.1246 -0.03 0.7628 0.12 0.3084 0.25 0.0014** 0.04 0.9522 
GP31 0.37 0.0001** 0.21 0.0057** 0.07 0.5181 0.14 0.2704 0.36 0.0001** 0.06 0.9522 
GP32 0.49 0.0001** 0.33 0.0001** 0.14 0.1659 0.16 0.2704 0.28 0.0003** 0.07 0.9522 
GP33 -0.15 0.0529 -0.06 0.6092 0.04 0.7486 -0.09 0.4241 -0.06 0.4729 0.01 0.9917 
GP34 0.44 0.0001** 0.29 0.0001** 0.10 0.3677 0.16 0.2704 0.37 0.0001** 0.05 0.9522 
GP35 -0.02 0.8185 0.05 0.6698 0.11 0.3106 -0.03 0.8388 0.06 0.5281 0.02 0.9522 
GP36 0.27 0.0002** 0.10 0.2700 -0.01 0.862 0.11 0.3144 0.32 0.0001** 0.04 0.9522 
GP37 0.09 0.2467 0.00 0.9652 -0.19 0.1434 0.02 0.8388 0.14 0.0797 0.00 0.9917 
GP38 0.26 0.0004** 0.12 0.1593 -0.15 0.1517 0.09 0.3889 0.27 0.0004** 0.05 0.9522 
GP39 0.02 0.8185 0.07 0.5233 0.05 0.7229 -0.02 0.8388 0.01 0.9637 0.03 0.9522 
Tests of significance were two tailed **q<0.05 significant after correction for FDR and are bold. 
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As shown in Table 6.5b, 14 N-glycan peaks correlated with TG among the controls 
while 5 correlated with TG among the cases. There were 19 correlations between GPs 
and LDL-c among controls whereas no correlations were seen in the cases. 
Table 6.5b. Correlation between plasma N-glycan peaks, TG, and LDL-c. 
 TG LDL-c 
 Controls Cases Controls Cases  
Peak        rs                   q rs q                rs                    
             
q             rs            q  
GP1 0.01 0.9087 0.02 0.8379 -0.06 0.4791 -0.02 0.9927 
GP2 -0.05 0.5469 0.02 0.8379 0.01 0.875 -0.02 0.9927 
GP3 -0.14 0.0829 -0.02 0.8379 -0.27 0.0013** -0.01 0.9927 
GP4 -0.14 0.0992 -0.17 0.0658 -0.23 0.0037** -0.03 0.9927 
GP5 -0.11 0.169 -0.17 0.0658 -0.29 0.0006** -0.05 0.9927 
GP6 -0.10 0.2697 -0.02 0.8379 -0.09 0.2836 -0.07 0.9927 
GP7 0.11 0.1986 0.07 0.4913 0.15 0.0599 -0.04 0.9927 
GP8 -0.15 0.0808 -0.05 0.5652 -0.15 0.0587 0.03 0.9927 
GP9 -0.18 0.0317** -0.03 0.8163 -0.20 0.0132** -0.01 0.9927 
GP10 -0.22 0.0057** -0.26 0.0020** -0.25 0.0024** -0.05 0.9927 
GP11 -0.17 0.0445** -0.08 0.4277 -0.09 0.2836 -0.10 0.9927 
GP12 -0.04 0.6813 0.06 0.5652 0.24 0.0027** 0.05 0.9927 
GP13 -0.14 0.0992 -0.11 0.2173 -0.25 0.0016** 0.02 0.9927 
GP14 0.05 0.5325 0.04 0.6962 0.19 0.0186** 0.05 0.9927 
GP15 -0.09 0.3124 0.08 0.3874 -0.11 0.1609 0.04 0.9927 
GP16 -0.21 0.0074** -0.17 0.0599 -0.20 0.0112** 0.01 0.9927 
GP17 -0.10 0.2389 0.00 0.9987 0.00 0.9532 -0.08 0.9927 
GP18 -0.22 0.0074** -0.17 0.0599 0.09 0.3028 -0.04 0.9927 
GP19 0.34 0.0009** 0.15 0.0826 0.35 0.0006** 0.13 0.9927 
GP20 0.12 0.1489 0.11 0.2173 0.17 0.0351** 0.01 0.9927 
GP21 -0.01 0.9087 0.07 0.4876 -0.19 0.0132** 0.02 0.9927 
GP22 0.05 0.5325 0.05 0.5652 -0.09 0.301 0.03 0.9927 
GP23 -0.07 0.4025 -0.01 0.9249 -0.12 0.1583 0.02 0.9927 
GP24 0.07 0.4366 0.08 0.4277 0.14 0.0741 0.00 0.9927 
GP25 -0.12 0.169 -0.08 0.418 0.04 0.6197 0.01 0.9927 
GP26 0.29 0.0006** 0.20 0.0196**  0.21 0.0093** 0.03 0.9927 
GP27 -0.04 0.6813 -0.12 0.181 -0.03 0.7272 0.04 0.9927 
GP28 0.06 0.5289 0.06 0.5652 0.15 0.0587 -0.01 0.9927 
GP29 -0.20 0.0124** -0.11 0.2173 0.07 0.3854 0.02 0.9927 
GP30 0.21 0.0078** 0.15 0.0768 0.17 0.036** 0.00 0.9927 
GP31 0.31 0.0002** 0.26 0.002** 0.26 0.0013** -0.01  0.9927 
GP32 0.37 0.0009** 0.28 0.0006** 0.20 0.0114** 0.01 0.9927 
GP33 -0.03 0.7552 -0.11 0.2173 -0.03 0.7272 0.02 0.9927 
GP34 0.39 0.0009** 0.30 0.0006** 0.27 0.0013** -0.02 0.9927 
GP35 0.07 0.4366 -0.02 0.8379 0.06 0.462 0.00 0.9927 
GP36 0.24 0.0023** 0.15 0.0768 0.29 0.0006** -0.01 0.9927 
GP37 0.03 0.7035 0.05 0.5705 0.15 0.0587** -0.01 0.9927 
GP38 0.21 0.0092** 0.15 0.0768 0.27 0.0013** 0.00 0.9927 
GP39 0.08 0.3599 0.05 0.5652 0.03 0.7272 0.00 0.9927 
Tests of significance were two tailed **q<0.05 significant after correction for FDR and are bold.
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Figure 6.3a. Line graph of the relationship between selected N-glycans and age in T2DM. Overall, advancing in age was associated with decreasing levels of GP10 
(FA2G2) and GP11 (FA2BG2) whereas increasing in age was associated with increasing levels of GP12 (A2[3] BG1S[3]1). 
                             
Figure 6.3b. A line graph of the relationship between selected N-glycans and Age among controls. The shaded region represents 95% confidences interval on the fitted 
values.Advancing in age was associated with decreasing levels of  GP10 (FA2G2) and GP16 (FA2G2S [6]1) whereas increasing in age was associated with increasing levels 
of GP14(A2G26 [6]1).
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Table 6.6 Adjusted logistic regression model 
   
Model Fitting 
Criteria    
 Beta S.E AIC BIC 
-2 Log 
Likelihood     χ2 q 
GP1 0.342 0.073 521.311 558.255 503.311 27.584 0.000 
GP4 -1.109 0.16 554.319 591.262 536.319 60.592 0.000 
GP7 5.639 1.088 524.123 561.066 506.123 30.396 0.000 
GP11 4.381 1.538 502.132 539.075 484.132 8.405 0.004 
GP17 -3.199 0.57 529.583 566.526 511.583 35.856 0.000 
GP19 -4.421 0.914 519.778 556.721 501.778 26.051 0.000 
GP22 0.849 0.171 521.073 558.016 503.073 27.346 0.000 
GP26 1.496 0.428 506.602 543.545 488.602 12.875 0.000 
GP29 -6.113 2.951 498.112 535.056 480.112 4.385 0.036 
S.E Standard error of the beta. AIC: Akaike information criterion, BIC: Bayesian information criterion,   
χ2: Chi-square. Tests of statistical significance are two tailed and q<0.05 is bold 
 
 
Figure 6.4. Receiver operative characteristic (ROC) curve illustrating the performance of the age 
and sex adjusted logistic regression model in predicting the status of patients with T2DM and healthy 
controls. Nine GPs were found to predict case status using a step-wise Akaike’s information criterion (AIC) 
and Bayesian information criterion (BIC) logistic regression model selection (Table 6.6). This model 
yielded an area under curve of 80.5% [95% CI 76.4%-84.6%]. 
 
6.6 Discussion 
This first comprehensive whole human plasma N-glycan profiling study using a 
Ghanaian population is premised on the hypothesis that there is a differential abundance 
of plasma N-glycan structures between T2DM and healthy controls.  
Association between T2DM risk factors and measured plasma N-glycans 
Several T2DM risk factors were significantly associated with either increased or 
decreased levels of specific plasma N-glycans (Tables 6.4 & 6.5). Consistent with 
previous findings (Krištić et al., 2014; Lemmers et al., 2017; Perkovic et al., 2014; 
Reiding et al., 2017; Russell et al., 2017; Yu et al., 2016), the present study has shown 
that there were significant correlations between plasma N-glycans and age (Figure 6.3), 
WHtR, BMI and TG in both cases and controls whereas there were no correlations 
AUC =80.5% [76.4%-84.6%] 
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between N-glycans and HDL-c in both groups. Surprisingly, nearly all significant 
correlations between N-glycans and TC, FPG, LDL-c, SBP and DBP (Tables 6.4, 6.5a 
& 6.5b and Supplementary Tables S2-4, See Appendix) were only observed among 
the controls. This outcome could partly be attributed to the impact of medications. All 
T2DM patients were recruited from a hospital and our previous investigations among 
these people revealed that they were on glucose lowering, lipid lowering and anti-
hypertensive therapy at the time of blood sampling (Adua et al., 2017).  
Core and antennary fucosylation 
While it is still not well understood, altered plasma N-glycosylation patterns 
between T2DM and healthy controls could be attributed to the differential expression of 
glycosyltransferases particularly α-1,6-fucosyltransferase 8 (FUT8) which catalyses core 
fucosylation (Simala-Grant, & Taylor, 2006; Yarema & Bertozzi, 2001). Core 
fucosylation, the attachment of fucose to inner N-acetylglucosamine (GlcNAc), is a 
significant phenomenon in the glycosylation machinery that mediates important cellular 
events, including notch signalling, growth factor receptor expression and adhesion 
molecule activity. Thus, its alteration has been linked to many metabolic events such as 
inflammation and T2DM (Ma et al., 2006; Miyoshi, Moriwaki, & Nakagawa, 2008). For 
example, an increased core fucose level was associated with diabetes mellitus (DM) 
(McMillan, 1972) and α-1,6 core fucosylation was higher in the sera of db/db mice (a 
model of T2DM with obesity) and humans with T2DM (Itoh et al., 2007). On the 
contrary, our results show that T2DM patients had a decreased FUC_C (Table 6.2b) and 
additionally, core fucosylated N-glycans with bisection; GP5 (FA2[3]G1), 
GP11(FA2BG2) and GP17 (FA2BG2S[3]1) were significantly decreased in T2DM 
(Table 6.2a). Our findings however, are consistent with recent N-glycomics 
investigations involving larger populations (Lemmers et al., 2017; McLachlan et al., 
2016).  For example, in a large cohort study comprising 2,155 individuals from the 
Orkney Islands (UK), a subclass of individuals suffering from metabolic syndrome 
(MetS) had decreased levels of FUC_C N-glycans (McLachlan et al., 2016). A possible 
explanation for this is that decreased expression of FUT8 or decreased/absence of 
fucosyltransferase may lead to overexpression of matrix metalloproteinase and decreased 
expression of extracellular matrix proteins. This inhibits the binding of epidermal growth 
factor (EGF) to its receptor in the transforming growth factor β1 signalling pathway. Also, 
absence of core fucosylation leads to impaired function of low-density lipoprotein 
receptor-related protein 1, which is involved in the endocytosis of insulin-like growth 
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factor (IGF)-binding protein-3 (IGFBP-3) (Brinkman-van der Linden, de Haan, 
Havenaar, & van Dijk, 1998; Ma et al., 2006). Alternatively, β-1,4 N-
acetylglucosaminyltranferase III (GnT III) is an enzyme that catalyses the addition to N-
acetylglucosamine to the β mannose of the core of the trimannosyl core of N-glycans but 
also suppresses the elongation or the formation of multiantennary chains on N-glycans 
(Li et al., 2007). Moreover, while the focus of this study was not on specific proteins, it 
is worth noting that the glycosylation of certain plasma proteins has implications for 
T2DM pathophysiology. For example, one study has shown that decreased FUC_C IgG 
N-glycans, with or without bisecting GIcNAc, was associated with T2DM in European 
populations (Lemmers et al., 2017). Particularly, bisecting N-acetyl glucosamine on IgG 
facilitates antibody dependent cellular cytotoxicity (ADCC) or a pro-inflammatory state 
since the presence of bisecting N-acetyl glucosamine on N-glycans inhibits core 
fucosylation and therefore indirectly promotes the binding of IgG molecules to Fcγ 
receptor III (Russell et al., 2018).  
In some cases, fucose is attached to C-3 and C-4 of GlcNAc of an antennary glycan 
in which case it is referred to as antennary fucosylation (FUC_A). Similar to FUC_C, 
dysregulation of FUC_A could have biological consequences (Mackiewicz & 
Mackiewicz, 1995). In this present study, there was a significantly higher level of FUC_A 
in T2DM compared to controls. This result agrees with the findings of other studies. For 
example, α-1, 3 fucosylation in bi, tri and tetra-antennary N-glycans was increased in 
acute and chronic inflammation (Mackiewicz & Mackiewicz, 1995). In addition, α-1, 3 
fucosylation of α1-acid glycoprotein (AGP) was associated with type I diabetes mellitus. 
Further, Mackiewicz and Mackiewicz, (1995) showed that FUC_A was increased in 
inflammation.  
Branching 
This present study showed that T2DM individuals had significantly decreased 
levels of low-branching and increased levels of high branching plasma N-glycans (Table 
6.2b). The increased branching could be attributed to the increased activity of N-
acetylglucosaminyltransferase V (GnT V) and the relative abundance of sugar nucleotide 
donors or co-factors. N-glycosylation is regulated by a nutrient dependent hexosamine 
biosynthetic pathway (HBP). This pathway yields uridine diphosphate-N-
acetylglucosamine (UDP-N-GlcNAc), a metabolite for N-glycosylation. HBP is part of 
the metabolic cascade that processes between 3-5% of glucose and its activity is largely 
dependent on the presence of glucose. As such, a decrease in cellular uptake of glucose 
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leads to a reduction of UDP-N-GlcNAc. Compelling evidence suggests that 
hyperglycaemia up regulates UDP-N-GlcNAc levels by inducing metabolic flux in the 
HBP pathway (Keser et al., 2017). UDP-N-GlcNAc in turn, is utilised by different GnTs 
particularly MGAT4 and MGAT5 to generate high branching N-glycans such as tri-and 
tetraantennary N-glycans (Buse, 2006; Marshall, Bacote, & Traxinger, 1991; Schleicher 
& Weigert, 2000; Wellen & Thompson, 2012). Moreover, branching generates extra sites 
for terminal N-acetylneuraminic acid (sialic acid) in a process termed sialylation (Dube 
& Bertozzi, 2005).  
Sialylation 
Sialylated glycans are present in cell membranes but their overexpression may 
indicate vascular tissue damage (Nayak et al., 2008). As is obvious in Table 6.2b, there 
were statistically significantly increased levels of di (S2) and trisialylated (S3) plasma N-
glycans among T2DM compared to healthy controls. This is consistent with other studies, 
which showed that elevated levels of sialic acids were associated with hyperglycaemia 
(Englyst et al., 2006; Ibrahim et al., 2016; Khalili et al., 2014; Malik, Bashir, Khan, & 
Iqbal, 2009). Possible explanations for this are that insulin resistance and hyperglycaemia 
lead to increased production of acute phase proteins and sialyltransferases in the liver and 
kidneys (Gokmen, Kilicli, Ozcelik, Ture, & Gulen, 2002). Consequently, higher levels of 
sialic acids are released into the blood stream. In addition, increased levels of sialic acids 
could be the outcome of increased gluconeogenesis, which in turn leads to elevated 
phosphoenolpyruvate, a precursor for sialic acid biosynthesis (Ibrahim et al., 2016). 
 
Galactosylation 
It has been suggested that galactosylation has an important function in cellular 
regulation and has several physiological outcomes. For example, agalactosylation of IgG 
was weakly associated with BMI in Caucasians (Knežević et al., 2010; Perkovic et al., 
2014). Similarly, the present study found that loss of galactosylation was correlated with 
BMI among controls but non-significant after correction for multiple testing 
(Supplementary Table S5, See Appendix) (Perkovic et al., 2014). However, there was 
no difference in the level of G0 between cases and controls and this may be because BMI 
was not statistically different in the two groups. Again, studies have shown that loss of 
galactosylation was associated with ageing (Russell et al., 2017; Lemmers et al., 2017). 
Likewise, in this present study, G0 was associated with age in both cases and controls. 
These findings could be due to the fact that ageing results in the decline of β-1,4-
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galactosyl transferase (β-1, 4-GalT) or upregulation of β-galactosidase; enzymes that 
regulate galactose metabolism (Vanhooren et al., 2007; Vanhooren, Laroy, Libert, & 
Chen, 2008). In addition, compared to controls, T2DM patients had increased G3 N-
glycans and reduced A2G. This agrees with the findings by Keser et al., (2017) and shows 
that higher galactosylation is a characteristic of hyperglycaemic status (Keser et al., 
2017).  
As stated earlier, differences in glycosylation patterns between T2DM and controls could 
propel biomarker discovery. Nine GPs (GP1, GP4, GP7, GP11, GP17, GP19, GP22,26, 
GP29 were found to predict case status using a step-wise Akaike’s information criterion 
(AIC) and Bayesian information criterion (BIC) logistic regression model selection 
(Table 6.7). This model yielded an area under curve of 80.5% [95% CI 76.4%-84.6%] 
indicating the predicting power of N-glycans as robust biomarkers (Tables 6.7, Figures 
6.3a & 6.3b).  
Some of this study’s limitations are worth mentioning. Firstly, the sample size was 
not large and hence the interpretation of the results may not be absolute. Secondly, the 
reported findings were based on a cross-sectional design and do not represent N-glycan 
changes over time. Thirdly, a treatment with different medications could have influenced 
the results among the cases. For example, research showed that oral contraceptives and 
oestrogen treatment triggered a decrease in branching (Brinkman-Van der Linden et al., 
1996) and an increase in core fucosylation among women (Saldova et al., 2012). In 
addition, non-steroidal anti-inflammatory drug use resulted in a decrease in core-
fucosylation and sialyl Lewis x (sLex) (Saldova et al., 2012). However, the present study 
could not control for medication use since T2DM participants were given multiple drugs 
with different dosages (Adua et al., 2017).   
6.7 Conclusion 
The application of high throughput HILIC-UPLC has enabled the identification of 
complex plasma N-glycan structures that are characteristic of T2DM within a West 
African population, Ghana. Strikingly, many of our findings were similar to Caucasian 
populations affirming the potentiality of N-glycan profiles as generic and universal 
biomarkers. Further investigation of N-glycosylation processes in large and distinct 
populations will be crucial for better understanding of T2DM pathogenesis worldwide 
and facilitate the development of N-glycan based therapies.  
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CHAPTER SEVEN 
Prelude 
Apart from perceived suboptimal health documented in Study I (Chapter Four), it was 
also revealed that there was poor control of modifiable risk factors among T2DM 
sufferers. This finding was surprising especially because all T2DM patients were 
recruited from the hospital and were known to be on some form of medication. This 
observation therefore provided enough stimulus for a longitudinal investigation. 
Accordingly, Study IV explored major risk factors among T2DM sufferers, taking into 
consideration medication usage among T2DM patients over six months. This study has 
been published in the Journal of Clinical and Translational Medicine and it can be cited 
as: 
 
Adua, E., Roberts, P., Sakyi, S. A., Yeboah, F. A., Dompreh, A., Frimpong, K., ... & 
Wang, W. (2017). Profiling of cardio-metabolic risk factors and medication utilisation 
among Type II diabetes patients in Ghana: a prospective cohort study. Clinical and 
Translational Medicine, 6(1), 1-11.  
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Profiling of cardio-metabolic risk factors and medication utilisation 
among Type II diabetes patients in Ghana: A prospective cohort study 
 
 
7.1 Abstract 
Type II diabetes mellitus (T2DM) is complicated by multiple cardio-metabolic risk 
factors. Controlling these factors requires lifestyle modifications alongside utilisation of 
anti-diabetic medications. Different glucose lowering [(biguanides (BIG), sulfonylureas 
(SUA), thiazolidinedione (TNZ)], lipid lowering (statins), and anti-hypertensive 
medicines [angiotensin converting enzyme inhibitors (ACEIs), calcium channel blockers 
(CCB), angiotensin II receptor blockers (ARB) and central acting drugs (CADs)] have 
been approved for controlling hyperglycaemia, dyslipidaemia and hypertension 
respectively. Here, we examined factors that characterise T2DM and explored the 
response to medication therapy among T2DM patients. This prospective cohort study 
recruited 241 T2DM patients reporting at a clinic in Ghana, from January to August 2016. 
Each patient’s demographics, medications and anthropometric data was obtained while 
information on medication adherence was captured using the Morisky adherence scale-8 
(MMAS-8). Fasting blood samples were collected for biochemical analysis. The mean 
age of participants was 57.82 years for baseline and 6-month follow-up. Physical activity 
differed at baseline and follow up (p<0.05) but not body mass index (BMI).  BIG alone, 
or in combination with SUA and TNZ did not improve glycaemic status at follow up 
(p>0.05). Many participants using either ACEI or ARB were able to control their blood 
pressures. Among dyslipidaemia patients under statin treatment, there was an improved 
lipid profile at follow-up. Statin medications are effective in reducing dyslipidaemia in 
T2DM patients. However, control of modifiable risk factors, particularly blood glucose 
and to a lesser degree blood pressure is suboptimal. Addressing these will require 
concomitant interventions including education on medication adherence and correct 
dietary plans, lifestyle modifications and physical activity.  
 
 
 
 
Key words: type II diabetes mellitus, hypertension, anti-diabetic medications, risk 
factors, Ghana.  
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7.2 Introduction   
Despite substantial efforts, type II diabetes mellitus (T2DM) remains a major 
contributor to the world’s morbidity and mortality (Action to Control Cardiovascular Risk 
in Diabetes Study Group, 2008; Stratton et al., 2000; Tuomilehto et al., 2001). In 2014 
alone, more than 2.2 million people died from the disease and at approximately the same 
time, nearly 415 million adults were affected worldwide, representing a prevalence rate 
of ≈ 8.5% (International Diabetes Federation (IDF), 2014; World Health Organisation 
(WHO), 2014). This prevalence rate is expected to translate into 439 million T2DM cases 
by 2030 (Epstein, Shepherd, & Kahn, 1999; WHO, 2014; 2015a). Unfortunately, 
countries with less healthcare resources such as those in sub-Saharan Africa (SSA) are 
among the most affected with some 14.2 million people presently suffering from the 
disease (WHO, 2014). For example, in Ghana, T2DM affected more than 266,200 
individuals at a prevalence rate of 6% in 2015, and it is presently ranked among the top 
10 causes of all adult deaths (Danquah et al., 2012; International Diabetes Federation, 
2015).  
People with T2DM have an increased risk of developing many health problems 
such as cardiovascular diseases (Herder, Karakas, & Koenig, 2011; Resnick & Howard, 
2002), amputations (Lavery, Armstrong, Wunderlich, Tredwell, & Boulton, 2003; 
Resnick & Howard, 2002), depression (Campayo, Gómez-Biel, & Lobo, 2011), and 
cognitive impairment (Action to Control Cardiovascular Risk in Diabetes Study Group, 
2008; Biessels, Koffeman, & Scheltens, 2006; Luchsinger, 2012; Zilliox, Chadrasekaran, 
Kwan, & Russell, 2016). Moreover, prolonged hyperglycaemia is strongly linked with 
many microvascular and, to a lesser extent, macrovascular complications and premature 
mortality (DeFronzo & Abdul-Ghani, 2011). In fact, just a 1% rise in glucose level will 
lead to an 18% increased risk for cardiovascular events (Gerstein et al., 2005), 37% 
increased risk for renal diseases (Action to Control Cardiovascular Risk in Diabetes Study 
Group, 2008) and 12-14% increased risk of premature mortality (Gerstein et al., 2005; 
Stratton et al., 2000).  
Additionally, the majority of T2DM patients are physically inactive which has led 
to dyslipidaemia, obesity and hypertension (Cooper-DeHoff et al., 2010; Echouffo‐
Tcheugui et al., 2015). These in turn lead to further consequences. Studies have shown 
that obesity accounts for 14% of all adult deaths while hypertension alone is an 
independent risk factor for cognitive decline (Reitz et al., 2007), renal dysfunction 
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(Agarwal & Andersen, 2005; Vaes et al., 2015) and ultimately responsible for 45% of all 
deaths. Therefore, given these detrimental outcomes, controlling known modifiable 
factors should be a priority.  
It has long been documented that achieving good glycaemic levels is pivotal to 
delaying T2DM complications. According to the American Diabetes Association (ADA), 
reduction of microvascular and macrovascular complications is possible at HbA1c < 7% 
(American Diabetes Association, 2010). This could be achieved with single, combination 
or multiple glucose lowering medications (Wong et al., 2014). 
Alongside maintaining normal glycaemic levels, therapeutic intervention should be 
extended to target other concomitant factors such as dyslipidaemia, hypertension and 
obesity (Esposito, Ciotola, Maiorino, & Giugliano, 2008; Nathan et al., 2009). Different 
lipid lowering and anti-hypertensive drugs have been approved for controlling 
dyslipidaemia and hypertension respectively; the majority of which are currently 
available in Ghana (Sarfo et al., 2017). Yet, the control of T2DM modifiable risk factors 
has been suboptimal, partly because studies to create awareness of T2DM are generally 
scarce in SSA countries such as Ghana. Moreover, these studies have mainly been cross-
sectional, providing limited information on association or causality. Therefore, in this 
study, we explored the manifestations and the associated factors that characterise T2DM 
in a longitudinal design. Additionally, this study highlights the proportion of T2DM 
patients that have good glycaemic control, blood pressure and lipid levels and addresses 
the factors that contribute to poor blood pressure control, high lipid levels and poor 
glycaemic status. 
7.3 Methods and Study Design 
This prospective cohort study was conducted at the diabetic clinic of the Komfo 
Anokye Teaching Hospital (KATH) from January to August 2016. In all, 241 participants 
with T2DM aged 35 to 70 years who reported to the clinic for review and medications 
were recruited. Ethical clearance was approved and written informed consent was 
obtained from each participant as described in Chapter Four. 
Inclusion and Exclusion Criteria 
The study included only those who were diagnosed as having T2DM, based on the 
international classification of diabetes (ICD 10) criteria. Participants who were taking 
insulin injections were assumed to be suffering from type I diabetes mellitus and therefore 
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were excluded. Additionally, among the original 260 T2DM participants recruited for the 
study, 19 were excluded, mainly because of missing clinical data.   
 
Anthropometric and Blood Pressure Measurements  
After obtaining demographic data and information on the general health status from 
each participant, information on medication adherence was obtained using the validated 
Morisky adherence scale-8 (MMAS-8). This questionnaire comprises 8 items and 
responses for item 1 through 7 are either ‘yes’ or ‘no’ whereas item 8 comprises a 5-point 
Likert scale (Okello et al., 2016). Following this, anthropometric measurements including 
weight, height, BMI, WHR, SBP and DBP were measured by standard methods as 
described in Chapter Four of this thesis. To assess the level of physical activity, we 
asked basic questions such “as what is the level of physical activity?” and during the last 
7 days, on how many days did you walk for at least 10 minutes at a time in your leisure 
time”. 
Blood Sample Collection and Biochemical Assay 
Venous fasting blood samples were collected from each participant into tubes 
containing EDTA (ethylene diamine tetraacetic acid), fluoride oxalate and gel separator. 
Different clinical tests including FPG, HbA1c, TC, HDL-c, LDL-c, TG and VLDL-c 
were measured on the automated chemistry analyser (Roche Diagnostics, COBAS 
INTEGRA 400 Plus, USA). Non-HDL and coronary risk (CR) ratios were then 
calculated. Details are provided in Chapter Four of this thesis. Various medications 
utilised by the T2DM patients at the clinic are shown in Figure 7.1. 
 145 
 
 
Figure 7.1. Category of medications utilised by T2DM patients. T2DM patients are given different 
medications including glucose lowering, lipid lowering and blood pressure lowering agents. 
 
Definitions of terms 
High plasma glucose; FPG > 7 mmol/L, HbA1c > 7.2 % (WHO, 2015b)  
Normal BP <140/90 mmHg, high SBP > 140mmHg, high DBP > 90mmHg (Echouffo‐
Tcheugui et al., 2015).  
Dyslipidaemia: High TG ≥ 1.7 mmol/l, HDL-c < 1.0 (male), 1.03 (female), high LDL-c 
≥ 2.59 mmol/l, high total cholesterol ≥ 5.18 mmol/l, high non-HDL ≥ 3.37 mmol/l (Panel, 
2002).  
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7.4 Statistical Analysis 
Normality of the distribution was checked using the Kolmogov Smirnov test. All 
continuous data was recorded as mean ± standard deviation (SD) and as frequency 
(percentages) for categorical variables. Between groups comparisons for continuous 
variables were performed using student t-tests, and intergroup comparisons of categorical 
variables were performed using chi-square tests. Association between categorical 
variables and FPG or HbA1c were performed using logistic regression models and odds 
ratios (ORs) at 95% confidence intervals (95% CI) were recorded. All statistical analyses 
were performed using the Statistical Package for Social Sciences (SPSS), version 22. A 
p<0.05 was considered significant.  
7.5 Results  
Among the study population, the male to female ratio was 99/142 at baseline and 
66/94 at follow up respectively. BMI and WHR of participants did not significantly differ 
from baseline to follow up [i.e. (p=0.172) and (p=0.276) respectively]. However, there 
was a significant difference in levels of physical activity from baseline to 6-month follow 
up (p = 0.0001) (Table 7.1).  
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Table 7.1 Socio-demographic characteristics of study participants: Baseline and follow-up 
Variable     Total Baseline (n = 240) Follow up (n = 160) X2, df p-value 
Age (years) 57.80 ± 10.63 57.82 ± 10.88  57.79 ± 10.39 0.370t 0.981 
Male: Female ratio 165/236 99/142 66/94   
BMI (Kg/m2) 26.80 ± 9.44  26.13 ± 5.11  27.47 ± 13.78  1.367t 0.172 
WHR 0.93 ± 0.05  0.93 ± 0.06  0.92 ± 0.05  1.090t 0.276 
Marital status   17.5, 3 0.002 
Married 269 (67.1) 164 (68.0) 105 (65.6)   
Never married 6(1.5) 4 (1.7) 2(1.3)   
Divorced 41 (10.2) 25 (10.4) 16 (10.0)   
Widowed 85 (21.2) 48 (19.9) 37 (23.1)   
Education    3.01, 4 0.55 
Tertiary 58 (14.5) 36 (14.9) 22 (13.8)   
Senior high school 104(25.9) 57 (23.7) 47 (29.4)   
Junior high school 133(33.2) 78 (32.4) 55 (34.4)   
Lower primary 43(10.7) 28 (11.6) 15(9.4)   
No formal education 63(15.7) 42 (17.4) 21(13.1)   
Occupation   39.65, 3 0.0001 
Employed 229(57.1) 133(55.2) 96(60.0)   
Retired 85(21.2) 35(14.5) 50(31.1)   
Unemployed 65(16.2) 51(21.1) 14(8.8)   
Informal employment 22(5.5) 21(9.0) 1(1)   
Physical activity   25.22, 1 0.0001 
Primarily sedentary 101(25.2) 79(32.8) 22(13.8)   
Moderate activity 300(74.6) 162(67.2) 138(85.5)   
Values are presented as frequency (percentage); mean ± SD;  t :t-test value 
The majority of the study participants were aged 51-60 years [81 (33.6%) vs 55 
(34.4%) while the lowest age range was 31-40 years [14 (5.8%) vs 10 (6.3%) (Table 
7.2).  The severity and mean levels of the measured parameters were not significantly 
different from baseline to follow-up; [SBP (p=0.474 and p=0.600), DBP (p=0.382 and 
p=0.620), FPG (p=0.364 and p=0.940), TC (p=0.328 and p=0.160), non-HDL-c (p=0.270 
and p=0.250) and LDL-c (p=0.092 and p=0.430)]. However, there was a difference in the 
severity and mean levels of HbA1c [(p=0.004 and p=0.0001)], TG [(p=0.006 and 
p=0.0001)] and HDL-c [(p<0.0001 and p=0.0001)] from baseline to follow up (Table 
7.2).  
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Table 7.2 Distribution of clinical characteristics among study participants 
Values expressed as Mean ± SD, X2=Chi-Square test, t t-statistic, test of statistical significance is two tailed 
and are bolded. 
 
Table 7.3 demonstrates that after adjusting for age and medication use, high BMI, SBP, 
DBP, TC, TG, HDL-c, non-HDL-c, and LDL-c status were not significant independent 
risk factors for high FPG in both baseline and follow-up groups (p>0.05). 
Variables Total Baseline  Follow-up X2 , df P 
Age    0.909, 4 1.000 
31-40  24(6.0) 14(5.8) 10(6.3)   
41-50 76(19.0) 49(20.3) 27(16.9)   
51-60  136(33.9) 81 (33.6) 55(34.4)   
61-70  118(29.4) 68(28.2) 50(31.3)   
71-80  47(11.7) 29(12.0) 18(11.3)   
BMI     3.386, 3 0.336 
Underweight 11(2.8) 9(3.80) 2(1.30)   
Normal weight 175(43.9) 170(44.6) 68(42.8)   
Overweight 132(33.10) 80(33.3) 52(32.7)   
Obese 81(20.3) 44(18.3) 37(23.3)   
SBP    0.028, 1 0.474 
Normal 121 (55.1) 132 (54.8) 89 (55.6)   
High  180 (44.9) 109 (45.2) 71 (44.4)   
DBP     0.178, 1 0.382 
Normal 298 (74.5) 177 (73.8) 121 (75.6)   
High  102 (25.5) 63(26.3) 39 (24.4)   
HbA1c    7.280, 1 0.004 
Normal 104(26.0) 74 (30.8) 30 (18.8)   
High 296 (74.0) 166 (69.2) 130 (81.3)   
FPG     0.202, 1 0.364 
Normal 160 (39.9) 94(39.0) 66(41.3)   
High 241 (60.1) 147 (61.0) 94(58.8)   
TG    6.679, 1 0.006 
Good 343(86.2) 199(82.6) 144(91.7)   
High 55(13.8) 42(17.4) 13(8.3)   
TC    0.308, 1 0.328 
Good 259 (65.2) 154 (64.2) 105(66.9)   
High 138(34.8) 86(35.8) 52(33.1)   
HDL    94.80, 1 <0.0001 
Good 235 (59.0) 189(78.4) 46(29.3)   
Low 163(41.0) 52(21.6) 111(70.7)   
NonHDL    0.474, 1 0.270 
Normal 188(47.4) 117(48.8) 71(45.2)   
High 209(52.6) 123(51.3) 86(54.8)   
LDL    2.040, 1 0.092 
Good 164(41.3) 106(44.2) 58(36.9)   
High 233(58.7) 134(55.8) 99(63.1)   
SBP (mmHg) 140.06 ± 24.09  139.41 ± 24.31  140.71 ± 23.88  0.525 t 0.600 
DBP (mmHg) 81.96 ± 13.18  81.63 ± 13.71  82.28 ± 12.65  0.484 t 0.620 
FPG (mmol/l) 18.32 ± 4.31  9.18 ± 4.42  9.14 ± 4.20  0.082 t 0.940 
HbA1c (mmol/l) 8.79 ± 2.49  8.27 ± 2.10  9.32 ± 2.88  4.201 t 0.0001 
TC (mmol/l) 4.63 ± 1.27  4.73 ± 1.27  4.54 ± 1.27  1.406 t 0.160 
TG (mmol/l) 1.17 ± 0.56  1.27 ± 0.57  1.07 ± 0.56  3.520 t 0.0001 
HDL-c (mmol/l) 1.19 ± 1.19  1.35 ± 1.35  1.03 ± 1.03  9.960 t 0.0001 
Non-HDL-c (mmol/l) 3.44 ± 1.22  3.37 ± 1.24  3.52 ± 1.20   1.142 t 0.250 
LDL-c (mmol/l) 2.91 ± 0.57  2.79 ± 1.16  3.03 ± 1.13  2.029 t 0.430 
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Table 7.3 Association between metabolic risk factors and FPG levels at baseline and follow-up 
Variables FPG (Baseline) X2, df (p-value) p FPG (Follow-up) X2, df (p-value) p 
 High Normal aOR (95% CI)  High Normal aOR (95% CI)  
 (n=147) (n=94)   (n=94) (n=66)   
Gender   1.38, 1 (0.239)    3.55, 1(0.06)  
Male 56(38.1) 43(45.7) 1.0#  33(35.1) 33(50.0) 1.0#  
Female 91(61.9) 51(54.3) 1.37(0.81-2.32) 0.283 61(64.9) 33(50.0) 1.85(0.97-3.51) 0.073 
BMI    2.18, 3 (0.537)    1.77, 3(0.622)  
Underweight 6(4.1) 3(3.2) 1.05(0.25-4.47) 1.000 2(2.1) 1(1.5) 1.40(0.12-16.21) 1.000 
Normal 70(47.9) 37(39.4) 1.0#  40(42.6) 28(43.1) 1.0#  
Overweight 46(31.5) 34(36.2) 0.72(0.39-1.29) 0.289 29(30.9) 23(35.4) 0.88 (0.43-1.83) 0.852 
Obese 24(16.4) 20(21.3) 0.63(0.31-1.30) 0.268 23(24.5) 14(21.5) 1.15(0.51-2.62) 0.836 
SBP    0.87, 1 (0.351)    1.13, 1(0.288)  
Normal 77(52.4) 55(58.5) 1.0#  49(52.1) 40(60.6) 1.0#  
High  70(47.6) 39(41.5) 1.28(0.76-2.16) 0.357 45(47.9) 26(39.4) 1.41(0.75-2.68) 0.333 
DBP    0.02, 1(0.901)    2.34, 1(0.126)  
Normal 108(73.5) 69(74.2) 1.0#  67(73.1) 54(81.8) 1.0#  
High 39(26.5) 24(25.8) 1.04(0.57-1.88) 1.000 27(28.7) 12(18.2) 1.81(0.84-3.91) 0.139 
TC    0.22, 1(0.642)    0.09, 1 (0.764)  
Good 92(63.0) 62(66.0) 1.0#  62(66.0) 43(68.3) 1.0#  
High 54(37.0) 32(34.0) 1.14(0.67-1.96) 0.681 32(34.0) 20(31.7) 1.11(0.56-2.19) 0.863 
TG    0.23, 1(0.630)    0.52,1(0.472)  
Good 120(81.6) 79(84.0) 1.0#  85(90.4) 59(93.7) 1.0#  
High 27(18.4) 15(16.0) 1.19(0.59-2.37) 0.729 9(9.6) 4(6.3) 1.56(0.46-5.31) 0.565 
HDL-c   0.01, 1(0.928)    0.83,1(0.363)  
Good 115(78.2) 74(78.7) 1.0#  25(26.6) 21(33.3) 1.0#  
Low 32(21.8) 20(21.30) 1.03(0.55-1.93) 1.000 69(73.4) 42(66.7) 1.38(0.69-2.77) 0.377 
Non-HDL   0.05, 1 (0.827)    0.24,1(0.621)  
Normal 72(49.3) 45(47.5) 1.0#  41(43.6) 30(47.6) 1.0#  
High 74(50.7) 49(52.1) 0.94(0.56-1.59) 0.895 53(56.4) 33(52.4) 1.18(0.62-2.23) 0.628 
LDL-c    0.88, 1 (0.349)    0.84,1 (0.358)  
Good 68(46.6) 38(40.4) 1.0#  32(34.0) 26(41.3) 1.0#  
High 78(53.4) 56(59.6) 0.78(0.46-1.32) 0.355 62(66.0) 37(58.7) 1.36(0.71-2.63) 0.401 
X2, df: chi-square value, degrees of freedom; aOR: adjusted odds ratio; CI: confidence interval. Logistic regression model, adjusted for age and medication.  
1.0#: reference point for odds ratio 
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Table 7.4 demonstrates that after adjusting for age and medication use, high BMI, SBP, DBP, TC, TG, HDL-c, non-HDL-c, and  
LDL-c status were not significant independent risk factors for high HbA1c in both baseline and follow-up groups (p>0.05).  
 
Table 7.4 Association between metabolic risk factors and HbA1c levels at baseline and follow-up 
Variables HbA1c (baseline) X2, df (p-value) p HbA1c (follow-up) X2, df (p-value) p 
 Poor  Good   aOR (95% CI)  Poor  Good  aOR (95% CI)  
 (n=167) (n=74)   (n=130) (n=30)   
Gender   0.18,1 (0.675)    0.96, 1(0.328)  
Male 67(40.4) 32(43.2) 1.0#  56(43.1) 10(33.3) 1.0#  
Female 99(59.6) 42(56.8) 1.13(0.65-1.96) 0.673 74(56.9) 20(66.7) 0.66(0.29-1.52) 0.413 
BMI    1.35,3(0.718)    4.38,3 (0.224)  
Underweight 5(3.0) 4(5.4)                                       0.49(0.12-1.94) 0.445 2(1.6) 0(0.0)   
Normal 77(46.7) 30(40.5) 1.0#  56(43.4) 12(40.0) 1.0#  
Overweight 53(32.1) 26(35.1) 0.79(0.42-1.49) 0.519 45(34.90 7(23.3) 1.38 (0.50-3.78) 0.619 
Obese 30(18.2) 14(18.9) 0.83(0.39-1.79) 0.695 26(20.2) 11(36.7) 0.50(0.19-1.29) 0.216 
SBP    2.22,1 (0.136)    0.47, 1(0.491)  
Normal 86(51.8) 46(62.2) 1.0#  74(56.9) 15(50.0) 1.0#  
High SBP 80(48.2) 28(37.8) 1.53(0.87-2.68) 0.161 56(43.1) 15(50.0) 0.76(0.34-1.68) 0.544 
DBP   0.16,1(0.692)    0.022, 1 (0.883)  
Normal 121(72.9) 55(75.3) 1.0#  98(75.4) 23(76.7) 1.0#  
High DBP 45(27.1) 18(24.7) 1.14(0.60-2.14) 0.752 32(24.6) 7(23.3) 1.07(0.42-2.73) 1.000 
TC    2.42, 1(0.12)    0.49, 1(0.483)  
Good 101(61.2) 53(71.6) 1.0#  84(65.6) 21(72.4) 1.0#  
High 64(38.8) 21(28.4) 1.60(0.88-2.89) 0.144 44(34.4) 8(27.6) 1.38(0.56-3.36) 0.522 
TG    0.00,1(0.985)    1.42,1(0.233)  
Good 137(82.5) 61(82.4) 1.0#  119(93.0) 25(86.2) 1.0#  
High 29(17.5) 13(17.6) 0.99(0.48-2.04) 1.000 9(7.0) 4(13.8) 0.47(0.14-1.68) 0.262 
HDL-c   0.11,1(0.743)    0.46,1(0.499)  
Good 132 (79.0) 57(77.0) 1.0#  39(30.5) 7(24.1) 1.0#  
Low 35(21.0) 17(23.0) 0.90(0.46-1.73) 0.737 89(69.5) 22(75.9) 0.73(0.29-1.84) 0.652 
Non-HDL  0.25,1(0.620)    0.002,1 (0.962)  
Normal 79(47.9) 38(51.4) 1.0#  58(45.3) 13(44.8) 1.0#  
High 86(52.1) 36(48.6) 1.15(0.66-1.99) 0.675 70(54.7) 16(55.2) 0.98(0.44-2.21) 1.000 
LDL-c    0.05,1(0.817)    0.53,1(0.465)  
Good 74(44.8) 32(43.2) 1.0#  49(38.3) 9(31.0) 1.0#  
High 91(55.2) 42(56.8) 0.94(0.54-1.630 0.888 79(61.7) 20(69.0) 0.73(0.31-1.72) 0.528 
X2, df: chi-square value, degrees of freedom; aOR: adjusted odds ratio; CI: confidence interval. Logistic regression model, adjusted for age and medication. 1.0#: 
reference point for odds ratio.
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From baseline to follow-up, FPG levels increased by 25.0% when (BIG) was 
administered alone. In a combination therapy with either SUA or TNZ, there was only 
a decrease in FPG levels by 1% (p=0.9924) and 1.6% (p=0.1098) respectively. 
However, FPG levels decreased by 15.8% when all three medications; BIG, SUA and 
TNZ were administered (p=0.216). Meanwhile, levels of HbA1c were increased by 
29.6% after BIG treatment alone (p=0.0094), increased by 19.2% and 16.7% when 
BIG was combined with SUA (p=0.0175) and TNZ (p=0.0903) respectively. 
However, a multiple therapy of BIG, SUA and TNZ resulted in only a 1.3% increase 
in HbA1c levels (p=0.8308) (Table 7.5). 
 
Table 7.5 Utilisation of glucose lowering medications among T2DM patients 
BIG-Biguanide; SUA-Sulfonylurea; TNZ- Thiazolidinedione. p<0.05 is considered significant and are 
bolded. 
 
 There was a mean percentage decrease effect in levels of HDL-c (p<0.0001), 
TG (p=0.0259) and VLDL-c (p=0.0237) by 22.8%, 18.4% and 17.3% respectively, 
after atorvastatin treatment alone. Conversely, there was an increased effect in levels 
of TC (p=0.743) by 1.7%, non-HDL-c (p=0.075) by 14.5%, LDL-c (p=0.022) by 
21.5% and CR (p=0.955) by 0.5% after atorvastatin treatment (Table 7.6).   
 
 
 
 
 
 
 Baseline Follow up 
Mean difference  
(95% CI) P % effect 
Treatment      
 FPG (mmol/l)    
BIG only 8.02 ± 0.65 10.08 ± 1.12 2.05(-1.25 to 5.36) 0.2162 25.00% 
BIG+ SUA 8.45 ± 0.49 8.441 ± 0.82 -0.01(-1.83 to 1.82) 0.9924 -0.10% 
BIG+TNZ 9.63 ± 0.59 11.88 ± 1.47 2.25 (-0.52 to 5.02) 0.1098 23.40% 
BIG+ SUA+TNZ 9.921 ± 0.66 8.36 ± 1.04 -1.57 (-4.06 to 0.93) 0.216 -15.80% 
      
 HbA1c (%)    
BIG only 7.34 ± 0.28 9.51 ± 1.10 2.17 (0.57 to 3.78) 0.0094 29.60% 
BIG+ SUA 8.11 ± 0.32 9.67 ± 0.65 1.55 (0.28 to 2.83) 0.0175 19.20% 
BIG+TNZ 8.68 ± 0.33 10.12 ± 1.04 1.45 (-0.23 to 3.14) 0.0903 16.70% 
BIG+SUA+TNZ 8.46 ± 0.26 8.57 ± 0.47 0.11 (-0.91 to 1.12) 0.8308 1.30% 
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Table 7.6 Utilisation of lipid lowering medications among T2DM patients 
CI: confidence interval, p<0.05 is considered significant and are bolded. 
 
 
For non-hypertensive T2DM participants, there was neither a significant change 
in SBP nor DBP from baseline to follow-up (Table 7.7). SBP levels were reduced by 
0.1% after CCB+ACEI treatment (p=0.969). Levels of both SBP and DBP were 
reduced by 1.9% (p=0.644) and 5.8% (p=0.128) respectively after ACEI treatment 
alone and decreased by 1.0% (p=0.835) and 0.1% (p=0.912) respectively after CCB + 
ARB combination therapies. However, levels of both SBP and DBP increased by 3.0% 
(p=0.683) and 0.4% (p=0.942) respectively after CCB treatment alone and increased 
by 17.3% (p=0.061) and 11.3% (p=0.086) respectively after CAD treatment alone, 
while a combination therapy of CCB+ACEI increased DBP by 1.9% (p=0.666) (Table 
7.7).  
 
 
 
 
 
 
 
 
Variable Baseline Follow up Mean difference (95% CI)   P     % difference   
TC (mmol/l)      
No statin 5.03 ± 0.12 4.95 ± 0.13 -0.07 (-0.42 to 0.28) 0.6817 1.39% 
Atorvastatin 4.06 ± 0.16 4.13 ± 0.16 0.07 (-0.37 to 0.51) 0.7434 1.72% 
TG (mmol/l)      
No statin 1.32 ± 0.06 1.19 ± 0.06 -0.13(-0.30 to 0.04) 0.1322 9.85% 
Atorvastatin 1.14 ± 0.06 0.93 ± 0.06 -0.21(-0.39 to -0.03) 0.0259 18.42% 
HDL-c (mmol/l)      
No statin 1.36 ± 0.03 1.05 ± 0.03 -0.30(-0.39 to -0.21) < 0.0001 22.06% 
Atorvastatin 1.36 ± 0.04 1.04 ± 0.04 -0.31(-0.42 to -0.19) < 0.0001 22.79% 
Non-HDL (mmol/l)      
No statin 3.67 ± 0.11 3.89 ± 0.12 0.23(-0.09 to 0.55) 0.1617 6.27% 
Atorvastatin 2.69 ± 0.15 3.09 ± 0.15 0.39(-0.04 to 0.81) 0.0754 14.50% 
LDL-c (mmol/l)      
No statin 3.06 ± 0.11 3.36 ± 0.11 0.30(-0.01 to 0.60) 0.058 9.80% 
Atorvastatin 2.19 ± 0.15 2.68 ± 0.14 0.47(0.06 to 0.87) 0.022 21.46% 
CR      
No statin 5.24 ± 0.15 5.57 ± 0.49 0.33(-0.68 to 1.34) 0.5202 6.29% 
Atorvastatin 4.31 ± 0.19 4.32 ± 0.20 0.02(-0.53 to 0.57) 0.9547 0.46% 
VLDL-c (mmol/l)      
No statin 0.60 ± 0.03 0.58 ± 0.05 -0.01(-0.12 to 0.09) 0.8181 1.67% 
Atorvastatin 0.52 ± 0.03 0.42 ± 0.03 -0.09(-0.18 to -0.01) 0.0237 17.3% 
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Table 7.7 Utilisation of anti-hypertensive medicines among T2DM patients. 
Anti-hypertensive 
drugs 
Baseline Follow up 
Mean difference 
(95%CI) 
p-value %effect 
 SBP (mmHg)    
DM only (n=38) 127.1 ± 4.09 130.5 ± 3.45 
 
0.534 2.63% 
3.34(-7.33 to 14.01) 
 
150.2 ± 7.99 154.6 ± 7.21 
 
0.683 2.96% DM+HPT  
CCB (n=11) 4.46(-18.02 to 26.92) 
ARB (n=22) 130.1 ± 3.04 130.0 ± 4.36 0.01(-10.74 to 10.74) > 0.999 0.00% 
ACEI  (n=30) 130.4 ± 3.93 128.0 ± 3.59 -2.47(-13.12 to 8.19) 0.644 -1.90% 
CAD (n=8) 150.6 ± 9.07 176.6 ± 8.33 26.0(-2.43 to 54.43) 0.061 17.30% 
CCB+ ARB  (n=24) 153.3 ± 5.74 151.7 ± 4.98 -1.58(-16.88 to 13.72) 0.835 1.03% 
CCB+ACEI (n=27) 143.1 ± 3.33 142.9 ± 3.46   -0.19(-9.83 to 9.46) 0.969 0.13% 
      
 DBP (mmHg)    
 
74.87 ± 2.25 77.87 ± 1.80 
 
0.301 4.00% 
DM only (n=38) 3.00(-2.75 to 8.74) 
 
83.18 ± 3.74 83.55 ± 3.23 
 
0.942 0.43% 
DM+HPT  
CCB (n=11)  
 0.36(-9.95 to 10.68) 
ARB  (n=22) 80.00 ± 2.31 80.02 ± 2.09 1.00(-5.29 to 7.30) 0.75 1.25% 
ACEI  (n=30) 80.01 ± 1.89 76.43 ± 2.37 -4.67(-10.73 to 1.40) 0.128 5.76% 
CAD (n=8) 93.80 ± 5.23 104.4 ± 7.22 10.6(-9.96 to 31.16) 0.086 11.30% 
CCB+ ARB (n=24) 86.13 ± 3.33 86.08 ± 2.62 -0.04(-8.58 to 8.50) 0.992 0.05% 
CCB+ACEI (n=27) 82.81 ± 2.78 84.41 ± 2.40 1.59(-5.78 to 8.96) 0.666 1.92% 
CCB-calcium channel blockers; ACEI-angiotensin converting enzyme inhibitors; ARB-angiotensin II 
receptor blockers; CAD-central acting drugs. 
 
7.7 Discussion 
The prevalence of T2DM has increased tremendously in the past few decades 
among different countries worldwide (Adua, Frimpong, Li, & Wang, 2017; Asweto, 
Alzain, Andrea, Alexander, & Wang, 2016; WHO, 2014; Wang,  2016). SSA remains 
one of the most affected regions due to rapid urbanisation and increased adoption of a 
westernised diet with less physical activity (Danquah et al., 2012; Frank et al., 2014). 
In this present hospital-based study, we examined the major risk factors that 
characterise T2DM and how these factors influence anti-diabetes medication response. 
As reported by Danquah et al., (Danquah et al., 2012), the majority of T2DM patients 
in urban Ghana are middle aged, of low socio-economic status and their lifestyle is 
primarily sedentary (Danquah et al., 2012). Moreover, our findings on clinical 
parameters such as SBP, DBP, HDL-c, LDL-c, TG, TC and FPG are similar to those 
reported in their study (Danquah et al., 2012).  
Overall, several of these biomarkers are higher than the recommended threshold 
for T2DM as suggested by the WHO and the ADA (American Diabetes Association, 
2015; WHO, 2006). For example, approximately 60% and 69.2% of the participants 
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were not able to achieve the desired FPG and HbA1c targets respectively. This is in 
fact disturbing given the direct association between abnormal plasma glucose levels 
and macrovascular and or microvascular complications. Efforts to control glucose 
levels are necessary and could be achieved in several ways. After diagnosis, medical 
nutrition therapy (MNT) is necessary to reduce weight and normalise glucose levels 
(Esposito et al., 2008; Esposito et al., 2010). However, it has been established that 
MNT alone is not sufficient for improving plasma glucose levels. As such, the use of 
medications becomes the next phase of intervention (Esposito et al., 2008). 
In Ghana, several glucose lowering medications have been approved for the 
treatment of hyperglycaemia including SUAs, TNZs and biguanides, the latter being 
the first line anti-diabetic medicine. Like many other countries, its popularity is 
because: 1) its less expensive, 2) its effective for weight reduction and plasma glucose 
levels, and 3) it has a reduced risk for hypoglycaemia (Wong et al., 2014). Not 
surprisingly, a high proportion of our participants (>80%) were on this medication, 
most of whom had used this drug for a period long before the start of this study. 
However, the majority of those who used metformin alone could not achieve the 
desired glycaemic level even at follow up although there seems to be a minimal 
percentage effect (29.6%, p=0.0094) on HbA1c level (Tables 7.3-7.5). This 
emphasises the failure of metformin as a monotherapy to achieve glucose control. At 
this point, the focus shifts towards individuals undergoing combination and multiple 
therapies. SUAs and TNZs have been recognised as second line anti-diabetic 
medications and their efficacy is similar to metformin (Cox & Feinglos, 2013; Wong 
et al., 2014). However, it was apparent after six months that even with multiple 
therapies; the majority of the patients could not attain the desired glucose target levels. 
Only a minimal percentage effect of BIG+SUA (19.2%, p=0.0175) on HbA1c was 
observed (Table 7.5). Several reasons can be attributed to this: 
Firstly, there is a possibility of poor adherence to oral medications, especially 
among those taking combination and multiple therapies, not only for hyperglycaemia 
but also for other comorbidities (Emslie-Smith, Dowall, & Morris, 2003). Moreover, 
many of these drugs are associated with side effects and hence it is possible that some 
participants will be selective in their choice of medication. In a study among 2,849 
T2DM patients in the UK, it was shown that only 13% of the patients adhered strictly 
to the drug regimen (Donnan, MacDonald, & Morris, 2002). This could possibly be 
the case in our study as some participants may have become bored with swallowing 
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different medications daily. Efforts to simplify treatment regimens should therefore be 
intensified. For example, instead of multiple medications, single-dose combination 
pills with minimal side effects could be administered.  
Secondly, ensuring adequate control of glycaemic status requires a paradigm 
shift from sedentary behaviour to a more physically active lifestyle. One study has 
shown that moderate-intensity physical activity such as brisk walking and reducing 
time spent watching television to less than 30 minutes per day could reduce several 
modifiable T2DM risk factors including plasma LDL-c and TG while increasing 
HDL-c (Laaksonen et al., 2002). A meta-analysis also showed that physical activity is 
inversely associated with risk for T2DM (Aune et al., 2015). Moreover, intense 
exercise is necessary to stimulate 5-adenosine monophosphate-activated kinase (5-
AMPK) causing the release of glucose to the muscles rather than it accumulating in 
the plasma (Epstein et al., 1999). In our study however, we were unable to assess the 
level or intensity of physical activity by the individuals. Therefore, an effective 
physical assessment tool such as the international physical activity questionnaire 
(IPAQ) could be useful (Lee et al., 2011). 
Thirdly, poor dietary preferences may have been a contributory factor. Studies 
have shown that healthy diets or consumption of vegetables, low calorie diets, low 
trans fats, legumes, fruits, poultry, whole grains and cereal fibre is linked to a reduced 
risk of metabolic syndrome and T2DM (Frank et al., 2014). Conversely, consumption 
of red and processed meats, sweets, desserts and fried foods is associated with an 
increased risk of T2DM (Esposito et al., 2008; Frank et al., 2014). However, whether 
or not the majority of the study participants utilised a particular food was unverified 
and therefore, a validated food frequency questionnaire would have been useful. 
Despite the increasing use of anti-hypertensives, BP control was suboptimal in 
our study population. With an attrition rate of nearly 40%, only 52 T2DM participants 
who took anti-hypertensive medications were able to maintain a target BP (both SBP 
and DBP) at follow up (Table 7.7). The majority were unable to achieve a desired 
target although they took more than one antihypertensive drug. This is a striking result 
given that high BP is by far the most critical risk factor for cardiovascular disease 
(CVD) and stroke (Zhou, & Cai, 2011). Studies that explore the role of intensive BP 
control in preventing CVD have produced conflicting results. One study showed that 
a DBP of ≤ 80 mmHg could reduce the risk of CVD by 50% (Hansson et al., 1998). 
However, another study reported that SBP ≤ 120 mmHg was not associated with a 
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reduced risk for CVD (Cooper-DeHoff et al., 2010). Notwithstanding this, our 
findings agree with several other studies that BP is poorly controlled among T2DM 
patients worldwide (Cheung et al., 2009; Saydah, Fradkin, & Cowie, 2004). 
Statins are well-known lipid lowering medications and the common one used by 
participants in this study is atorvastatin. More than half of the participants taking 
atorvastatin had good lipid profiles and this is consistent with the findings by Wong et 
al., (Wong et al., 2014). Moreover, our study showed that there was a significant 
improvement in several lipid markers such as TG, LDL-c, HDL-c and VDL-c at follow 
up (Table 7.6). Whether atorvastatin interfered with glucose homeostasis is yet to be 
determined but our study confirms that atorvastatin is a potent drug for treating 
dyslipidaemia.  
The present study does have some limitations. Firstly, because it was an 
observational longitudinal study, it was limited by confounding factors such as 
differences in dosage regimen. Dosage regimen refers to the modality of drug 
administration/doses per unit of time to reach a therapeutic objective. This comprises 
the time or frequency when the drug should be administered, the time between doses 
and the amount or unit dose of medicine to be administered at a specific time (Claxton, 
Cramer, & Pierce, 2001; Patrick, 2013; Ritschel & Kearns, 2009). However, given the 
number of participants, each with a different medication dosage at a point in time, it 
was difficult to take into consideration the dosage regimen. At the same time, certain 
tests, especially FPG, are influenced by biological variation even when fluoride tubes 
are used. For example, stressful situations in the hours preceding a FPG test could 
increase FPG levels (Bonora & Tuomilehto, 2011). Thus, we were unable to provide 
a full explanation of the poor drug response among some participants. Secondly, a 
clinical randomised control trial would have eliminated potential confounding factors, 
and shed further light on the effect of the various medications in lowering modifiable 
risk factors.  Thirdly, the sample size of the study was small and therefore cannot be 
representative of the entire T2DM population. Finally, over 40% of the participants 
were lost to follow-up and this may have had an effect on our assessments.    
7.7 Conclusion  
This study showed that the use of statins is effective for improving lipid profiles 
and can be regarded as a potent medication for treating dyslipidaemia in the Ghanaian 
population. However, utilisation of oral hypoglycaemic agents whether as a 
monotherapy, combination or polytherapy was not effective for achieving plasma 
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glucose targets of < 7%. This is alarming and therefore, alternative approaches 
including a less sedentary lifestyle while engaging in vigorous exercise may reduce 
weight and obesity; enforcing healthy eating practices and administration of 
single/fixed-dose combination tablets or pills with minimal side effects may improve 
medication adherence. 
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CHAPTER NINE 
9.1 General Discussion 
Study I: Incorporation of suboptimal health status as a potential risk assessment 
for type II diabetes mellitus: A case-control study in Ghana 
Due to the exponential growth of the economy, improvement in living standards, 
industrialisation and urbanisation, a significant number of people in Ghana suffer from 
many chronic diseases such as T2DM. A study has indicated that up to 6% of the adult 
population have T2DM and the disease is responsible for many hospitalisations, huge 
costs to the government and increased out-of-pocket costs to the taxpayers (Danquah 
et al., 2012). However, available data suggest that the development of T2DM takes up 
to 30 years, leaving room for early intervention. Hence, Study I applied the SHSQ-25 
to reveal those who could develop T2DM over time. It was shown that age, education, 
physical activity, DBP, SBP and TG levels were significantly associated with high 
SHS. This result is consistent with previous studies among Chinese and Caucasians 
and confirms the robustness of SHSQ-25. However, this study could not validate the 
association between high SHS and FPG, HbA1c, TC, LDL-c and HDL-c as previously 
found among Chinese populations. In addition, the median SHS score of 22 found in 
this study was lower than that of the Chinese cohorts. The possible explanation for 
these discrepancies are the sample size. The previous investigations were mainly 
conducted among large Chinese cohorts, i.e.  2,799 participants in 2009 (Yan et al., 
2009), 3,019 in 2012 (Yan et al., 2012), 3,405 in 2012 (Wang & Yan, 2012) and 4,313 
in 2016 (Wang et al., 2016). 
Further in Study I, the control of risk factors among the T2DM patients was 
poor and this could be blamed on delayed intervention, ineffective treatments, 
untargeted medications, drug resistance, poor infrastructure, genetic, epigenetic and 
environmental factors (Golubnitschaja, 2010; Golubnitschaja et al., 2016; 
Golubnitschaja et al., 2014; Lemke & Golubnitschaja, 2014). Overall, the findings of 
this study provide a stimulus for risk prediction, patient stratification, disease 
modelling, surveillance, optimal diagnosis and prediction of adverse drug-drug 
interaction. 
While this study indicated the usefulness of SHSQ-25 as a subjective marker for 
risk stratification for T2DM, it was obvious that the biological underpinnings of 
T2DM could not be unravelled with the SHSQ-25 alone. It was necessary to 
complement it with robust objective markers, and this led to Study II.  
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Study II: Utilisation of N-glycosylation profiles as risk stratification 
biomarkers for suboptimal health status and metabolic syndrome  
In this study, HILIC-UPLC was used to profile the plasma N-glycome in healthy 
individuals, as well as those with SHS and MetS. It was found that 
GP31(FA3G3S[3,3,6]3), p=0.0437)), GP34 A4G4S[3,3,6]3) p=0.0110)), and GP38 
(A4G4S[3,3,3,6]4); p=0.0493)) were increased in high SHS. Intriguingly, these 
associations were obvious in patients with MetS and strengthens the link between high 
SHS and MetS. Thus, high SHS could be a unique checkpoint for intervention. As 
stated previously, individuals with high SHS could be targeted for tailored 
interventions that may postpone the development of MetS or T2DM. This study also 
demonstrated that N-glycan complexity was linked with MetS. HB, G3, FUC_A, 
TRIA were all increased in MetS compared to controls. These associations could be 
attributed to the over expression of N-acetylglucosaminyltransferase, the enzyme that 
catalyses β 1, 6 GlcNAc branching and drives the inflammatory processes that 
characterises MetS (Dube & Bertozzi, 2005).  
Recently, N-glycomics has gained considerable interest worldwide; yet, studies 
that focus on inter-population N-glycan profile comparisons are relatively scarce. 
Moreover, it is proposed that the N-glycosylation machinery is affected by at least 1% 
of genes (Lauc, 2016; Lauc et al., 2010). Thus, the pattern of glycosylation across 
multiple populations may change. Therefore, the findings of this study were compared 
to those from Chinese Han, Croatian and Orcadian populations. It was revealed that 
N-glycans not only correlated with biochemical/clinical measures of MetS but also the 
pattern of N-glycan associations were similar across multiple populations. For 
example, G3, S3 and TRIA were positively associated with BMI in all four populations 
(i.e. Ghanaians, Scottish, Chinese and Croatians) (Table 5.5a). This study therefore 
confirms the potential of N-glycosylation as a generic and universal biomarker for 
MetS. However, it should be noted that the direction of association was not always the 
same across the different populations. This is largely because the various populations 
may be exposed to different environmental factors and stressors. For example, the 
climatic conditions within the African population are different from those in the Asian 
or Caucasian populations and this may affect the N-glycosylation process.  
While glycomics is a relatively new emerging field, it holds great potential in 
helping us to understand the pathophysiology of diabetes. However, it is expensive at 
this stage. The SHS promises a much less expensive means of revealing those at-risk 
of T2DM but this needs to be validated in very large longitudinal studies. Already, 
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SHS studies are being conducted among 50,000 Chinese individuals and it is hoped 
that a clearer understanding of the link between SHS and MetS or T2DM will be 
revealed (Wang, Russell and Yan, 2014). 
 
Study III: High-throughput profiling of whole plasma N-glycans in Type II 
diabetes mellitus patients and healthy individuals 
The aim of this study was to determine the N-glycan changes that exist in people 
with T2DM when compared to healthy individuals. It was revealed that N-glycan 
structures in healthy individuals differed significantly from T2DM patients, and that 
T2DM was associated with increased plasma N-glycosylation structures. Specifically, 
and similar to the findings of Study II, the present study revealed increased HB, tri-
galactosylated (G3), antennary fucosylated (FUC_A) and triantennary (TA) N-glycan 
structures was associated with T2DM. These findings agree with other studies (Keser 
et al., 2017; McLachlan et al., 2016), confirming that N-glycan complexity is linked 
with poor plasma glucose control. There is compelling evidence that reduction of 
sialylation was associated with chronic diseases including colorectal cancers 
(Theodoratou et al., 2016), chronic kidney disease (Barrios et al., 2016) and SLE 
(Vučković et al., 2015), whereas it is increased in hypertension (Wang et al., 2016). 
The results of this study seems to agree with that of Wang et al., (2016) as increased 
sialylation was associated with T2DM and confirmed the link between hypertension 
and T2DM. This could be explained by the fact that during the hyperglycaemic state, 
there is an increased expression of sialyltransferase (Gokmen et al., 2001). 
Consequently, more sialic acid is synthesised and released into the plasma. In another 
study involving a European population, it was shown that decreased IgG sialylation 
was linked to T2DM (Lemmers et al., 2017). However, since the present study was 
not restricted to IgG, but the whole human plasma N-glycome, we could not 
investigate this finding. Further, LB, S0, G1, FUC_C, A2G and BA structures were 
decreased in T2DM compared to controls.  
Overall, Studies I-III have given an overview of the health status of the 
Ghanaian population and demonstrated the efficiency of the HILIC-UPLC technique 
for glycoprofiling. However, the findings of the study were based on a one-time 
sampling approach (cross-sectional), lacking cause-effect relationship. Hence, 
Studies IV and V were designed in an attempt to reveal small changes that were 
associated with T2DM progression by observing the clinical/biochemical data of 
T2DM patients and examining their N-glycan profiles over time.  
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Study IV: Profiling of cardio-metabolic risk factors and medication utilisation 
among Type II diabetes patients in Ghana: A prospective cohort study  
Renowned health organisations such as the WHO and the IDF have issued 
guidelines for risk factor control among T2DM (IDF, 2015; WHO, 2005). However, 
to date, this effort has yielded mixed results. This study therefore sought to determine 
the prevalence of risk factors, and trends in medication use among T2DM patients in 
Ghana and to propose better management approaches.  
The results of the study showed that more than 80% of the participants were on 
anti-diabetic medications, as previously documented by Danquah et al., (2012). 
Despite the substantial use of these medications, the majority of the T2DM patients 
could not meet targets for reduced blood pressure and blood glucose levels even at 6-
month follow-up. For example, the use of BIG alone could cause only a 29.6% effect 
on HbA1c levels. When BIG was combined with SUA, a 19.2% effect on HbA1c was 
observed. In parallel, anti-hypertension medication, use normalised the blood pressure 
for only 52 out of 122 T2DM patients while half could achieve reduced targets for 
blood lipid levels after atorvastatin use. There is the need for stringent and better 
management approaches. For example, dosages should be optimised and patient 
adherence promoted. This should be complemented with lifestyle changes, such as 
restriction of dietary carbohydrates, increased exercise and smoking cessation. 
Further, comprehensive medical and clinical rehabilitation services should be 
accessible to all T2DM patients (Golubnitschaja et al., 2016; Golubnitschaja, 
Kinkorova, & Costigliola, 2014; Lemke & Golubnitschaja, 2014). 
Study V: N-Glycosylation Profiling of Type II Diabetes Mellitus from Baseline to 
Follow-up  
To date, studies on the stability of plasma N-glycans have only been reported in two 
studies (Gornik et al., 2009; Hennig et al., 2016). However, their conclusions were 
based on only 12 and 5 healthy individuals, respectively, and employed analytical 
tools that allowed the quantification of a limited number of N-glycan peaks. Therefore, 
the aim of Study V was to determine plasma N-glycosylation patterns among T2DM 
patients, in relation with environmental factors over a 6-month period. It was shown 
that at baseline, BMI, education, occupation and WHtR as well as levels of HDL-c 
differed significantly between males and females. In addition, HDL-c levels for all 
participants differed significantly from baseline to follow-up while N-glycan 
structures were gender specific, as described in Lu et al., (2011). In particular, levels 
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of HB, S2, S3, S4, G3, FUC_A and TRIA were statistically significantly higher in 
females, whereas LB, S0, S1, G1, FUC_C, BA, BAMS and A2G were statistically 
significantly higher in males compared to females. After calculating the CVs of the N-
glycans at baseline and follow-up, it was shown that intra-individual variability of the 
N-glycans was small, whereas at the population level, the variability was large. 
However, none of these results could reach statistical significance. These findings 
confirm the long-term stability of N-glycan structures as previously documented by 
Gornik et al., (2009) and Hennig et al., (2016). There are discrepancies in the half-life 
of glycoproteins. In a quantitative study of 39 glycoproteins, it was shown that human 
cell surface glycoproteins had a median half-life of 19.6 hr (Xiao and Wu, 2017). In 
another study, it was found that the half-life of more than 20% of glycoproteins 
exceeded 100hr (Sun et al., 2016). On the other hand, the half-life of IgG in the plasma 
is almost 26 days with an average plasma concentration of 15g/L days (Novokmet et 
al., 2014). Given these half-lives, it appears unlikely that there would be significant 
changes the whole plasma N-glycome through the degradation of old glycans and 
regeneration of new ones. 
Moreover, it is worth noting that N-glycan structures may have changed in the 
presence of T2DM co-morbidities such as neuropathy, glaucoma, myocardial 
infarction, coronary artery disease, retinopathy and peripheral ulcers (Testa et al., 
2015). However, patients who had these complications did not meet the inclusion 
criteria of this study. Thus, the lack of change of N-glycan structures was expected. 
This study highlights the inclusion of N-glycans for T2DM prognosis as monitoring 
N-glycan profiles over time could reveal biochemical changes that link T2DM and co-
morbidities.  
9.2 Limitations and Future Perspectives 
Although the present overall project produced a number of publications and 
manuscripts, it was not devoid of limitations. Firstly, the major limitation relates to 
the small sample size. Moreover, a large number of participants were lost to follow-
up while a significant volume of missing data was seen. Combined, these introduced 
bias and loss of statistical power. Larger cohorts should be considered in future studies, 
and to compensate for dropouts, multiple imputation of the baseline data should be 
made. Secondly, there were higher numbers of females than males in both cases and 
controls and this may have introduced some bias. Thirdly, the project was largely a 
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cross-sectional one; a 6-month follow up study was only possible among T2DM 
patients. As such, the project was unable to determine the direction of causality. To 
better explain this, longitudinal studies are required. Presently, there are ongoing retro 
(1994-2016) and prospective (2016-2022) longitudinal analyses of plasma N-glycome 
occurring as part of the Busselton Healthy Ageing Cohort. Results from that study will 
explain whether changes of N-glycan structure is a cause or a consequence of T2DM.  
While there is a possible role for genes in the glycosylation pattern across 
different populations, the present study could not adequately verify this. However, 
buffy coat aliquots for these participants are still stored. These samples will be 
available for GWAS in the near future and could help us to understand the involvement 
of genes in glycosylation. Increasing evidence suggests that perturbed lipid levels are 
associated with insulin resistance and T2DM (Boden et al., 2002). This conclusion has 
largely been accepted in the context of traditional clinical markers including HDL-c, 
LDL-c, TC, and TG as well as body fat measures such as BMI, WHR and central 
obesity (Boden et al., 2002). However, the complexity of T2DM cannot be fully 
described by these markers alone. Hence, a deep profiling of distinct lipid classes, 
taking into consideration the structure, function and role (lipidomics) is required to 
provide further insights.  
It is known that there is a negative association between hyperglycaemia and the 
levels of circulating glycocalyx. It is also worth noting the potential impact of high 
plasma glucose on the glycocalyx volume and increase in vascular vulnerability. As 
well, other glycocalyx degrading factors including matrix metalloproteinases, 
sialidases and heparanase may compromise the integrity of the endothelial cells 
(Sieve, Munster-Kuhnel and Hilfiker, 2018). However, it was beyond the scope of this 
thesis to measure the levels/volume of glycocalyx or perform such investigations.  
Further, the majority of the results from this thesis are associative in nature and 
mechanistic studies are necessary in the future to understand how N-glycosylation 
may differ in the population from Ghana. 
9.3 General Conclusions 
The conclusions from this thesis are: 1) the management of T2DM in Ghana is 
suboptimal and undiagnosed risk factors remain prevalent, 2) Statin medications are 
effective for reducing dyslipidaemia in T2DM patients. However, control of 
modifiable risk factors, particularly blood glucose and to a lesser degree blood 
pressure is suboptimal, 3) SHS is a significant, albeit modest, risk factor for metabolic 
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syndrome (MetS) while MetS and T2DM are significantly associated with complex 
N-glycans. 4) N-glycan structures in T2DM patients are stable over 6 months and may 
change in the presence of co-morbidities. 
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CHAPTER TEN 
Appendix I 
Sample Size 
An estimated sample size of 515 yielded a statistical power of 80%, with an effect size 
of 0.5 at an alpha level of 0.01 based on power analyses using G*Power software 
version 3.1.9.2.  
Risk Assessment 
There was a possibility of cross contamination in the biochemistry laboratory of 
KATH since different samples were analysed concurrently. However, this was 
controlled by ensuring quality control measures such as maintaining strict hygienic 
conditions, proper handling and adequate labelling of samples. Collected blood 
samples were then frozen at -80oC before transporting to Australia and then to Genos, 
Croatia for N-glycan analysis. I was aware of possible contamination during sample 
transportation and so we ensured proper packaging and strict adherence to shipping 
legislations and requirements.  
 
  
Figure: A) map of Ghana             B) Komfo Anokye Teaching Hospital, Kumasi 
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Plate Randomisation 
Summary (p1) #mean age=54.96, 40.26% F, 1-30 2-29 3-18 
Summary (p2) #mean age=55.37, 38.16% F, 1-29 2-28 3-19 
Summary (p3) #mean age=53.61, 39.47% F, 1-32 2-28 3-16 
Summary (p4) #mean age=55.47, 40.79% F, 1-30 2-26 3-20 
Summary (p5) #mean age=54.71, 35.53% F, 1-29 2-31 3-16 
Summary (p6) #mean age=56.20, 36.84% F, 1-30 2-29 3-17 
Summary (p7) #mean age=55.63, 39.47% F, 1-31 2-29 3-16 
Summary (p8) #mean age=54.42, 39.47% F, 1-29 2-28 3-19 
Summary (p9) #mean age=54.57, 38.16% F, 1-32 2-28 3-16 
 
R-Packages  
1. ggplot2 
2. magrittr 
3. ggpubr 
4. glots 
5. rColorBrewer/colorRampPalette 
6. heatmap.plus 
7. corrgram 
8. corrplot 
9. devtools 
10. easyGgplot2 
11. blockrand 
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Appendix II  
Chapter Five Supplementary Data 
Supplementary Table 5.1. Derived plasma N-glycan traits calculated from 39 directly 
measured N-glycan peaks 
Variable Label Description 
LB Low Branching GP1+GP2+GP3+GP4+GP5+GP6+GP7+GP8+GP9+GP10+GP11+GP12+
GP13+GP14+GP15+GP16+GP17+GP18+GP19+GP20+GP21+GP22+GP
23 
HB High Branching GP24+GP26+GP27+GP28+GP29+GP30+GP31+GP32+GP33+GP34+GP
35+GP36+GP37+GP38+GP39 
S0 Neutral  GP1+GP2+GP3+GP4+GP5+GP6+GP7+GP8+GP9+GP10+GP11 
S1 Monosialylated GP12+GP13+GP14+GP15+GP16+GP17 
S2 Disialylated GP18+M9+GP20.21+GP22+GP23+GP24++ GP25+GP26 
S3 Trisialylated GP27+GP28+GP29+GP30+GP31+GP32+GP33+GP34+GP35 
S4 Tetrasialylated GP36+GP37+GP38+GP39 
G0 Agalactosylated GP1+GP2+GP7 
G1 Monogalactosylated GP3+GP4+GP5+GP6+GP12+GP13 
G2 Digalactosylated GP8+GP9+GP10+GP11+GP14+GP15+GP16+GP17+GP18+M9+GP20+
GP21+GP22+GP23 
G3 Trigalactosylated GP24+GP26+GP27+GP28+GP29+GP30+GP31+GP32+GP35 
G4 Tetragalactosylated GP33+GP34+GP36+GP37+GP38+GP39 
FUC_A Antennary Fucose GP32+GP35+GP39 
FUC_C Core Fucose GP1+GP2+GP4+GP5+GP6+GP10+GP11+GP13+GP16+GP17+GP22+G
P23+GP29+GP31 
BA Biantennary GP1+GP2+GP3+GP4+GP5+GP6+GP8+GP9+GP10+GP11+GP12+GP13
+GP14+GP15+GP16+GP17+GP18+GP20+GP21+GP22+GP23 
A2 Biantennary 
Agalactosylated 
GP1+GP2 
A2G Biantennary 
Galactosylated 
GP3+GP4+GP5+GP6+GP8+GP9+GP10+GP11+GP12+GP13+GP14+GP
15+GP16+GP17+GP18+GP20+GP21+GP22+GP23 
BAMS Monosialylated 
Biantennary 
GP12+GP13+GP14+GP15+GP16+GP17 
BADS Disialylated 
Biantennary 
GP18+GP20+GP21+GP22+GP23 
TRIA Triantennary GP19+GP24+GP26+GP27+GP28+GP29+GP30+GP31+GP32 
TA Tetraantennary GP33+GP34+GP35+GP36+GP37+GP38+GP39 
 
 
 
 
 195 
 
Supplementary Table 5.2 Distribution of individual plasma N-glycan peaks in low and 
high SHS 
  Low SHS  High SHS  
N-glycan Median(IQR) Range Median(IQR) Range p-value 
GP1 5.92(3.00) 4.52 - 7.52 6.34(2.38) 5.08 - 7.47 0.13049 
GP2 2.22(0.73) 1.91 - 2.64 2.34(0.77) 2.04 - 2.81 0.12836 
GP3 0.08(0.05) 0.07 - 0.12 0.08(0.04) 0.07 - 0.12 0.58256 
GP4 5.19(1.60) 4.34 - 5.94 5.33(1.70) 4.35 - 6.05 0.49885 
GP5 2.16(0.69) 1.78 - 2.47 2.14(0.72) 1.76 - 2.48 0.8679 
GP6 1.25(0.42) 1.04 - 1.47 1.28(0.36) 1.13 - 1.49 0.19439 
GP7 0.98(0.19) 0.90 - 1.1 0.97(0.18) 0.88 - 1.07 0.18638 
GP8 1.13(0.27) 1.04 - 1.31 1.14(0.34) 0.99 - 1.34 0.5872 
GP9 0.10(0.03) 0.09 - 0.12 0.10(0.02) 0.09 - 0.12 0.92533 
GP10 4.62(1.68) 3.67 - 5.35 4.37(1.52) 3.47 - 5 0.07834 
GP11 0.81(0.24) 0.69 - 0.94 0.78(0.20) 0.69 - 0.89 0.38403 
GP12 0.98(0.16) 0.90 - 1.06 0.97(0.17) 0.89 - 1.06 0.37761 
GP13 0.84(0.27) 0.72 - 0.99 0.84(0.26) 0.72 - 0.98 0.87322 
GP14 10.48(1.46) 9.76 - 11.23 10.42(1.66) 9.54 - 11.2 0.49885 
GP15 0.36(0.08) 0.34 - 0.42 0.37(0.08) 0.34 - 0.43 0.36765 
GP16 6.20(1.65) 5.47 - 7.12 6.02(1.42) 5.38 - 6.8 0.14434 
GP17 1.77(0.58) 1.43 - 2.01 1.74(0.45) 1.51 - 1.96 0.8892 
GP18 3.57(0.77) 3.21 - 3.98 3.44(0.65) 3.18 - 3.84 0.25261 
GP19 1.10(0.19) 1.02 - 1.21 1.11(0.23) 1.00 - 1.23 0.94413 
GP20 25.24(3.79) 23.68 - 27.47 25.01(3.38) 23.35 - 26.74 0.23485 
GP21 0.51(0.13) 0.45 - 0.59 0.50(0.12) 0.45 - 0.58 0.71215 
GP22 4.17(0.92) 3.77 - 4.7 4.21(1.00) 3.80 - 4.81 0.4428 
GP23 1.94(0.57) 1.66 - 2.24 1.99(0.76) 1.68 - 2.44 0.21864 
GP24 1.66(0.58) 1.35 - 1.93 1.64(0.52) 1.36 - 1.89 0.86259 
GP25 0.14(0.04) 0.13 - 0.17 0.14(0.05) 0.12 - 0.18 0.8033 
GP26 1.46(0.45) 1.23 - 1.68 1.47(0.43) 1.28 - 1.72 0.40275 
GP27 0.43(0.29) 0.30 - 0.6 0.46(0.29) 0.33 - 0.62 0.57678 
GP28 0.77(0.30) 0.64 - 0.94 0.77(0.23) 0.67 - 0.91 0.92265 
GP29 0.19(0.05) 0.18 - 0.23 0.20(0.05) 0.18 - 0.24 0.62973 
GP30 5.49(1.82) 4.51 - 6.34 5.67(2.07) 4.46 - 6.54 0.58488 
GP31 0.46(0.18) 0.37 - 0.55 0.51(0.21) 0.38 - 0.6 0.04369 
GP32 1.31(0.53) 1.05 - 1.58 1.32(0.43) 1.14 - 1.57 0.51072 
GP33 1.74(1.17) 1.21 - 2.39 1.82(1.42) 1.27 - 2.69 0.43979 
GP34 0.34(0.08) 0.30 - 0.39 0.37(0.10) 0.33 - 0.43 0.01096 
GP35 0.23(0.11) 0.17 - 0.29 0.25(0.15) 0.18 - 0.34 0.05454 
GP36 0.41(0.09) 0.37 - 0.46 0.42(0.08) 0.39 - 0.48 0.04733 
GP37 0.52(0.21) 0.40 - 0.61 0.51(0.24) 0.42 - 0.66 0.33962 
GP38 0.86(0.26) 0.73 - 0.99 0.92(0.25) 0.79 - 1.04 0.04925 
GP39 0.47(0.21) 0.40 - 0.61 0.52(0.26) 0.42 - 0.69 0.05781 
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Supplementary Table 5.3 Distribution of derived plasma N-glycan traits in 
Normal and MetS 
 Normal MetS  
N-glycan Median(IQR) Range Median(IQR) Range p-value 
Branching     
LB 82.97(4.33) 80.80 - 85.13 81.96(3.24) 80.51 - 83.76 0.006 
HB 16.68(4.03) 14.45 - 18.49 17.84(3.39) 15.74 - 19.13 0.004 
Level of sialylation     
S0 24.97(5.92) 22.16 - 28.09 24.79(6.23) 21.29 - 27.53 0.685 
S1 20.87(1.95) 20.05 - 22 20.25(1.62) 19.48 - 21.1 0.004 
S2 39.75(4.06) 37.57 - 41.63 39.99(3.81) 37.82 - 41.64 0.591 
S3 11.09(2.77) 9.67 - 12.45 11.90(2.35) 10.36 - 12.72 0.011 
S4 2.29(0.64) 2.02 - 2.66 2.46(0.59) 2.12 - 2.72 0.013 
Level of galactosylation    
G0 9.23(3.62) 7.58 - 11.2 9.70(2.96) 8.28 - 11.25 0.155 
G1 10.77(2.59) 9.35 - 11.95 10.60(2.69) 9.21 - 11.91 0.71 
G2 62.81(5.71) 59.98 - 65.69 61.61(4.14) 59.47 - 63.62 0.017 
G3 11.97(3.52) 10.07 - 13.59 12.81(3.87) 11.07 - 14.94 0.001 
G4 4.44(1.40) 3.87 - 5.28 4.36(1.96) 3.63 - 5.59 0.606 
Position of fucose     
FUC_A 1.99(0.66) 1.70 - 2.37 2.25(0.66) 1.99 - 2.65 0 
FUC_C 38.29(7.13) 34.99 - 42.13 39.06(6.03) 35.27 - 41.3 0.783 
Level of sialylation of biantennary glycans   
A2 8.23(3.50) 6.64 - 10.14 8.76(2.92) 7.21 - 10.13 0.17 
A2G 72.30(4.50) 69.97 - 74.48 70.98(3.73) 69.16 - 72.9 0.001 
BAMS 20.87(1.95) 20.05 - 22 20.25(1.62) 19.48 - 21.1 0.004 
BADS 35.58(3.83) 33.63 - 37.47 35.60(3.62) 33.53 - 37.16 0.94 
Degree of branching    
BA 80.75(4.23) 78.81 - 83.04 79.78(3.57) 78.09 - 81.67 0.003 
TRIA 12.90(3.61) 10.92 - 14.53 13.79(3.82) 11.95 - 15.77 0 
TA 4.71(1.49) 4.06 - 5.56 4.60(2.05) 3.85 - 5.9 0.622 
DG9index 0.29(0.04) 0.27 - 0.32 0.31(0.05) 0.29 - 0.35 0 
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Supplementary Table 5.4 Correlation between derived plasma N-glycan traits and liver function markers 
 Albumin   Globulin   ALP   GAMMAGT   DirectBil   
Peaks          rs       p      q          rs      p     q        rs      p      q rs p q rs p q 
Branching                
LB -0.01 0.9322 0.932 0.11 0.0829 0.1203 -0.22 0.0005 0.0013 -0.129 0.0440 0.0660 0.144 0.0248 0.0702 
HB 0.01 0.9012 0.932 -0.12 0.0535 0.0922 0.22 0.0005 0.0013 0.138 0.0311 0.0502 -0.145 0.0237 0.0702 
Level of sialylation                
S0 -0.14 0.0256 0.134 0.23 0.0003 0.0013 -0.05 0.407 0.4498 -0.154 0.0165 0.0346 0.019 0.7676 0.8060 
S1 0.07 0.2858 0.500 -0.11 0.0974 0.1203 -0.23 0.0004 0.0013 -0.16 0.0127 0.0346 0.219 0.0006 0.0040 
S2 0.18 0.0062 0.055 -0.18 0.0045 0.0158 0.05 0.4637 0.4869 0.195 0.0023 0.0346 -0.04 0.5383 0.6650 
S3 0.03 0.6249 0.820 -0.08 0.1988 0.2319 0.24 0.0002 0.0013 0.147 0.0221 0.0422 -0.13 0.0421 0.0750 
S4 -0.08 0.2240 0.470 -0.11 0.087 0.1203 0.14 0.0246 0.0414 0.024 0.7085 0.7440 -0.122 0.0579 0.0875 
Level of galactosylation              
G0 -0.12 0.0675 0.177 0.31 0 0.0000 0.12 0.0539 0.0809 -0.04 0.5397 0.6093 -0.136 0.0340 0.0714 
G1 -0.12 0.0580 0.177 0.18 0.0056 0.0168 -0.07 0.2566 0.2994 -0.161 0.0119 0.0346 0.073 0.2567 0.3369 
G2 0.17 0.0078 0.055 -0.23 0.0003 0.0013 -0.18 0.0045 0.0086 0.008 0.8989 0.8989 0.166 0.0094 0.0492 
G3 0.03 0.5948 0.820 -0.12 0.0536 0.0922 0.2 0.0015 0.0032 0.156 0.0151 0.0346 -0.13 0.0428 0.0750 
G4 -0.01 0.8387 0.932 -0.04 0.5041 0.5572 0.1 0.1383 0.1815 0.056 0.3857 0.4764 -0.03 0.6364 0.7034 
A2 -0.12 0.0630 0.177 0.32 0 0.0000 0.12 0.06 0.0840 -0.038 0.5513 0.6093 -0.139 0.0302 0.0704 
A2G 0.11 0.1020 0.238 -0.16 0.0159 0.0371 -0.27 0.0000 0.0000 -0.101 0.1148 0.1607 0.244 0.0001 0.0025 
Position of fucose               
FUC_A -0.05 0.4300 0.645 0.03 0.6533 0.6533 0.24 0.0001 0.0011 0.159 0.0132 0.0346 -0.15 0.0196 0.0702 
FUC_C -0.13 0.0504 0.177 0.24 0.0002 0.0013 -0.14 0.0256 0.0414 -0.175 0.0063 0.0346 0.082 0.2027 0.2837 
Level of sialylation of biantennary glycans             
BAMS 0.07 0.2858 0.500 -0.11 0.0974 0.1203 -0.23 0.0004 0.0013 -0.16 0.0127 0.0346 0.219 0.0006 0.0040 
BADS 0.17 0.0073 0.055 -0.17 0.007 0.0184 0.01 0.8938 0.8938 0.18 0.0050 0.0346 -0.016 0.8070 0.8070 
Degree of branching               
BA -0.02 0.7381 0.912 0.12 0.0571 0.0922 -0.23 0.0003 0.0013 -0.14 0.0290 0.0502 0.142 0.0268 0.0702 
TRIA 0.05 0.4170 0.645 -0.12 0.053 0.0922 0.21 0.0009 0.0021 0.163 0.0110 0.0346 -0.122 0.0583 0.0875 
TA -0.01 0.8457 0.932 -0.03 0.6314 0.6533 0.09 0.1521 0.1879 0.059 0.3560 0.4672 -0.031 0.6301 0.7034 
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Supplementary Table 5.5 Correlations between derived plasma N-glycan traits and SBP, DBP, TC, TG, LDL-c, VLDL-c and HDL-c 
  SBP   DBP   TC   TG   LDL-C   
VLDL-
C   HDL-C 
  rs p  rs p  rs p q rs p q rs p q rs p q rs p q 
Level of branching                      
LB  -0.0378 0.544 0.709 -0.13 0.038 0.078 0.14 0.028 0.071 0.14 0.025 0.065 -0.13 0.044 0.065 -0.21 0.001 0.002 0.13 0.036 0.157 
HB  0.0373 0.548 0.709 0.13 0.036 0.078 -0.16 0.015 0.067 -0.15 0.024 0.065 0.14 0.031 0.049 0.23 0.000 0.001 -0.14 0.025 0.157 
S0  -0.0216 0.728 0.728 -0.02 0.791 0.870 -0.01 0.858 0.899 0.02 0.768 0.804          
Level of 
sialylation             -0.15 0.016 0.033 -0.10 0.111 0.144 0.03 0.635 0.986 
S1  -0.108 0.082 0.200 -0.14 0.019 0.074 0.21 0.001 0.008 0.22 0.001 0.004 -0.16 0.013 0.032 -0.17 0.008 0.016 -0.02 0.806 0.986 
S2  0.0222 0.722 0.728 -0.01 0.895 0.895 0.00 0.957 0.957 -0.04 0.538 0.658 0.19 0.002 0.025 0.12 0.073 0.113 0.00 0.997 1.000 
S3  0.0604 0.331 0.607 0.13 0.039 0.078 -0.13 0.036 0.071 -0.13 0.042 0.072 0.15 0.022 0.040 0.22 0.000 0.001 -0.11 0.081 0.254 
S4  0.0923 0.137 0.274 0.16 0.009 0.065 -0.10 0.113 0.177 -0.12 0.058 0.086 0.02 0.709 0.742 0.11 0.102 0.141 -0.09 0.184 0.404 
Level of 
galactosylation                      
G0  0.1616 0.009 0.073 0.11 0.089 0.142 -0.14 0.027 0.071 -0.14 0.034 0.068 -0.04 0.540 0.606 0.06 0.390 0.451 0.09 0.170 0.404 
G1  -0.0465 0.454 0.709 -0.01 0.858 0.895 0.03 0.659 0.740 0.07 0.257 0.332 -0.16 0.012 0.032 -0.12 0.066 0.111 0.00 0.989 1.000 
G2  -0.1038 0.094 0.207 -0.16 0.008 0.065 0.20 0.002 0.011 0.17 0.009 0.042 0.01 0.899 0.899 -0.11 0.077 0.113 0.02 0.796 0.986 
G3  -0.0279 0.654 0.728 0.10 0.099 0.145 -0.14 0.029 0.071 -0.13 0.043 0.072 0.16 0.015 0.033 0.25 0.000 0.001 -0.18 0.005 0.061 
G4  0.1482 0.017 0.073 0.05 0.389 0.504 -0.03 0.672 0.740 -0.03 0.636 0.700 0.06 0.386 0.471 0.03 0.628 0.628 0.00 1.000 1.000 
A2  0.1686 0.006 0.073 0.11 0.086 0.142 -0.15 0.023 0.071 -0.14 0.030 0.066 -0.04 0.551 0.606 0.05 0.423 0.465 0.09 0.149 0.404 
A2G  -0.1339 0.031 0.096 -0.18 0.003 0.065 0.24 0.000 0.004 0.24 0.000 0.003 -0.10 0.115 0.158 -0.22 0.000 0.001 0.03 0.690 0.986 
Position of fucose                       
FUC_A  0.1494 0.016 0.073 0.14 0.021 0.074 -0.12 0.056 0.095 -0.15 0.020 0.065 0.16 0.013 0.032 0.28 0.000 0.000 -0.04 0.513 0.940 
FUC_C  -0.0264 0.671 0.728 -0.03 0.668 0.817 0.07 0.257 0.354 0.08 0.203 0.279 -0.17 0.006 0.032 -0.14 0.032 0.059 0.08 0.211 0.421 
Level of sialylation of biantennary 
glycans                    
BAMS  -0.108 0.082 0.200 -0.14 0.019 0.074 0.21 0.001 0.008 0.22 0.001 0.004 -0.16 0.013 0.032 -0.17 0.008 0.016 -0.02 0.806 0.986 
BADS  0.0435 0.484 0.709 -0.02 0.727 0.842 0.03 0.591 0.740 -0.02 0.807 0.807 0.18 0.005 0.032 0.06 0.377 0.451 0.04 0.555 0.940 
Degree of 
branching                      
BA  -0.0381 0.540 0.709 -0.13 0.037 0.078 0.14 0.034 0.071 0.14 0.027 0.065 -0.14 0.029 0.049 -0.24 0.000 0.001 0.14 0.035 0.157 
TRIA  -0.0266 0.669 0.728 0.10 0.091 0.142 -0.13 0.050 0.091 -0.12 0.058 0.086 0.16 0.011 0.032 0.27 0.000 0.000 -0.18 0.006 0.061 
TA  0.1543 0.013 0.073 0.06 0.363 0.499 -0.03 0.661 0.740 -0.03 0.630 0.700 0.06 0.356 0.461 0.03 0.602 0.628 0.01 0.938 1.000 
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Supplementary Table 5.6 Correlations between derived plasma N-glycan traits and Age, WHtR, BMI and FPG 
 Age   WHtR   BMI   FPG   
Peaks rs p q rs q q rs p q rs p q 
Level of branching            
LB -0.10 0.127 0.225 -0.26 0.000 3E-05 -0.22 0.000 0.001 -0.01 0.854 0.904 
HB 0.10 0.127 0.225 0.29 0.000 3E-05 0.25 0.000 0.000 0.01 0.825 0.904 
Level of sialylation            
S0 -0.03 0.612 0.612 -0.11 0.075 1E-01 -0.11 0.087 0.137 -0.03 0.591 0.904 
S1 -0.12 0.051 0.153 -0.20 0.001 2E-03 -0.16 0.009 0.017 -0.09 0.164 0.402 
S2 0.03 0.584 0.612 0.09 0.153 2E-01 0.10 0.110 0.151 0.11 0.084 0.402 
S3 0.11 0.090 0.209 0.28 0.000 3E-05 0.23 0.000 0.001 0.03 0.586 0.904 
S4 0.06 0.364 0.425 0.21 0.001 2E-03 0.19 0.002 0.005 -0.13 0.045 0.328 
Level of galactosylation           
G0 0.30 0.000 0.000 -0.04 0.553 6E-01 -0.15 0.013 0.022 0.09 0.131 0.402 
G1 -0.11 0.069 0.182 -0.08 0.193 3E-01 -0.04 0.545 0.601 -0.08 0.207 0.456 
G2 -0.17 0.006 0.031 -0.12 0.059 1E-01 -0.04 0.546 0.601 -0.01 0.904 0.904 
G3 0.06 0.321 0.421 0.33 0.000 3E-05 0.29 0.000 0.000 0.02 0.766 0.904 
G4 0.09 0.160 0.240 0.02 0.788 8E-01 0.02 0.713 0.713 0.01 0.882 0.904 
A2 0.30 
    
0.000 0.000 -0.04 0.484 6E-01 -0.16 0.009 0.017 0.10 0.128 0.402 
A2G -0.28 0.000 0.000 -0.22 0.000 8E-04 -0.10 0.100 0.147 -0.07 0.248 0.497 
Position of fucose            
FUC_A 0.15 0.013 0.053 0.35 0.000 3E-05 0.34 0.000 0.000 0.13 0.043 0.328 
FUC_C -0.08 0.195 0.272 -0.11 0.073 1E-01 -0.07 0.232 0.300 -0.05 0.384 0.705 
Level of sialylation of biantennary glycans         
BAMS -0.12 0.051 0.153 -0.20 0.001 2E-03 -0.16 0.009 0.017 -0.09 0.164 0.402 
BADS 0.03 0.605 0.612 0.03 0.687 8E-01 0.04 0.502 0.601 0.10 0.126 0.402 
Degree of branching           
BA -0.09 0.139 0.225 -0.29 0.000 3E-05 -0.25 0.000 0.000 -0.02 0.753 0.904 
TRIA 0.06 0.344 0.425 0.35 0.000 3E-05 0.31 0.000 0.000 0.03 0.653 0.904 
TA 0.09 0.137 0.225 0.02 0.789 8E-01 0.02 0.707 0.713 0.02 0.752 0.904 
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Supplementary Table 5.7 Correlation between N-glycans and albumin, globulin, alkaline 
phosphatase 
 
 
 
 
 
 
 Albumin  Globulin  Total protein ALP  
Peaks rs p rs p rs p rs p 
GP1 -0.136 0.03393 0.319 <0.00001 0.194 0.00233 0.128 0.04587 
GP2 -0.032 0.62182 0.209 0.00103 0.104 0.1073 0.047 0.46726 
GP3 0.036 0.57499 0.031 0.63465 -0.005 0.93833 -0.066 0.30732 
GP4 -0.135 0.03493 0.169 0.00837 0.068 0.29436 -0.087 0.17775 
GP5 -0.110 0.08598 0.111 0.08342 0.034 0.60055 -0.025 0.69565 
GP6 -0.119 0.06292 0.190 0.00295 0.053 0.41206 -0.010 0.87865 
GP7 0.034 0.597 -0.050 0.43579 -0.038 0.55667 0.057 0.37985 
GP8 0.081 0.20597 -0.188 0.00325 -0.115 0.07305 -0.170 0.00779 
GP9 -0.006 0.92059 0.014 0.8265 -0.015 0.81034 -0.103 0.10937 
GP10 -0.031 0.63183 -0.104 0.10657 -0.087 0.17665 -0.295 <0.00001 
GP11 -0.083 0.19701 0.098 0.12834 0.055 0.39141 -0.117 0.06753 
GP12 0.159 0.01271 -0.150 0.01901 -0.065 0.31642 -0.111 0.08428 
GP13 -0.125 0.05104 0.187 0.00346 0.090 0.16077 -0.024 0.71099 
GP14 0.098 0.12543 -0.176 0.00591 -0.089 0.16598 0.013 0.84135 
GP15 -0.026 0.68608 0.088 0.17318 0.054 0.40036 -0.060 0.35328 
GP16 0.009 0.88663 -0.031 0.63521 0.010 0.87949 -0.324 <0.00001 
GP17 -0.108 0.09337 0.163 0.01075 0.082 0.20089 -0.009 0.88872 
GP18 0.170 0.00769 -0.207 0.00115 -0.112 0.08264 -0.118 0.06547 
GP19 0.253 0.00006 -0.106 0.10006 0.001 0.9825 0.250 0.00008 
GP20 0.173 0.00667 -0.185 0.00372 -0.072 0.26322 0.100 0.12144 
GP21 0.057 0.37754 0.010 0.88195 -0.001 0.98661 -0.044 0.49722 
GP22 0.096 0.13516 0.062 0.33699 0.087 0.17746 -0.136 0.03398 
GP23 -0.094 0.14357 0.200 0.00175 0.097 0.13178 -0.058 0.36499 
GP24 0.019 0.77054 -0.212 0.0009 -0.129 0.04494 0.058 0.36962 
GP25 0.015 0.8138 -0.111 0.08436 -0.108 0.09258 -0.185 0.00383 
GP26 0.008 0.90384 -0.082 0.20126 -0.038 0.55367 0.192 0.00271 
GP27 0.023 0.72362 0.038 0.55046 0.023 0.72377 0.015 0.81501 
GP28 0.027 0.67334 -0.156 0.01508 -0.095 0.14163 0.076 0.23882 
GP29 0.103 0.10942 -0.061 0.34493 -0.018 0.77546 -0.074 0.25352 
GP30 0.046 0.47535 -0.116 0.07196 -0.039 0.54393 0.182 0.00443 
GP31 0.030 0.63707 0.006 0.92574 0.027 0.6794 0.124 0.05265 
GP32 -0.025 0.69786 0.023 0.72512 0.018 0.78094 0.321 <0.00001 
GP33 0.003 0.95726 0.036 0.58158 0.017 0.78946 0.030 0.64158 
GP34 -0.041 0.51901 0.006 0.9253 -0.025 0.69981 0.190 0.00299 
GP35 0.004 0.95309 0.074 0.25129 0.039 0.54206 0.039 0.54616 
GP36 -0.074 0.25129 -0.168 0.00863 -0.183 0.0042 0.155 0.01589 
GP37 -0.043 0.50406 -0.119 0.06293 -0.104 0.10702 0.092 0.15506 
GP38 -0.069 0.28655 -0.076 0.23678 -0.093 0.14731 0.174 0.00647 
GP39 -0.029 0.6487 -0.032 0.61824 -0.057 0.37957 0.057 0.37573 
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Supplementary Table 5.8 Correlation between derived traits and albumin, globulin, total 
protein, ALP 
 Albumin  Globulin  Total protein ALP 
Peaks rs p rs p rs p rs p 
Branching       
LB -0.005 0.93222 0.111 0.08287 0.082 0.20397 -0.220 0.00054 
HB 0.008 0.90123 -0.124 0.0535 -0.092 0.15406 0.220 0.00054 
Level of sialylation  
S0 -0.143 0.02557 0.229 0.00032 0.108 0.09299 -0.053 0.40702 
S1 0.069 0.28579 -0.107 0.09742 -0.036 0.58098 -0.227 0.00037 
S2 0.175 0.00624 -0.182 0.0045 -0.073 0.25718 0.047 0.46373 
S3 0.031 0.6249 -0.083 0.1988 -0.051 0.42614 0.235 0.00022 
S4 -0.078 0.224 -0.110 0.08702 -0.135 0.03593 0.144 0.02459 
Level of galactosylation 
G0 -0.117 0.06746 0.310 <0.00001 0.183 0.00416 0.124 0.0539 
G1 -0.122 0.05803 0.177 0.00564 0.076 0.23753 -0.073 0.2566 
G2 0.170 0.00775 -0.231 0.00028 -0.101 0.11673 -0.182 0.00453 
G3 0.034 0.59477 -0.124 0.05355 -0.059 0.36132 0.203 0.0015 
G4 -0.013 0.83867 -0.043 0.50414 -0.051 0.42604 0.095 0.13827 
A2 -0.119 0.06297 0.318 <0.00001 0.190 0.00297 0.121 0.06002 
A2G 0.105 0.10198 -0.155 0.01591 -0.080 0.21486 -0.270 0.00002 
Position of fucose      
FUC_A -0.051 0.43 0.029 0.65326 -0.015 0.82106 0.242 0.00014 
FUC_C -0.125 0.05041 0.239 0.00017 0.130 0.04371 -0.143 0.02556 
Level of sialylation of biantennary glycans     
BAMS 0.069 0.28579 -0.107 0.09742 -0.036 0.58098 -0.227 0.00037 
BADS 0.172 0.00725 -0.173 0.007 -0.074 0.25253 0.009 0.89381 
Degree of branching     
BA -0.022 0.73812 0.122 0.0571 0.086 0.18286 -0.232 0.00026 
TRIA 0.052 0.41702 -0.124 0.05299 -0.052 0.41752 0.211 0.00092 
TA -0.013 0.84572 -0.031 0.63144 -0.043 0.50389 0.092 0.1521 
DG9ind -0.033 0.6128 0.195 0.00222 0.140 0.02878 0.143 0.02566 
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Supplementary Table 5.9 Correlation between N-glycans and ALT/GPT, AST/GOT, GAMMAGT, direct 
and indirect bilirubin 
 ALTGPT  ASTGOT  GAMMAGT  DBil  IndBil  TBil  
Peaks rs p rs p rs p rs p rs p rs  
GP1 0.038 0.5541 0.076 0.24092 -0.038 0.55538 -0.160 0.01258 -0.185 0.00382 -0.175 0.00633 
GP2 0.077 0.22899 0.109 0.08898 -0.043 0.50822 -0.008 0.90411 -0.005 0.93364 0.007 0.91364 
GP3 0.066 0.30336 0.102 0.11225 -0.030 0.64103 0.102 0.1125 0.123 0.05607 0.134 0.03756 
GP4 -0.030 0.64279 -0.047 0.46401 -0.160 0.01234 0.061 0.34727 -0.046 0.47551 0.015 0.81085 
GP5 0.018 0.78107 0.027 0.67238 -0.138 0.03162 0.021 0.74968 -0.084 0.19374 -0.030 0.64671 
GP6 -0.038 0.55242 -0.008 0.90249 -0.098 0.12903 0.087 0.1744 0.022 0.73339 0.058 0.36746 
GP7 -0.009 0.89113 -0.020 0.75449 -0.005 0.93744 0.037 0.56507 0.070 0.27913 0.056 0.38663 
GP8 -0.018 0.77435 0.020 0.75743 -0.047 0.46836 0.149 0.02012 0.099 0.12406 0.135 0.03523 
GP9 -0.065 0.31558 0.065 0.31659 -0.107 0.09501 0.136 0.03437 0.157 0.01436 0.163 0.01116 
GP10 -0.101 0.11722 -0.016 0.80473 -0.220 0.00055 0.230 0.00031 0.118 0.06709 0.177 0.00567 
GP11 -0.148 0.02139 0.006 0.93184 -0.173 0.00686 0.125 0.05236 0.114 0.07722 0.112 0.08134 
GP12 -0.071 0.27003 -0.051 0.43207 0.015 0.81134 0.100 0.12121 0.103 0.11034 0.107 0.09593 
GP13 0.046 0.47165 0.098 0.12665 -0.128 0.04669 0.024 0.71424 -0.027 0.67163 -0.004 0.94714 
GP14 -0.042 0.51854 -0.063 0.32766 0.041 0.52982 -0.015 0.81946 -0.031 0.62824 -0.031 0.63342 
GP15 -0.133 0.03845 0.051 0.43307 -0.127 0.04725 0.091 0.15945 0.187 0.00348 0.149 0.02010 
GP16 -0.095 0.13778 0.084 0.19405 -0.193 0.00258 0.236 0.00021 0.206 0.00124 0.226 0.00038 
GP17 -0.141 00.0280 0.009 0.886 -0.132 0.04041 0.028 0.66 0.09 0.140 0.05 0.43 
GP18 -0.013 0.83841 -0.064 0.32314 -0.014 0.82531 0.127 0.04803 0.077 0.23453 0.092 0.15100 
GP19 0.219 0.00059 -0.002 0.971 0.273 0.00002 -0.004 0.94762 0.069 0.28578 0.041 0.52147 
GP20 0.130 0.04227 -0.006 0.92152 0.227 0.00035 -0.045 0.48456 0.009 0.88789 -0.021 0.74451 
GP21 0.091 0.15687 0.110 0.08814 -0.048 0.46003 0.038 0.5505 0.106 0.10084 0.078 0.22869 
GP22 0.088 0.17353 0.129 0.04525 0.046 0.47148 0.087 0.17788 0.193 0.00246 0.155 0.01539 
GP23 -0.036 0.57205 0.121 0.0591 -0.049 0.44601 0.057 0.37536 0.173 0.00674 0.131 0.04161 
GP24 -0.125 0.05102 -0.248 0.00009 0.084 0.19281 -0.053 0.41415 -0.123 0.05579 -0.097 0.1328 
GP25 -0.117 0.06892 -0.113 0.07978 -0.129 0.04496 0.080 0.21188 0.092 0.15471 0.093 0.1486 
GP26 -0.044 0.49016 -0.173 0.00684 0.169 0.00815 -0.125 0.05201 -0.132 0.03941 -0.135 0.03534 
GP27 0.093 0.14877 0.105 0.10221 0.050 0.43774 0.034 0.60104 0.017 0.78659 0.019 0.76675 
GP28 -0.106 0.1002 -0.184 0.00392 0.065 0.31317 -0.031 0.63288 -0.054 0.40585 -0.051 0.43186 
GP29 0.010 0.87278 0.056 0.38218 0.070 0.27783 0.053 0.4113 0.063 0.3289 0.051 0.42628 
GP30 -0.057 0.37643 -0.174 0.00645 0.113 0.0796 -0.109 0.08888 -0.094 0.14213 -0.110 0.08851 
GP31 -0.017 0.78901 -0.108 0.09434 0.159 0.01297 -0.179 0.00516 -0.111 0.0848 -0.150 0.01897 
GP32 0.023 0.7156 -0.090 0.16411 0.212 0.00087 -0.182 0.00433 -0.122 0.05657 -0.155 0.01558 
GP33 0.068 0.28982 0.090 0.16003 0.042 0.5134 0.030 0.64235 0.026 0.68297 0.023 0.72384 
GP34 -0.051 0.42898 -0.101 0.11589 0.179 0.00511 -0.207 0.00117 -0.154 0.01594 -0.188 0.00321 
GP35 0.064 0.32143 0.047 0.46554 0.074 0.25271 -0.045 0.48349 -0.034 0.59917 -0.049 0.44479 
GP36 -0.123 0.0546 -0.153 0.01667 0.062 0.33635 -0.141 0.02796 -0.134 0.0371 -0.146 0.02296 
GP37 -0.149 0.02006 -0.136 0.03369 -0.005 0.9383 -0.069 0.28735 -0.064 0.32398 -0.073 0.25641 
GP38 -0.084 0.19061 -0.097 0.13308 0.057 0.37609 -0.160 0.01257 -0.087 0.17686 -0.130 0.04335 
GP39 0.029 0.65197 0.022 0.73278 0.030 0.64133 -0.040 0.53796 0.004 0.95574 -0.023 0.71591 
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Supplementary Table 5.10 Correlation between derived N-glycans and ALT/GPT, AST/GOT, 
GAMMAGT, Direct and indirect bilirubin 
      ALTGPT  ASTGOT  GAMMAGT  DirectBil  IndirectBil  TotalBil 
Peaks rs p rs p rs             p        rs p rs p rs p  
Branching        
LB 0.032 0.61427 0.135 0.03579 -0.129 0.04401 0.144 0.02483 0.114 0.07586 0.141 0.02761 
HB -0.048 0.45569 -0.144 0.02471 0.138 0.03109 -0.145 0.02374 -0.139 0.03017 -0.155 0.01532 
Level of sialylation 
S0 -0.017 0.78751 0.031 0.63525 -0.154 0.01648 0.019 0.76764 -0.055 0.39028 -0.012 0.85833 
S1 -0.186 0.0036 -0.016 0.80645 -0.160 0.01268 0.219 0.00057 0.201 0.00168 0.208 0.00113 
S2 0.102 0.11199 0.000 0.99699 0.195 0.00227 -0.040 0.53831 0.048 0.45427 0.003 0.95721 
S3 -0.010 0.87704 -0.112 0.08066 0.147 0.02208 -0.130 0.04214 -0.116 0.07185 -0.135 0.03566 
S4 -0.108 0.09372 -0.086 0.18351 0.024 0.70854 -0.122 0.05794 -0.070 0.27967 -0.102 0.11262 
Level of galactosylation        
G0 0.056 0.38828 0.088 0.16983 -0.040 0.53974 -0.136 0.03398 -0.150 0.01912 -0.142 0.02724 
G1 -0.016 0.80266 0.001 0.98905 -0.161 0.0119 0.073 0.25672 -0.032 0.61429 0.028 0.65885 
G2 -0.023 0.72094 0.017 0.79568 0.008 0.89894 0.166 0.00937 0.222 0.00048 0.198 0.00192 
G3 -0.044 0.49357 -0.178 0.00532 0.156 0.01511 -0.130 0.04283 -0.130 0.04213 -0.140 0.02897 
G4 -0.012 0.85463 0.000 0.99992 0.056 0.38567 -0.030 0.63641 -0.011 0.87005 -0.027 0.67236 
A2 0.054 0.40071 0.093 0.14942 -0.038 0.55129 -0.139 0.03016 -0.155 0.01542 -0.146 0.023 
A2G -0.041 0.52173 0.026 0.69031 -0.101 0.11482 0.244 0.00012 0.220 0.00056 0.239 0.00017 
Position of fucose        
FUC_A 0.041 0.52069 -0.042 0.51261 0.159 0.01318 -0.150 0.01955 -0.084 0.19328 -0.123 0.05614 
FUC_C -0.039 0.54993 0.081 0.21057 -0.175 0.00625 0.082 0.20265 0.044 0.49202 0.073 0.25736 
Level of sialylation of biantennary glycans      
BAMS -0.186 0.0036 -0.016 0.80645 -0.160 0.01268 0.219 0.00057 0.201 0.00168 0.208 0.00113 
BADS 0.116 0.07004 0.038 0.5552 0.180 0.00501 -0.016 0.80695 0.084 0.19138 0.035 0.5913 
Degree of branching         
BA 0.019 0.77302 0.135 0.03493 -0.140 0.02896 0.142 0.02676 0.106 0.09887 0.136 0.0339 
TRIA -0.031 0.63044 -0.177 0.00555 0.163 0.01095 -0.122 0.05833 -0.116 0.07177 -0.126 0.04961 
TA -0.004 0.94492 0.005 0.93815 0.059 0.35596 -0.031 0.63011 -0.011 0.86278 -0.028 0.66099 
DG9ind 0.141 0.02758 0.126 0.04929 0.221 0.00053 -0.166 0.00958 -0.043 0.50002 -0.098 0.12622 
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Supplementary Table 5.11 Correlation between N-glycans and kidney function markers-creatinine, urea 
and uric acid 
 Creatinine Urea  
Uric 
acid  CKD-risk 
Peaks rs p rs p rs p rs p 
GP1 -0.109 0.08953 0.029 0.6544 0.018 0.78082 0.011 0.86523 
GP2 -0.023 0.72477 0.006 0.9216 -0.006 0.92811 -0.013 0.84295 
GP3 0.053 0.40829 -0.039 0.5419 -0.058 0.36818 0.025 0.69545 
GP4 -0.113 0.07935 0.020 0.7576 -0.132 0.04001 0.180 0.00523 
GP5 -0.069 0.28723 0.040 0.5392 -0.048 0.45849 0.129 0.04587 
GP6 -0.175 0.00625 -0.052 0.4197 -0.188 0.00339 0.069 0.28748 
GP7 -0.052 0.42274 -0.044 0.4982 -0.046 0.47348 0.050 0.43899 
GP8 0.140 0.02954 -0.019 0.7642 -0.080 0.21384 0.054 0.40261 
GP9 -0.029 0.65591 -0.081 0.2072 -0.094 0.14773 0.117 0.07012 
GP10 -0.035 0.58495 -0.075 0.2464 -0.170 0.00808 0.261 0.00004 
GP11 -0.098 0.12858 -0.130 0.043 -0.177 0.00593 0.116 0.07195 
GP12 0.024 0.70604 -0.010 0.8731 -0.049 0.45172 0.009 0.89116 
GP13 -0.107 0.09755 -0.046 0.4811 0.003 0.96454 0.128 0.04801 
GP14 0.081 0.20811 0.030 0.6398 -0.026 0.6931 -0.125 0.05384 
GP15 -0.102 0.11266 -0.077 0.2301 -0.034 0.6013 0.119 0.06535 
GP16 -0.031 0.63441 -0.163 0.011 -0.050 0.43689 0.274 0.00002 
GP17 -0.087 0.17979 -0.082 0.2031 -0.072 0.26671 0.024 0.70801 
GP18 0.156 0.01528 0.071 0.2689 -0.028 0.66223 -0.063 0.32909 
GP19 0.081 0.20991 0.051 0.4272 0.264 0.00003 -0.136 0.03465 
GP20 0.159 0.01303 0.094 0.1445 0.113 0.0799 -0.205 0.00144 
GP21 0.101 0.11676 0.050 0.437 0.136 0.03426 -0.087 0.17993 
GP22 -0.008 0.90189 -0.117 0.0687 0.203 0.00153 0.173 0.00736 
GP23 -0.128 0.04651 -0.089 0.1681 0.076 0.24123 0.114 0.07701 
GP24 -0.040 0.53155 0.053 0.4162 -0.114 0.0778 -0.071 0.27501 
GP25 0.005 0.93574 -0.027 0.6796 0.096 0.1358 0.018 0.77902 
GP26 -0.133 0.03829 0.017 0.7922 -0.044 0.4965 -0.040 0.53917 
GP27 0.204 0.00141 0.025 0.7015 0.107 0.09792 -0.177 0.006 
GP28 -0.050 0.44328 0.007 0.9095 -0.066 0.30398 -0.001 0.98196 
GP29 0.086 0.18313 -0.024 0.7159 0.018 0.78209 -0.008 0.90031 
GP30 -0.074 0.25077 0.038 0.56 -0.027 0.67771 -0.050 0.43868 
GP31 -0.194 0.00243 -0.072 0.2617 0.004 0.95672 0.030 0.6405 
GP32 -0.094 0.14655 0.055 0.3908 0.045 0.48746 -0.122 0.05974 
GP33 0.203 0.00153 0.024 0.7052 0.104 0.10628 -0.180 0.00507 
GP34 -0.196 0.0022 -0.048 0.4598 0.026 0.68472 -0.030 0.64922 
GP35 0.117 0.06893 -0.039 0.5485 0.095 0.14038 -0.165 0.01034 
GP36 -0.069 0.28334 -0.018 0.7804 -0.021 0.74265 -0.171 0.00796 
GP37 -0.092 0.15463 -0.042 0.5192 -0.093 0.15215 0.018 0.77753 
GP38 -0.078 0.22628 -0.061 0.3446 -0.030 0.6482 -0.086 0.18312 
GP39 0.122 0.05781 -0.017 0.7927 0.079 0.22152 -0.186 0.00375 
 
 
 
 
 
 
 
 
 205 
 
Supplementary Table 5.12 Correlation between derived N-glycans traits and kidney function 
markers-creatinine, urea and uric acid 
 Creatinine Urea  Uric acid CKD-risk 
Peaks rs p rs p rs p rs p 
Branching      
LB -0.013 0.83741 -0.018 0.775 -0.031 0.63757 0.182 0.00468 
HB -0.003 0.96217 0.037 0.5636 0.023 0.72537 -0.18 0.00474 
Level of sialylation      
S0 -0.116 0.07231 -0.007 0.915 -0.117 0.07068 0.154 0.0167 
S1 0.036 0.57552 -0.082 0.2016 -0.049 0.44462 0.083 0.20019 
S2 0.109 0.09165 0.044 0.5001 0.149 0.02059 -0.13 0.0448 
S3 0.027 0.67576 0.047 0.467 0.059 0.359 -0.2 0.00233 
S4 -0.025 0.70092 -0.057 0.3735 -0.021 0.74547 -0.13 0.03801 
Level of galactosylation     
G0 -0.096 0.13537 0.027 0.6789 0.014 0.82538 0.011 0.86424 
G1 -0.116 0.0718 0.015 0.8156 -0.118 0.06742 0.169 0.00872 
G2 0.132 0.04068 -0.046 0.4753 0.059 0.36235 0.013 0.83586 
G3 -0.062 0.33506 0.045 0.4825 -0.014 0.82355 -0.1 0.14102 
G4 0.153 0.01712 -0.016 0.8044 0.082 0.20681 -0.21 0.00114 
A2 -0.095 0.13911 0.030 0.6394 0.024 0.71532 0.01 0.87318 
A2G 0.072 0.26174 -0.048 0.4544 -0.040 0.54001 0.131 0.04203 
Position of fucose     
FUC_A -0.005 0.93491 0.032 0.6203 0.107 0.09733 -0.2 0.00172 
FUC_C -0.136 0.03513 -0.075 0.2478 -0.061 0.34776 0.241 0.00016 
Level of sialylation of biantennary glycans   
BAMS 0.036 0.57552 -0.082 0.2016 -0.049 0.44462 0.083 0.20019 
BADS 0.146 0.02351 0.038 0.5522 0.162 0.01174 -0.13 0.03867 
Degree of branching     
BA -0.011 0.85923 -0.022 0.7346 -0.041 0.53152 0.184 0.00422 
TRIA -0.064 0.31973 0.052 0.418 0.001 0.98578 -0.09 0.15883 
TA 0.152 0.01817 -0.017 0.7963 0.087 0.17955 -0.21 0.00111 
DG9ind -0.089 0.16955 -0.042 0.5147 0.120 0.06199 -0.05 0.47177 
 
 206 
 
Appendix II  
Chapter Six Supplementary Data 
Supplementary Table 6.2 Correlations between individual plasma N-glycan peaks and SBP and DBP 
 SBP  DBP 
 CONTROLS CASES CONTROLS  CASES 
Peak rs p q rs p q rs p q rs p q 
GP1 0.14 0.0383 0.1949 0.06 0.3729 0.8039 0.12 0.0784 0.3666 0.07 0.2881 0.9149 
GP2 0.12 0.0856 0.3073 0.13 0.0438 0.4308 0.05 0.5063 0.7354 0.06 0.3411 0.9149 
GP3 0.04 0.5863 0.9018 0.16 0.0145 0.4156 -0.06 0.3565 0.6214 0.07 0.3191 0.9149 
GP4 -0.06 0.3411 0.7174 -0.15 0.0204 0.4156 -0.01 0.8573 0.9338 -0.09 0.1784 0.9149 
GP5 -0.04 0.5389 0.9018 -0.09 0.1998 0.7248 -0.01 0.9213 0.9646 -0.03 0.6672 0.9149 
GP6 0.01 0.9090 0.9377 0.05 0.4086 0.8039 0.04 0.5571 0.7388 -0.03 0.6853 0.9149 
GP7 -0.08 0.2478 0.6820 0.04 0.5435 0.8961 0.00 0.9733 0.9733 -0.03 0.6147 0.9149 
GP8 0.01 0.8867 0.9377 0.05 0.4257 0.8114 -0.11 0.1053 0.3666 0.01 0.8584 0.9533 
GP9 -0.02 0.7673 0.9327 0.14 0.0294 0.4308 -0.06 0.3466 0.6214 0.05 0.4343 0.9149 
GP10 -0.21 0.0018 0.1086 -0.19 0.0032 0.1940 -0.17 0.0140 0.3666 -0.12 0.0691 0.9149 
GP11 -0.12 0.0841 0.3073 0.01 0.8394 0.9562 -0.05 0.4518 0.7017 -0.06 0.3965 0.9149 
GP12 -0.01 0.8766 0.9377 -0.02 0.7633 0.9502 -0.08 0.2675 0.6214 -0.02 0.7248 0.9149 
GP13 0.02 0.7219 0.9327 0.04 0.5381 0.8961 0.05 0.4601 0.7017 0.04 0.5579 0.9149 
GP14 0.01 0.8649 0.9377 -0.01 0.9195 0.9562 -0.07 0.3229 0.6214 -0.06 0.3362 0.9149 
GP15 0.03 0.6218 0.9018 0.11 0.1080 0.6590 0.06 0.3787 0.6418 0.04 0.5946 0.9149 
GP16 -0.17 0.0134 0.1949 -0.09 0.1575 0.7248 -0.11 0.0925 0.3666 -0.07 0.2681 0.9149 
GP17 0 0.9786 0.9786 0.06 0.3835 0.8039 0.07 0.3335 0.6214 -0.02 0.7349 0.9149 
GP18 -0.04 0.5372 0.9018 -0.09 0.1915 0.7248 -0.08 0.2638 0.6214 -0.07 0.2644 0.9149 
GP19 0.04 0.5116 0.9018 0.07 0.2799 0.7248 0.03 0.6889 0.8576 0.09 0.1602 0.9149 
GP20 0.01 0.9224 0.9377 0.08 0.2385 0.7248 -0.02 0.7276 0.8702 0.04 0.5627 0.9149 
GP21 0.03 0.6089 0.9018 0.11 0.0844 0.5754 0.02 0.8243 0.9301 0.03 0.6800 0.9149 
GP22 0.07 0.2950 0.6820 0.02 0.7200 0.9502 0.02 0.7238 0.8702 0.01 0.8841 0.9533 
GP23 0.14 0.0430 0.2016 0.13 0.0451 0.4308 0.06 0.3902 0.6433 0.04 0.5867 0.9149 
GP24 -0.09 0.1701 0.5462 -0.08 0.2398 0.7248 -0.02 0.7766 0.8938 -0.03 0.6263 0.9149 
GP25 -0.02 0.7983 0.9327 0.02 0.7439 0.9502 -0.13 0.0532 0.3666 -0.12 0.0747 0.9149 
GP26 -0.03 0.6505 0.9018 -0.03 0.6413 0.9159 0.04 0.5478 0.7388 0.02 0.7092 0.9149 
GP27 0.15 0.0309 0.1949 -0.01 0.8369 0.9562 0.01 0.8386 0.9301 -0.06 0.3310 0.9149 
GP28 -0.07 0.2917 0.6820 -0.06 0.3403 0.7785 0.03 0.6306 0.8014 -0.01 0.8780 0.9533 
GP29 0.02 0.7819 0.9327 -0.11 0.0849 0.5754 0.04 0.5328 0.7388 -0.09 0.1747 0.9149 
GP30 -0.07 0.3122 0.6820 -0.03 0.6202 0.9159 0.05 0.4508 0.7017 0.04 0.5130 0.9149 
GP31 0.01 0.8688 0.9377 -0.03 0.6045 0.9159 0.12 0.0874 0.3666 0.01 0.9285 0.9533 
GP32 0.03 0.6247 0.9018 0.06 0.3446 0.7785 0.11 0.1142 0.3666 0.08 0.2325 0.9149 
GP33 0.14 0.0328 0.1949 0.01 0.9149 0.9562 0.02 0.7461 0.8753 -0.05 0.4589 0.9149 
GP34 0.06 0.3675 0.7472 -0.02 0.7623 0.9502 0.15 0.0269 0.3666 -0.01 0.9377 0.9533 
GP35 0.19 0.0045 0.1363 0.01 0.8259 0.9562 0.08 0.2162 0.5735 -0.05 0.4237 0.9149 
GP36 0.02 0.7365 0.9327 -0.08 0.2340 0.7248 0.08 0.2490 0.6214 -0.09 0.1794 0.9149 
GP37 -0.07 0.3131 0.6820 -0.07 0.2767 0.7248 0.07 0.2828 0.6214 0.00 0.9553 0.9553 
GP38 0.02 0.7515 0.9327 -0.06 0.4007 0.8039 0.14 0.0418 0.3666 -0.01 0.8610 0.9533 
GP39 0.15 0.0244 0.1949 0.00 0.9712 0.9874 0.05 0.4817 0.7167 -0.06 0.4019 0.9149 
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Supplementary Table 6.3 Correlation between derived plasma N-glycan traits and SBP and DBP in 
T2DM and controls 
 SBP    DBP   
 CONTROLS CASES CONTROLS CASES 
 rs p q rs p q rs p q rs p q 
LB -0.05 0.4443 0.8743 0.04 0.5004 0.8961 -0.11 0.1019 0.3666 0.01 0.8798 0.95332 
HB 0.04 0.5571 0.9018 -0.03 0.6623 0.9182 0.1 0.1285 0.3717 0.01 0.8966 0.95332 
S0 -0.02 0.8104 0.9327 -0.05 0.4979 0.8961 0.01 0.9174 0.9646 -0.01 0.9170 0.95332 
S1 -0.08 0.2683 0.6820 -0.01 0.9249 0.9562 -0.1 0.1341 0.3717 -0.08 0.2146 0.91491 
S2 0.01 0.9026 0.9377 0.07 0.2737 0.7248 -0.03 0.6248 0.8014 0.04 0.5539 0.91491 
S3 0.07 0.3037 0.6820 0 0.9993 0.9993 0.11 0.0976 0.3666 0.02 0.7194 0.91491 
S4 0.08 0.2341 0.6820 -0.07 0.3160 0.7709 0.14 0.0428 0.3666 -0.06 0.4012 0.91491 
G0 0.14 0.0364 0.1949 0.08 0.2467 0.7248 0.11 0.0922 0.3666 0.07 0.3059 0.91491 
G1 -0.04 0.5678 0.9018 -0.1 0.1240 0.6877 0 0.9674 0.9733 -0.07 0.3233 0.91491 
G2 -0.09 0.1642 0.5462 0.04 0.5962 0.9159 -0.15 0.0272 0.3666 -0.03 0.7023 0.91491 
G3 -0.03 0.6484 0.9018 -0.03 0.6195 0.9159 0.07 0.3350 0.6214 0.03 0.6148 0.91491 
G4 0.15 0.0313 0.1949 -0.01 0.8528 0.9562 0.06 0.3426 0.6214 -0.06 0.3403 0.91491 
FUC_A 0.15 0.0254 0.1949 0.07 0.2852 0.7248 0.12 0.0884 0.3666 0.03 0.6407 0.91491 
FUC_C -0.02 0.7368 0.9327 -0.02 0.7959 0.9562 0.01 0.9330 0.9646 -0.01 0.8614 0.95332 
BA -0.05 0.4804 0.9018 0.04 0.5422 0.8961 -0.11 0.1092 0.3666 0.01 0.9060 0.95332 
A2 0.15 0.0289 0.1949 0.07 0.2774 0.7248 0.11 0.0911 0.3666 0.07 0.3120 0.91491 
A2G -0.12 0.0737 0.2998 -0.02 0.7504 0.9502 -0.16 0.0177 0.3666 -0.07 0.3279 0.91491 
BAMS -0.08 0.2683 0.6820 -0.01 0.9249 0.9562 -0.1 0.1341 0.3717 -0.08 0.2146 0.91491 
BADS 0.03 0.7091 0.9327 0.09 0.1950 0.7248 -0.04 0.5459 0.7388 0.03 0.6899 0.91491 
TRIA -0.03 0.6263 0.9018 -0.03 0.6457 0.9159 0.06 0.3453 0.6214 0.04 0.5967 0.91491 
TA 0.15 0.0247 0.1949 -0.01 0.8806 0.9562 0.07 0.3103 0.6214 -0.06 0.3534 0.91491 
DG9ind 0.13 0.0527 0.2296 0.13 0.0494 0.4308 0.12 0.0866 0.3666 0.11 0.0981 0.91491 
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 Supplementary Table 6.4 Correlation between individual plasma N-glycan peaks and Age, HDL-c and BMI 
Age HDL-c BMI 
Control Case Control Case CONTROLS   CASES   
  
        
rs 
           p 
            
q 
        
rs 
           
p 
           
q 
      rs 
            
p 
q rs           p           q 
       rs 
            
p q       rs  p q 
GP1 0.18 0.0065 0.0393 0.14 0.0396 0.1725 0.06 0.4192 0.7307 0 0.9646 0.9932 -0.13 0.05339 0.098691 -0.02 0.72042 0.836186 
GP2 0.21 0.0016 0.0207 0.26 0.0001 0.0037 0.06 0.3981 0.7307 -0.06 0.3699 0.6838 -0.27 0.00005 0.000218 -0.21 0.0018 0.00732 
GP3 0.07 0.3298 0.4907 0.22 0.0008 0.0235 -0.07 0.3337 0.7307 -0.13 0.0587 0.5083 -0.29 0.00002 0.000122 -0.28 0.00002 0.000174 
GP4 -0.2 0.0027 0.0234 -0.03 0.6329 0.757 -0.05 0.5004 0.8033 -0.1 0.1339 0.5196 -0.06 0.38886 0.494176 0.03 0.60644 0.787082 
GP5 -0.17 0.0107 0.0592 0.02 0.7658 0.865 -0.04 0.6126 0.8897 -0.08 0.2158 0.5459 0.01 0.86935 0.914316 0.06 0.38667 0.55049 
GP6 0.06 0.399 0.5531 0.17 0.0098 0.0882 0.08 0.2565 0.6847 -0.08 0.2237 0.5459 -0.04 0.57052 0.656636 0.03 0.65697 0.834899 
GP7 -0.06 0.372 0.5403 0.01 0.9383 0.985 0.05 0.5183 0.8107 -0.01 0.8715 0.987 0.18 0.00783 0.019901 0.01 0.85159 0.911351 
GP8 -0.1 0.1364 0.3382 0.1 0.1168 0.2639 -0.12 0.1012 0.5476 -0.14 0.0431 0.5083 -0.3 0.00001 6.78E-05 -0.27 0.00004 0.000305 
GP9 0.03 0.6761 0.7499 0.14 0.0301 0.1534 -0.03 0.7227 0.9248 -0.1 0.1354 0.5196 -0.27 0.00007 0.000285 -0.28 0.00002 0.000174 
GP10 -0.41 0.0001 0.0031 -0.13 0.0523 0.1773 -0.1 0.1608 0.5744 -0.06 0.3693 0.6838 -0.04 0.54717 0.641873 0 0.95131 0.95628 
GP11 -0.07 0.2842 0.4446 0.04 0.5523 0.7165 0.06 0.3751 0.7307 -0.02 0.8096 0.9775 -0.03 0.61529 0.69505 -0.08 0.20148 0.361479 
GP12 0.11 0.1201 0.3382 0.04 0.5873 0.7165 0.22 0.0021 0.1226 0.1 0.1363 0.5196 -0.22 0.00118 0.003428 -0.31 0.00001 0.000122 
GP13 -0.03 0.6097 0.6932 0.08 0.2367 0.4011 -0.06 0.4177 0.7307 -0.06 0.3543 0.6838 -0.05 0.48829 0.588794 0.02 0.81375 0.886406 
GP14 0.16 0.0204 0.1039 0.14 0.035 0.1641 0.07 0.3500 0.7307 0.02 0.8228 0.9775 -0.08 0.26735 0.388294 -0.19 0.00406 0.014568 
GP15 0.12 0.0715 0.2423 0.12 0.0632 0.1926 -0.06 0.4151 0.7307 -0.01 0.8333 0.9775 -0.11 0.09717 0.155983 -0.25 0.00013 0.000721 
GP16 -0.3 0.0001 0.0031 -0.13 0.0571 0.1832 -0.12 0.0956 0.5476 -0.08 0.2114 0.5459 -0.07 0.29409 0.417197 -0.09 0.1615 0.31779 
GP17 0.11 0.1009 0.3239 0 0.9864 0.9864 0.09 0.1802 0.5744 0.04 0.5413 0.8255 -0.01 0.89926 0.929743 -0.11 0.10312 0.209677 
GP18 0.06 0.3832 0.5436 0 0.9531 0.985 0.1 0.1476 0.5744 0.09 0.1959 0.5459 -0.44 0.00001 6.78E-05 -0.29 0.00001 0.000122 
GP19 0.09 0.1852 0.353 -0.06 0.355 0.5414 -0.02 0.7965 0.9248 -0.01 0.9055 0.9932 0.33 0.00001 6.78E-05 0.31 0.00001 0.000122 
GP20 0.05 0.4823 0.6226 0 0.9689 0.985 -0.06 0.3694 0.7307 0.04 0.5277 0.8253 0.15 0.03154 0.066343 0.13 0.05636 0.127332 
GP21 0.02 0.7883 0.8436 0.06 0.3476 0.5414 -0.17 0.0127 0.2582 -0.07 0.3254 0.6769 -0.07 0.3347 0.462082 -0.14 0.03232 0.085718 
GP22 -0.04 0.5191 0.6333 -0.09 0.1821 0.3267 -0.13 0.0634 0.5162 -0.03 0.6064 0.8281 0.13 0.06036 0.108293 0.06 0.38805 0.55049 
GP23 0.24 0.0003 0.0055 0.1 0.135 0.2941 0.01 0.8494 0.9248 -0.05 0.5026 0.8187 -0.06 0.36983 0.479992 -0.05 0.43534 0.590128 
GP24 0.08 0.2217 0.3977 -0.08 0.2527 0.4166 0.15 0.0378 0.4616 0.1 0.1529 0.5283 0.06 0.34088 0.462082 0.02 0.76001 0.84292 
GP25 0.1 0.1597 0.3411 0.11 0.1031 0.2566 0.2 0.0040 0.1226 0.07 0.3015 0.6568 -0.17 0.01137 0.027743 -0.13 0.04998 0.117542 
GP26 0.12 0.0677 0.2423 -0.1 0.1465 0.3047 0.14 0.0457 0.4646 0.08 0.2151 0.5459 0.35 0.00001 6.78E-05 0.21 0.00126 0.00549 
GP27 0.02 0.745 0.8115 0.11 0.1097 0.2574 0.01 0.8470 0.9248 0 0.9919 0.9932 -0.13 0.06408 0.111682 -0.06 0.34702 0.543275 
GP28 0.07 0.2743 0.4404 -0.13 0.0459 0.1773 0.13 0.0677 0.5162 0.13 0.0465 0.5083 0 0.98094 0.98094 0 0.95628 0.95628 
GP29 0.02 0.8189 0.8612 -0.09 0.1729 0.3195 0.01 0.8485 0.9248 0.03 0.6381 0.8281 -0.27 0.00005 0.000218 -0.15 0.02631 0.073394 
GP30 0.05 0.477 0.6226 -0.18 0.0056 0.0854 0.08 0.2806 0.6847 0.11 0.0907 0.5083 0.22 0.00085 0.002729 0.12 0.06975 0.151955 
GP31 0.15 0.0285 0.1244 -0.19 0.0035 0.072 0.12 0.0824 0.5476 0.15 0.0271 0.5083 0.34 0.00001 6.78E-05 0.2 0.00254 0.009684 
GP32 0.08 0.2626 0.4329 -0.11 0.1052 0.2566 0.01 0.9379 0.9486 0.06 0.3963 0.7071 0.48 0.00001 6.78E-05 0.29 0.00001 0.000122 
GP33 0.01 0.8973 0.9277 0.09 0.1666 0.3176 -0.01 0.8945 0.9248 -0.01 0.8737 0.987 -0.12 0.08016 0.132156 -0.06 0.36327 0.55049 
GP34 0.2 0.0031 0.0234 -0.12 0.0663 0.1926 0.11 0.1077 0.5476 0.13 0.0573 0.5083 0.41 0.00001 6.78E-05 0.23 0.0004 0.002033 
GP35 0.07 0.3184 0.4856 0.07 0.2855 0.4583 0.05 0.4581 0.7552 0.03 0.6351 0.8281 0.02 0.79949 0.886707 0.02 0.72364 0.836186 
GP36 0.09 0.1678 0.3411 -0.04 0.5443 0.7165 0.16 0.0193 0.2936 0.09 0.2019 0.5459 0.27 0.00004 0.000203 0.06 0.40211 0.557471 
GP37 0 0.9452 0.9452 -0.14 0.0302 0.1534 -0.01 0.8768 0.9248 0.06 0.4073 0.7071 0.05 0.49227 0.588794 -0.04 0.52142 0.691448 
GP38 0.01 0.9228 0.9382 -0.16 0.0158 0.1077 0.01 0.8483 0.9248 0.07 0.2824 0.6381 0.25 0.00017 0.00061 0.06 0.34734 0.543275 
GP39 0.03 0.6136 0.6932 0.1 0.1506 0.3047 -0.01 0.8881 0.9248 0 0.9932 0.9932 0.05 0.42218 0.525571 0.01 0.93665 0.95628 
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 Supplementary Table 6.5 Correlations between derived plasma N-glycan traits and age, HDLC and BMI in cases and controls 
 
Age      HDL-c      BMI      
 controls   Cases   CONTROLS   CASES   CONTROLS   CASES   
 rs p q rs p q rs p q rs p q rs p q rs p q 
LB -0.11 0.1110 0.3382 0.13 0.0508 0.1773 -0.09 0.1883 0.5744 -0.11 0.1083 0.5083 -0.19 0.0038 0.0100 -0.15 0.0227 0.0691 
HB 0.1 0.1317 0.3382 -0.12 0.0737 0.2043 0.1 0.1757 0.5744 0.12 0.0787 0.5083 0.22 0.0010 0.0031 0.13 0.0501 0.1175 
S0 -0.1 0.1467 0.3411 0.08 0.2188 0.3814 -0.02 0.7945 0.9248 -0.08 0.2342 0.5495 -0.12 0.0763 0.1292 -0.06 0.3873 0.5505 
S1 -0.05 0.5001 0.6226 0.06 0.3943 0.5726 0.03 0.6978 0.9248 -0.03 0.6289 0.8281 -0.13 0.0484 0.0934 -0.26 0.0001 0.0004 
S2 0.1 0.1525 0.3411 -0.04 0.5477 0.7165 -0.04 0.5801 0.8631 0.05 0.4173 0.7071 0.13 0.0490 0.0934 0.12 0.0755 0.1589 
S3 0.1 0.1246 0.3382 -0.12 0.0792 0.2102 0.08 0.2803 0.6847 0.13 0.0619 0.5083 0.2 0.0026 0.0073 0.14 0.0403 0.1025 
S4 0.05 0.4709 0.6226 -0.09 0.1549 0.3047 0.03 0.7072 0.9248 0.04 0.5100 0.8187 0.16 0.0171 0.0386 0.02 0.7331 0.8362 
G0 0.19 0.0043 0.0289 0.17 0.0101 0.0882 0.06 0.4119 0.7307 0 0.9742 0.9932 -0.15 0.0242 0.0527 -0.08 0.2535 0.4331 
G1 -0.15 0.0257 0.1207 0.04 0.5655 0.7165 -0.02 0.7517 0.9248 -0.1 0.1559 0.5283 -0.06 0.3524 0.4672 0 0.9561 0.9563 
G2 -0.09 0.1658 0.3411 -0.02 0.7983 0.8854 -0.08 0.2686 0.6847 -0.07 0.3329 0.6769 0 0.9434 0.9591 -0.08 0.2556 0.4331 
G3 0.09 0.1768 0.3480 -0.16 0.0177 0.1077 0.1 0.1379 0.5744 0.13 0.0630 0.5083 0.26 0.0001 0.0005 0.15 0.0265 0.0734 
G4 0.04 0.5904 0.6926 0.05 0.4669 0.6472 0.02 0.8036 0.9248 0.02 0.7745 0.9642 0.01 0.8460 0.9054 -0.03 0.6768 0.8362 
FUC_A 0.13 0.0510 0.2075 -0.03 0.6533 0.7664 0 0.9486 0.9486 0.03 0.6155 0.8281 0.33 0.0000 0.0001 0.23 0.0006 0.0027 
FUC_C -0.12 0.0703 0.2423 0.04 0.5857 0.7165 -0.04 0.5708 0.8631 -0.09 0.1748 0.5459 -0.08 0.2501 0.3722 -0.02 0.7402 0.8362 
BA -0.1 0.1386 0.3382 0.13 0.0480 0.1773 -0.09 0.1990 0.5780 -0.11 0.1067 0.5083 -0.23 0.0007 0.0023 -0.16 0.0139 0.0472 
A2 0.2 0.0028 0.0234 0.17 0.0096 0.0882 0.06 0.4317 0.7314 0 0.9752 0.9932 -0.16 0.0156 0.0366 -0.07 0.3047 0.5024 
A2G -0.21 0.0017 0.0207 -0.01 0.8959 0.9588 -0.1 0.1756 0.5744 -0.11 0.1065 0.5083 -0.08 0.2430 0.3705 -0.09 0.1895 0.3512 
BAMS -0.05 0.5001 0.6226 0.06 0.3943 0.5726 0.03 0.6978 0.9248 -0.03 0.6289 0.8281 -0.13 0.0484 0.0934 -0.26 0.0001 0.0004 
BADS 0.08 0.2607 0.4329 -0.01 0.8560 0.9325 -0.07 0.3533 0.7307 0.03 0.6312 0.8281 0.08 0.2363 0.3696 0.09 0.1900 0.3512 
TRIA 0.09 0.1932 0.3571 -0.16 0.0165 0.1077 0.1 0.1438 0.5744 0.12 0.0785 0.5083 0.27 0.0000 0.0002 0.16 0.0173 0.0554 
TA 0.04 0.5513 0.6594 0.05 0.4470 0.6342 0.02 0.7850 0.9248 0.02 0.7528 0.9566 0.01 0.8307 0.9049 -0.02 0.7260 0.8362 
DG9ind 0.08 0.2470 0.4305 0.02 0.7310 0.8413 -0.02 0.7761 0.9248 0 0.9578 0.9932 0.44 0.0000 0.0001 0.28 0.0000 0.0001 
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Appendix III 
Chapter Eight Supplementary Data 
Supplementary Table 8.1 Correlations between derived plasma N-glycan traits and TC, TG, HDL-c and LDL-c at baseline and follow up 
 TC      TG      HDL-c      LDLC   
 Baseline   Follow up  Baseline  Follow  up Baseline  Follow up  Baseline  
          rs p q 
         
rs 
             
p q          rs 
            
p q         rs 
            
p q         rs 
           
p q        rs 
           
p q rs 
           
p q 
LB -0.1 0.201 0.589 -0.17 0.029 0.092 -0.15 0.072 0.290 -0.22 0.007 0.054 -0.12 0.135 0.535 -0.11 0.154 0.598 -0.08 0.328 0.834 
HB 0.11 0.162 0.589 0.18 0.029 0.092 0.16 0.046 0.290 0.22 0.006 0.054 0.12 0.131 0.535 0.12 0.148 0.598 0.09 0.285 0.834 
S0 -0.1 0.241 0.603 -0.17 0.030 0.092 -0.07 0.399 0.290 -0.15 0.059 0.187 -0.15 0.061 0.535 -0.07 0.394 0.780 -0.07 0.366 0.834 
S1 0.05 0.533 0.799 -0.02 0.827 0.871 -0.03 0.709 0.968 -0.05 0.568 0.775 -0.04 0.664 0.972 0.04 0.640 0.891 0.06 0.487 0.834 
S2 0.09 0.288 0.649 0.16 0.042 0.114 0.1 0.241 0.325 0.13 0.101 0.247 0.12 0.130 0.535 0.01 0.935 0.956 0.06 0.448 0.834 
S3 0.09 0.292 0.649 0.14 0.073 0.140 0.14 0.084 0.348 0.21 0.008 0.054 0.13 0.104 0.535 0.1 0.217 0.598 0.06 0.443 0.834 
S4 0.04 0.603 0.830 0.12 0.131 0.207 0.14 0.076 0.414 0.07 0.378 0.597 0.02 0.790 0.993 0.1 0.218 0.598 0.02 0.844 0.890 
G0 -0.03 0.732 0.833 -0.08 0.319 0.415 0.01 0.905 0.676 -0.01 0.928 0.955 -0.01 0.910 0.993 -0.03 0.684 0.891 -0.04 0.603 0.834 
G1 -0.11 0.175 0.589 -0.16 0.051 0.133 -0.11 0.199 0.348 -0.15 0.054 0.187 -0.19 0.017 0.507 -0.12 0.126 0.598 -0.07 0.413 0.834 
G2 0.05 0.570 0.815 0.01 0.888 0.888 -0.04 0.648 0.968 -0.03 0.685 0.874 -0.02 0.829 0.993 -0.05 0.516 0.836 0.06 0.449 0.834 
G3 0.15 0.063 0.551 0.21 0.009 0.069 0.22 0.007 0.275 0.21 0.009 0.055 0.12 0.144 0.535 0.11 0.162 0.598 0.11 0.177 0.834 
G4 -0.03 0.676 0.833 -0.07 0.397 0.497 -0.04 0.621 0.725 -0.01 0.863 0.955 0.00 0.986 0.993 0.01 0.906 0.956 -0.02 0.806 0.885 
FUC_A 0.01 0.867 0.897 0.06 0.461 0.532 0.18 0.029 0.725 0.13 0.118 0.273 0.07 0.376 0.704 0.06 0.442 0.780 -0.01 0.871 0.901 
FUC_C -0.1 0.225 0.589 -0.14 0.077 0.144 -0.07 0.417 0.348 -0.14 0.079 0.225 -0.14 0.082 0.535 -0.1 0.202 0.598 -0.07 0.378 0.834 
BA -0.12 0.144 0.589 -0.2 0.012 0.069 -0.16 0.045 0.275 -0.23 0.005 0.054 -0.12 0.147 0.535 -0.12 0.152 0.598 -0.09 0.261 0.834 
A2 -0.04 0.609 0.830 -0.09 0.275 0.384 0.00 0.958 0.676 -0.01 0.933 0.955 -0.01 0.883 0.993 -0.03 0.670 0.891 -0.05 0.504 0.834 
A2G -0.02 0.791 0.833 -0.02 0.827 0.871 -0.03 0.709 0.968 -0.05 0.568 0.775 -0.04 0.664 0.972 0.04 0.640 0.891 0.06 0.487 0.834 
BAMS 0.05 0.533 0.799 0.12 0.153 0.235 0.06 0.495 0.454 0.1 0.212 0.397 0.11 0.180 0.535 -0.04 0.657 0.891 0.04 0.643 0.839 
BADS 0.06 0.496 0.792 0.22 0.005 0.062 0.22 0.007 0.275 0.21 0.008 0.054 0.12 0.154 0.535 0.11 0.179 0.598 0.12 0.154 0.834 
TRIA 0.16 0.052 0.551 -0.07 0.375 0.479 -0.05 0.579 0.725 -0.01 0.893 0.955 0.00 0.986 0.993 0.01 0.892 0.956 -0.02 0.800 0.885 
TA -0.03 0.671 0.833 -0.01 0.875 0.888 0.17 0.033 0.968 0.04 0.591 0.788 0.06 0.500 0.810 -0.09 0.275 0.660 -0.03 0.683 0.845 
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Supplementary Table 8.2 Correlations between derived plasma N-glycan traits and Age, BMI, WHtR and FPG at baseline and follow-up 
 Age BMI WHtR FPG 
 Baseline Follow up Baseline Follow up BASELINE FOLLOW UP Baseline Follow up 
       rs p q       rs p q       rs p q rs p q rs p q rs p q   rs p q rs p q 
LB 0.15 0.054 0.235 0.15 0.061 0.216 -0.22 0.007 0.025 -0.26 0.001 0.004 -0.21 0.010 0.031 -0.24 0.003 0.010 -0.18 0.024 0.114 -0.15 0.065 0.163 
HB -0.13 0.104 0.291 -0.15 0.055 0.216 0.18 0.026 0.068 0.25 0.002 0.005 0.20 0.013 0.036 0.24 0.003 0.010 0.21 0.011 0.114 0.17 0.033 0.124 
S0 0.09 0.258 0.508 0.12 0.127 0.375 -0.1 0.230 0.369 -0.15 0.072 0.128 -0.05 0.496 0.709 -0.13 0.105 0.211 -0.14 0.074 0.221 -0.16 0.051 0.161 
S1 0.13 0.108 0.291 0.07 0.384 0.563 -0.32 0.000 0.001 -0.29 0.000 0.001 -0.31 0.000 0.001 -0.23 0.005 0.013 -0.01 0.947 0.974 -0.02 0.801 0.889 
S2 -0.06 0.460 0.668 -0.11 0.188 0.435 0.14 0.072 0.142 0.17 0.036 0.070 0.09 0.241 0.438 0.12 0.126 0.229 0.08 0.306 0.560 0.15 0.059 0.161 
S3 -0.13 0.099 0.291 -0.18 0.024 0.146 0.18 0.024 0.066 0.27 0.001 0.003 0.19 0.019 0.046 0.24 0.002 0.010 0.20 0.011 0.114 0.17 0.033 0.124 
S4 -0.09 0.253 0.508 0.02 0.832 0.876 -0.02 0.819 0.847 0.03 0.689 0.778 0.04 0.599 0.756 0.05 0.510 0.666 0.05 0.539 0.703 -0.02 0.842 0.893 
G0 0.18 0.024 0.189 0.22 0.006 0.090 -0.05 0.552 0.701 -0.08 0.326 0.442 0.04 0.589 0.756 0.00 0.994 0.994 -0.06 0.459 0.672 -0.06 0.443 0.605 
G1 0.07 0.404 0.632 0.08 0.297 0.558 -0.08 0.334 0.484 -0.10 0.213 0.317 -0.03 0.696 0.803 -0.11 0.158 0.256 -0.15 0.062 0.208 -0.19 0.016 0.104 
G2 -0.05 0.508 0.685 -0.08 0.341 0.563 -0.12 0.134 0.240 -0.10 0.235 0.341 -0.19 0.015 0.039 -0.14 0.092 0.190 -0.01 0.928 0.974 0.03 0.754 0.885 
G3 -0.18 0.028 0.189 -0.18 0.022 0.146 0.2 0.012 0.037 0.26 0.001 0.003 0.22 0.005 0.021 0.23 0.004 0.013 0.23 0.005 0.100 0.24 0.003 0.033 
G4 0.03 0.726 0.849 0.08 0.343 0.563 -0.04 0.661 0.776 0.00 0.989 0.995 -0.02 0.810 0.868 0.04 0.656 0.757 -0.02 0.831 0.959 -0.13 0.110 0.219 
FUC_A -0.05 0.556 0.696 -0.04 0.581 0.717 0.2 0.013 0.040 0.31 0.000 0.001 0.27 0.001 0.005 0.29 0.000 0.001 0.12 0.129 0.324 0.14 0.085 0.191 
FUC_C 0.05 0.497 0.685 0.07 0.376 0.563 -0.08 0.320 0.476 -0.16 0.047 0.090 -0.04 0.662 0.794 -0.16 0.051 0.117 -0.08 0.304 0.560 -0.09 0.284 0.405 
BA 0.16 0.052 0.235 0.15 0.058 0.216 -0.22 0.005 0.021 -0.26 0.001 0.003 -0.21 0.010 0.031 -0.25 0.002 0.008 -0.19 0.018 0.114 -0.15 0.062 0.161 
A2 0.18 0.022 0.189 0.22 0.005 0.090 -0.04 0.633 0.757 -0.07 0.362 0.479 0.05 0.511 0.712 0.00 0.972 0.994 -0.06 0.444 0.672 -0.06 0.485 0.637 
A2G -0.01 0.909 0.969 -0.03 0.667 0.770 -0.17 0.029 0.074 -0.17 0.032 0.065 -0.24 0.002 0.011 -0.24 0.003 0.010 -0.11 0.161 0.387 -0.12 0.152 0.260 
BAMS 0.13 0.108 0.291 0.07 0.384 0.563 -0.32 0.000 0.001 -0.29 0.000 0.001 -0.31 0.000 0.001 -0.23 0.005 0.013 -0.01 0.947 0.974 -0.02 0.801 0.889 
BADS -0.03 0.730 0.849 -0.06 0.430 0.575 0.09 0.286 0.436 0.12 0.125 0.207 0.04 0.605 0.756 0.08 0.311 0.434 0.04 0.609 0.746 0.11 0.168 0.263 
TRIA -0.18 0.027 0.189 -0.19 0.018 0.146 0.21 0.009 0.032 0.27 0.001 0.003 0.22 0.005 0.021 0.23 0.004 0.013 0.23 0.004 0.100 0.23 0.003 0.033 
TA 0.03 0.698 0.849 0.08 0.341 0.563 -0.03 0.701 0.792 0.00 0.961 0.995 -0.02 0.849 0.894 0.04 0.598 0.732 -0.01 0.857 0.960 -0.13 0.105 0.218 
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Supplementary Table 8.3 Correlations between derived plasma N-glycan traits and HbA1c, DBP and SBP at baseline and follow-up 
 HbA1c  DBP  SBP 
BASELINE FOLLOW UP Baseline Follow up Baseline Follow up  
HbA1c rs p q rs p q 
      
rs 
              
p q       rs p q 
         
rs p q rs p q 
LB -0.24 0.003 0.010 -0.05 0.529 0.873 -0.03 0.741 0.780 -0.03 0.741 0.873 0.03 0.695 0.886 0.00 0.954 0.961 
HB 0.27 0.001 0.005 0.08 0.294 0.826 0.05 0.551 0.740 0.05 0.551 0.768 -0.02 0.820 0.886 0.00 0.961 0.961 
S0 -0.24 0.002 0.010 -0.04 0.599 0.873 -0.06 0.493 0.716 -0.06 0.493 0.768 -0.07 0.378 0.846 0.02 0.781 0.927 
S1 0.02 0.815 0.843 -0.04 0.614 0.873 -0.16 0.041 0.522 -0.16 0.041 0.599 -0.02 0.793 0.886 -0.08 0.302 0.927 
S2 0.21 0.007 0.023 0.06 0.457 0.873 0.12 0.137 0.561 0.12 0.137 0.627 0.11 0.164 0.697 -0.03 0.710 0.927 
S3 0.27 0.001 0.005 0.08 0.299 0.826 0.07 0.415 0.649 0.07 0.415 0.760 0.03 0.719 0.886 -0.01 0.902 0.960 
S4 0.09 0.293 0.399 0.00 0.989 0.989 -0.1 0.211 0.561 -0.1 0.211 0.627 -0.11 0.178 0.697 0.07 0.408 0.927 
G0 -0.17 0.036 0.079 0.00 0.955 0.989 0.04 0.598 0.740 0.04 0.598 0.768 0.05 0.546 0.886 0.13 0.118 0.927 
G1 -0.26 0.001 0.006 -0.05 0.543 0.873 -0.12 0.151 0.561 -0.12 0.151 0.627 -0.11 0.165 0.697 0.02 0.812 0.927 
G2 0.09 0.277 0.387 0.00 0.980 0.989 0.00 0.987 0.987 0.00 0.987 0.987 0.05 0.505 0.886 -0.09 0.262 0.927 
G3 0.30 0.000 0.002 0.12 0.128 0.583 0.10 0.236 0.561 0.10 0.236 0.627 -0.03 0.698 0.886 -0.03 0.740 0.927 
G4 -0.01 0.949 0.965 -0.08 0.322 0.841 -0.15 0.063 0.522 -0.15 0.063 0.599 -0.02 0.810 0.886 0.08 0.349 0.927 
FUC_A 0.21 0.009 0.028 0.09 0.255 0.826 0.04 0.604 0.740 0.04 0.604 0.768 0.08 0.350 0.846 0.02 0.849 0.927 
FUC_C -0.19 0.017 0.047 0.00 0.971 0.989 -0.03 0.688 0.763 -0.03 0.688 0.839 -0.03 0.665 0.886 0.02 0.832 0.927 
BA -0.24 0.002 0.010 -0.06 0.462 0.873 -0.03 0.674 0.763 -0.03 0.674 0.838 0.03 0.708 0.886 -0.02 0.810 0.927 
A2 -0.17 0.039 0.085 -0.01 0.899 0.989 0.04 0.604 0.740 0.04 0.604 0.768 0.05 0.536 0.886 0.12 0.124 0.927 
A2G -0.10 0.214 0.321 -0.07 0.358 0.873 -0.08 0.321 0.561 -0.08 0.321 0.726 -0.02 0.825 0.886 -0.11 0.180 0.927 
BAMS 0.02 0.815 0.843 -0.04 0.614 0.873 -0.16 0.041 0.522 -0.16 0.041 0.599 -0.02 0.793 0.886 -0.08 0.302 0.927 
BADS 0.16 0.052 0.108 0.04 0.580 0.873 0.09 0.242 0.561 0.09 0.242 0.627 0.12 0.133 0.697 -0.03 0.707 0.927 
TRIA 0.30 0.000 0.002 0.12 0.132 0.583 0.10 0.219 0.561 0.1 0.219 0.627 -0.03 0.722 0.886 -0.02 0.785 0.927 
TA 0.00 0.971 0.971 -0.07 0.369 0.873 -0.15 0.069 0.522 -0.15 0.069 0.599 -0.02 0.828 0.886 0.07 0.361 0.927 
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Appendix IV 
Research Questionnaire for Type II Diabetes Mellitus 
Patient ID ………………Cat file No……………………   Date…………………………… 
Please answer every question. If you are uncertain about how to answer a question then do the best 
you can, but please do not leave a question blank. 
 
Demographics 
 
1. Age.................................. 
2. Gender 
[  ] Male 
[  ] Female 
 
3. Height……………..  cm and weight (shoeless)……………….. Kg? 
4. Waist circumference………cm and hip…………… cm? 
5. Resting blood pressure? 
a. Systolic……………………..... 
b. Diastolic ……………………….. 
 
6. What is your marital status? 
[  ] Married 
[  ] Never married 
[  ] Divorced 
[  ] Separated 
7. What is the highest level of education you have completed? 
[  ] Tertiary 
[  ] Senior high school  
[  ] Junior high school 
[  ] Lower primary 
[  ] No formal education 
 
8. Which of the following best describes your occupation? 
[  ] Employed (Including self-employed) 
[  ] Retired 
[  ] Keeping house 
[  ] Student 
[  ] other (please, specify type of job)………………………………….. 
 
9. What is the level of your daily physical activity 
[  ] Primarily sedentary (sitting down) 
[  ] Sedentary with frequent activity (sitting mostly but getting up several times an hour) 
[  ] Primarily physical (e.g. manual handling, mostly walking) 
[  ] Physical with high intensity activity (e.g. cycling, heavy work) 
 
10. During the last 7 days, on how many days did you walk for at least 10 minutes at a time in 
your leisure time? _____ days per week No walking in leisure time  
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11. How much time did you usually spend on one of those days walking in your leisure time? 
_____ hours per day _____ minutes per day 
 
Suboptimal Health Status 
Domain 1: Fatigue    
12. In the past 3 months, how often were you exhausted without greatly increasing your 
physical activity? 
[1] Always 
[2] Very often  
[3] Often 
[4] Occasionally 
[5] Never or almost never 
13. In the past 3 months, how often did you have fatigue which could not be substantially 
alleviated by rest? 
[1] Always 
[2] Very often  
[3] Often 
[4] Occasionally 
[5] Never or almost never 
14. In the past 3 months, how often were you lethargic in your daily life? 
[1] Always 
[2] Very often  
[3] Often 
[4] Occasionally 
[5] Never or almost never 
15. In the past 3 months, how often did you suffer from headaches? 
[1] Always 
[2] Very often  
[3] Often 
[4] Occasionally 
[5] Never or almost never 
16. In the past 3 months, how often did you suffer from dizziness? 
[1] Always 
[2] Very often  
[3] Often 
[4] Occasionally 
[5] Never or almost never 
17. In the past 3 months, how often did your eyes ache or feel tired? 
[1] Always 
[2] Very often  
[3] Often 
[4] Occasionally 
[5] Never or almost never 
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18. In the past 3 months, how often did your muscles or joints feel stiff? 
[1] Always 
[2] Very often  
[3] Often 
[4] Occasionally 
[5] Never or almost never 
19. In the past 3 months, how often did you have pain in your shoulders / neck / back? 
[1] Always 
[2] Very often  
[3] Often 
[4] Occasionally 
[5] Never or almost never 
20. In the past 3 months, how often did you have a heavy feeling in your legs when walking? 
[1] Always 
[2] Very often  
[3] Often 
[4] Occasionally 
[5] Never or almost never 
 
Domain 2: Cardiovascular System   
21. In the past 3 months, how often did you feel out of breath while resting? 
[1] Always 
[2] Very often  
[3] Often 
[4] Occasionally 
[5] Never or almost never 
22. In the past 3 months, how often did you suffer from chest congestion? 
[1] Always 
[2] Very often  
[3] Often 
[4] Occasionally 
[5] Never or almost never 
23. In the past 3 months, how often were you bothered by heart palpitations? 
[1] Always 
[2] Very often  
[3] Often 
[4] Occasionally 
[5] Never or almost never 
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Domain 3: Digestive System   
24. In the past 3 months, how often was your appetite poor? 
[1] Always 
[2] Very often  
[3] Often 
[4] Occasionally 
[5] Never or almost never 
 
25. In the past 3 months, how often did you suffer from heartburn? 
[1] Always 
[2] Very often  
[3] Often 
[4] Occasionally 
[5] Never or almost never 
 
26. In the past 3 months, how often did you suffer from nausea? 
 
[1] Always 
[2] Very often  
[3] Often 
[4] Occasionally 
[5] Never or almost never 
 
Domain 4: Immune System 
 
27. In the past 3 months, how often did you have difficulty tolerating hot and cold temperatures? 
 
[1] Always 
[2] Very often  
[3] Often 
[4] Occasionally 
[5] Never or almost never 
28. In the past 3 months, how often did you catch a cold? 
[1] Always 
[2] Very often  
[3] Often 
[4] Occasionally 
[5] Never or almost never 
 
29. In the past 3 months, how often did you suffer from a sore throat? 
 
[1] Always 
[2] Very often  
[3] Often 
[4] Occasionally 
[5] Never or almost never 
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Domain 5: Mental Health   
30. In the past 3 months, how often did you have difficulty falling asleep? 
[1] Always 
[2] Very often  
[3] Often 
[4] Occasionally 
[5] Never or almost never 
31. In the past 3 months, how often were you troubled by waking up during the night? 
[1] Always 
[2] Very often  
[3] Often 
[4] Occasionally 
[5] Never or almost never 
32. In the past 3 months, how often did you have trouble with your short-term memory? 
[1] Always 
[2] Very often  
[3] Often 
[4] Occasionally 
[5] Never or almost never 
 
33. In the past 3 months, how often did you have difficulty responding to situations quickly or 
making decisions? 
 
[1] Always 
[2] Very often  
[3] Often 
[4] Occasionally 
[5] Never or almost never 
34. In the past 3 months, how often did you have difficulty concentrating? 
[1] Always 
[2] Very often  
[3] Often 
[4] Occasionally 
[5] Never or almost never 
 
35. In the past 3 months, how often were you distracted for no reason? 
[1] Always 
[2] Very often  
[3] Often 
[4] Occasionally 
[5] Never or almost never 
36. In the past 3 months, how often did you feel nervous or jittery? 
[1] Always 
[2] Very often  
[3] Often 
[4] Occasionally 
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[5] Never or almost never 
 
Please, if you are not a type II diabetes patient, go to next section Q42 
 
Medical History and Type II Diabetes Complications 
 
37. Has either of your parents or any of your parents, brothers or sisters been diagnosed with 
diabetes (Type 1 or 2), hypertension, metabolic syndrome or dyslipidaemia? 
 
[  ] Yes 
[  ] No 
 
38. Within the past 12 months, has your doctor told you that you have high blood pressure? 
[  ] Yes 
[  ] No 
 
39. How old were you when you were first told that you had hypertension or high blood 
pressure?..................................... 
 
 
40. For how long have you been diagnosed of diabetes? 
[  ] less than a year 
[  ] 1-5 years 
[  ] 6-10 years 
[  ] 11-15 years 
[  ] 20-25 years 
[  ] 25-30 years 
[  ] other specify……………………. 
41. Are you currently or have you ever suffered from any of these diseases?................................. 
Please tick  
[  ] stroke 
[  ] neuropathy 
[  ] glaucoma 
[  ] erectile dysfunction 
[  ] myocardial infarction 
[  ] diabetic coma 
[  ] coronary artery disease 
[  ] retinopathy 
[  ] peripheral ulcers 
[  ] others e.g. cancers, arthritis, infectious diseases etc……………………………………….. 
 
Environmental, Dietary and Lifestyle Factors 
42. Have you ever smoked? If no, go to next section Q 45 
[  ] Yes 
[  ] No 
 
43. Do you currently smoke any tobacco products such as cigarettes, cigars, or pipes? 
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[  ] Yes 
[  ] No 
44. For how many years have you been smoking daily?........................................... 
45. Have you ever consumed a drink that contains alcohol (such as beer, wine, etc.)? 
[  ] Yes 
[  ] No, then skip to next section Q47 
 
46. In your life, how often do you drink alcohol? 
[  ] Never or almost never  
[  ] Occasionally 
[  ] Often 
[  ] Very often 
[  ] Always 
 
 
Food Preference Questions 
Skip the following questions if you are not suffering from Type II diabetes mellitus 
 
 
 
 
 
47. How often, in the past 3 months, did you 
eat the following? never 
Less than 
1 time 
per week 
1-6 times 
per week 
1-3 times 
per day 
4 or 
more 
times per 
day 
Dairy (cheese, milk, yogurt etc.)      
Poultry (chicken, turkey, duck etc.)       
Fish and Sea food (tilapia, tuna, shrimp, crab, etc.)      
Pork      
Beef      
Eggs      
Other meat (lamb, bush meat, venison, etc.)      
Fruits (apples, bananas, pawpaw, oranges, etc.)      
Sweets and soft drinks      
Vegetables (carrots, okro, green leafy vegetables 
mushrooms, potatoes, cabbage, tomatoes, 
Cucumber, potatoes, mushrooms, garlic, garden 
eggs, lettuce, cucumber, etc.) 
     
Cereals and cereal products (millet, maize, 
sorghum, oats, bread, wheat, porridge, rice) 
     
Fatty foods [(margarine, butter, pan fry foods 
(eggs, rice, potatoes meat, poultry, lamb, pork etc.)] 
     
Starchy foods (cassava, plantain, cocoyam)      
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Medications 
48. How do you currently manage or control your diabetes? 
[  ] Diet and/or exercise only 
[  ] Oral medications 
[  ] Insulin injection 
[  ] Insulin pump 
[  ] Other (Specify)………………… 
 
49. Because of your high blood pressure/hypertension, have you ever been told to take 
prescribed   medicine? 
[  ] Yes 
[  ] No 
 
50. Have you ever been told by a doctor or other health professional that your blood cholesterol 
level was high? 
[  ] Yes 
[  ] No 
 
51. Have you ever been told by a doctor or other health professional to take prescribed medicine 
to lower your blood cholesterol? 
[  ] Yes 
[  ] No 
 
 
52.  Please list below all prescription medicines and over-the counter medications you have been 
taking for the past 3 months. 
Medicine   reasons for taking     Amount/frequency 
………………………                           .……………………                        ………………………….                 
…………………..........                          ……………………                  …………………....……          
…….………………….                         ......... .......................                          .......................................                 
……………………. .....                        ..................................                          ......................................  
………………………..            ……………………..  …………………………… 
………………………..           ………………….....  …………………………… 
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 Appendix V  
Other Supporting Documents 
                                                                                                                                                                   
Participants Information Letter 
 
Validation of N-glycan profiles as risk stratification biomarker for type II diabetes mellitus 
 
Investigator: Eric Adua  
 
This is a collaborative research between Edith Cowan University and the Komfo Anokye 
Teaching Hospital (KATH). This collaborative research entitled Validation of N-glycan profiles as a 
risk stratification biomarker for Type II Diabetes Mellitus (T2DM), will lead to the award of a PhD 
degree in Medical Sciences.   
You are being invited to participate in this study because you have T2DM.  Please read the 
information carefully and ask any questions you might have.  You may also wish to discuss the study 
with a relative or friend or your doctor.  
We wish to identify a sugar called N-glycan, which could be used as an indicator for T2DM 
onset, its progression and the associated risk factors that contributes to its development. If you choose 
to participate, we will first ask you to fast overnight from 9 pm to 8 am and then you will answer a 
simple validated questionnaire about your present health status, dietary pattern, medication history and 
family history of diabetes and cardiovascular diseases. Following this, we will draw 10 ml of your blood 
for laboratory testing. The entire process will take approximately 1 hr to complete and the potential 
benefit is that you will be able to know your medical status. Copies of the test results will be given you 
for you to take to your doctor if need be. 
If you agree to participate in the study, you will be compensated with $10 for your time and 
trouble. Participation in this study is voluntary.  You do not have to participate if you do not want to 
and your decision to participate or not will in no way affect your current or future care at KATH. You 
are also free to withdraw from the study at any time without reason or justification. All the information 
you provide will be confidential. Your data will be stored in a password protected hard drives and kept 
in special cabinets in the principal supervisor’s office. All your data will be destroyed after five years. 
If the results of the trial are published in a medical journal, as is intended, no reader will be able to 
identify you.  
There are no foreseeable major risks or side effects associated with your participation. You will 
however experience a minimal discomfort during the blood withdrawal stage. In the event that you 
suffer an expected or unexpected side effect or medical accident during this study, you will be offered 
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all full and necessary treatment by KATH. The ECU Human Research Ethics Committee (ECU HREC) 
and the Committee On Human Research, Publications And  Ethics (CHRPE) of KATH has approved 
this study on the basis that the reported risk of such an event is either small or acceptable in terms of 
the risk you face as a result of your current illness. 
Contact Information 
If you have questions about this study, please contact  
 
1. Eric Adua 
School of Medical Sciences 
Edith Cowan University, WA 
Email: eadua@our.ecu.edu.au 
+233244861033 Ghana 
Mobile +61406113670 Australia 
 
2. Dr. Asamoah Sakyi 
School of Medical Sciences 
Kwame Nkrumah University of Science and Technology 
Kumasi, Ghana 
Email: sasakyi.chs@knust.edu.gh  
Mobile +2330244530214, +233204595000 
3. Wei Wang MD, PhD, FFPH 
            School of Medical Sciences  
            Edith Cowan University 
            270 Joondalup Drive, Perth 
            WA 6027, Australia 
 Email: wei.wang@ecu.edu.au 
            Tel: (61 8) 6304 3717 
 
4. Rowe Oakes       
            Ethics Support Officer 
            Office of Research & Innovation, Edith Cowan University 
            Phone: +61 08 6304 2943 
            Email: research.ethics@ecu.edu.au 
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CONSENT FORM 
 
 
Validation of N-glycan profiles as risk stratification biomarker for type II diabetes mellitus 
 
Investigator: Eric Adua, Edith Cowan University 
 
 
I, ………………………………….. agree to participate in the above study.  I have been provided with 
a copy of the participant information letter explaining the study which I have read and understood.   I 
have been given the opportunity to ask questions about the study by the Investigator and any questions 
have been answered to my satisfaction. I am aware that if I have additional questions, I can contact the 
research team. I understand that I will be required to fast overnight between 9 am and 8 am, answer 
questionnaire and provide a 10 ml of venous blood sample for laboratory testing. I understand that I 
may withdraw from the study at any time without affecting any future medical treatment, or the 
treatment of the condition which is the subject of the study. I am aware that all research data collected 
will only be used for the purpose of this study and will be kept confidential and that my participation 
will not be disclosed without my consent.  
 
Signed   ……………………………………….          Date  ……………………… 
 
Signature         ……………………………………….  Date  ……………………… 
of Investigator 
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Appendix VI 
Standard Operating Procedures 
N-glycan profiles as a risk stratification biomarker for type II diabetes 
mellitus and associated metabolic risk factors 
General guidelines  
 Before starting any blood sampling, strict hygienic conditions should be maintained.  
 The work bench should be disinfected with 70% ethanol.  
 New and sterile needles and syringes should be used on each participant and no two 
individuals should share needles or syringes.  
 After each use, needles and syringes should be disposed off appropriately into sharps 
bin. Waste disposal should strictly follow the procedures stipulated by Komfo Anokye 
Teaching Hospital (KATH).  
 A sterile environment should always be maintained during blood collection. All 
personnel should always wear personal protective equipments (PPEs) which include a 
comfortable laboratory coat, eye-wear and sterile gloves to protect themselves from 
contact with patient blood samples.  
 It is also mandatory for laboratory staff to carry out proper hand washing procedures 
before and after each blood collection session prior to carrying out any other task as 
part of their protocol. 
 Hygienic materials including laboratory coats, hand washing soaps, alcohol, sterile 
gloves and cotton wools must always be available before and after every venipuncture.  
 Infection-free or 70% alcohol-wiped tourniquets should be used for each venipuncture 
to prevent possible transmission of infection between the phlebotomist and the 
participant.  
 Before each venipuncture, a 70% alcohol swap is used to clean the arm of each 
participant before drawing blood.  
 To avoid swapping samples and cross-contamination, blood samples must be collected 
into vacutainer tubes and labelled immediately before arranging on a rack.  
Equipment, chemicals and consumables required 
Equipment 
 Centrifuge 
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 Freezer (-80oC) 
 1 ml pipette 
 Tourniquet 
 Biochemical/test kits 
 Permanent markers 
Consumables  
 Vacutainer tubes  
 Cryotubes 1.8 ml 
 1 ml pipette tips 
 2 ml eppendorf tubes  
 Sterile needles  
 Cotton wools 
Timeline for blood collection procedures 
Procedure                                                                                                                        Time 
1. Collection of one patient blood sample                                                                20 min 
2. Transfer to laboratory                                                                                           2 hrs   
3. Leave the tube resting at room temperature                                                         20 min 
4. Centrifugation of plasma                                                                                      10 min  
5. Transfer of plasma                                                                                                10 min 
6. Freezing of plasma                                                                                                5 min 
Approximate total time for procedure                                                                         3 hrs, 5 
min 
 
Method 
Collection of blood samples 
 Collect blood sample from each patient using a tourniquet + butterfly needle method.  
 10 ml of whole blood should be collected into two EDTA vacutainer tubes (5 ml each) 
and inverted 3X to ensure uniform mixture.  
 One tube will be used for routine biochemical tests including (LDL, cholesterol, 
triglycerides, C-reactive proteins, insulin, glucose and glycated hemoglobin).  
 The other tube will be processed for genetic and N-glycan analysis.  
Labelling 
 Note participant/patient ID and the date on each questionnaire. 
 Clearly mark the patient ID on both the vacutainer tubes and the cryotubes. 
 
NOTE: Make sure the labelling on the questionnaire corresponds to that on the tube!! 
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Transfer of sample to laboratory 
Place tubes in cool boxes packed with ice blocks/ freezing gels (4oC) and sent to the 
laboratory within 4 hours its draw. 
 
      Time of arrival ……………lab 
technician………………………….Date…………………………. 
       
NOTE: Samples must be processed on the same day upon arrival at the laboratory!!! 
Centrifugation of plasma 
 Leave the tube resting at the room temperature for 20-25 mins to prevent samples from 
being hemolysed. 
 Place the tube in a centrifuge and spin. 
 Ensure tube is balanced with equivalent water containing tube. 
 Set centrifuge to spin for 10 mins at 1620 g or the equivalent rpm at 4oC. 
 Check if samples are hemolysed and note it.  
 
 
Figure 1. The components of blood 
 
 
 
Aliquoting plasma and buffy coat  
 Transfer plasma to a 1.8 ml microcryotubes tubes.  
o label as PLS + Patient ID 
 Carefully aliquot buffy coat into new 1.8 ml microcryotubes. 
o Label microcryotubes as BC + Patient ID 
 
NOTE: Make the patient ID on both microcryotubes corresponds with each other!!! 
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Deviations from procedure 
Note any deviations from the procedure here, giving reasons and effects. Include sample 
details. 
…………………………………………………………………………………………………
………… 
…………………………………………………………………………………………………
………… 
…………………………………………………………………………………………………
………… 
…………………………………………………………………………………………………
………… 
…………………………………………………………………………………………………
………… 
…………………………………………………………………………………………………
………… 
 
Storage  
 Processed plasma and buffy coats in microcryotubes should be in clearly labelled 
plastic containers.  
 Place plastic containers in plastic bags.   
 Store at a specific space in a -80oC freezer.  
 Note samples in freezer log book.  
 Participant information and details of each sample should be noted in a processing 
notebook. 
 Export data into an Excel spreadsheet or a Microsoft access database. 
 
Sample transportation 
The transport of biosamples has to be performed strictly under standardized conditions to 
prevent a loss of sample quality.  
 Sample packing 
 Each tube/vial should be identified with printed labels including sample type. 
 Tubes should be packed in cardboard/plastic boxes, ideally in a Styrofoam box with 
a coating thickness of at least 5 cm for adequate stability.  
 A coated paperboard box is favored over a non-coated box.  
 Avoid packing tubes in plastic bags directly.  
 Paper toweling can be placed in the box to cushion the sample tubes while 
transporting. 
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 The paperboard or Styrofoam boxes must be labeled with the required hazardous 
material tags. 
 Mark packaged boxes with information concerning sender and recipient of the 
biosample delivery (address, contact person).  
 
Sample shipping 
 Ship plasma and Buffy coat samples on dry ice.  
 Ensure that the samples are properly packed to maintain the required temperature 
for the journey plus two days.  
 The biosamples should be surrounded from all sides by a dry ice layer with a 
thickness of at least 5 cm.  
 Vacuity above the dry ice layer should be filled-up with packing material or further 
dry ice in order to avoid a shift of the insulating bed (dry ice) during the transport.  
 For reasons of dispersal, dry ice pellets (nuggets) are favored over dry ice blocks. 
Shipping process 
Before shipping, please inform the recipient on the following information: 
 Mark contact details including sender and recipient name and phone numbers on 
the package. 
 Shipping details (shipping company, intended shipping date, shipment packaging 
and temperature). 
 Sample details (total number of samples, complete list of samples). 
 After shipping, inform the recipient on waybill number for tracking of shipment.  
 An acknowledgement will be sent to the shipper when the samples have been 
received and checked.  
 The process is not completed till the recipient confirms the acceptance of the 
consignment.
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